

01558370-24-01198810-Q ELUTIA INC. 2024081320240813092204092205092205 0 0001558370-24-011988 10-Q 80 20240630 20240813 20240813 ELUTIA INC. 0001708527 2836
474790334 DE 1231 10-Q 34 001-39577 24119905 12510 PROSPERITY DRIVE SUITE 370 SILVER SPRING MD 20904 240-247-1143 12510 PROSPERITY DRIVE SUITE 370 SILVER SPRING
MD 20904 AZIYO BIOLOGICS INC. 20170605 10-Q 1 elut-20240630x10q.htm 10-Q 24408651162089050001708527-12-
312024Q2false431340643134061888419623963101140000P30DPD3YP20Dhttp://fash.org/us-
gaap:2024#SecuredOvernightFinancingRateSoftMember1.50.0010001708527elut:CommonStockWarrantMember-gaap:MeasurementInputRiskFreeInterestRateMember2024-06-
300001708527elut:CommonStockWarrantMember-gaap:MeasurementInputPriceVolatilityMember2024-06-300001708527elut:CommonStockWarrantMember-
gaap:MeasurementInputExpectedTermMember2024-06-300001708527elut:CommonStockWarrantMemberelut:MeasurementInputCommonStockPriceMember2024-06-
300001708527elut:CommonStockWarrantMember-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001708527elut:CommonStockWarrantMember-
gaap:MeasurementInputPriceVolatilityMember2023-12-310001708527elut:CommonStockWarrantMember-gaap:MeasurementInputExpectedTermMember2023-12-
310001708527elut:CommonStockWarrantMemberelut:MeasurementInputCommonStockPriceMember2023-12-310001708527us-gaap:WarrantMember2024-06-300001708527us-
gaap:WarrantMember2023-12-310001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-04-012023-06-300001708527us-gaap:EmployeeStockOptionMember2024-04-
012024-06-300001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-01-012023-06-300001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2024-04-012024-06-300001708527us-gaap:CommonClassAMemberus-gaap:CommonStockMember2024-01-012024-06-300001708527us-
gaap:RetainedEarningsMember2024-04-012024-06-300001708527us-gaap:AdditionalPaidInCapitalMember2024-06-300001708527us-gaap:RetainedEarningsMember2024-03-310001708527us-
gaap:AdditionalPaidInCapitalMember2024-03-310001708527us-gaap:RetainedEarningsMember2023-12-310001708527us-gaap:AdditionalPaidInCapitalMember2023-12-
310001708527us-gaap:RetainedEarningsMember2023-06-300001708527us-gaap:AdditionalPaidInCapitalMember2023-06-300001708527us-gaap:RetainedEarningsMember2023-03-
310001708527us-gaap:AdditionalPaidInCapitalMember2023-03-310001708527us-gaap:RetainedEarningsMember2022-12-310001708527us-
gaap:AdditionalPaidInCapitalMember2022-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-06-300001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2024-06-300001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-03-310001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2024-03-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-12-310001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2023-12-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-06-300001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2023-06-300001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-03-310001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2023-03-310001708527us-gaap:CommonClassBMemberus-gaap:CommonStockMember2022-12-310001708527us-gaap:CommonClassAMemberus-
gaap:CommonStockMember2022-12-310001708527elut:StockOptionPlan2020Memberus-gaap:CommonClassAMember2023-06-012023-06-300001708527us-gaap:CommonClassAMemberus-
310001708527elut:PerformanceBasedOptionsMarketConditionsMember2024-06-300001708527elut:PerformanceBasedOptionsProductApprovalMember2024-01-012024-06-
300001708527elut:StockOptionPlan2020Memberus-gaap:CommonClassAMember2024-06-300001708527us-gaap:EmployeeStockOptionMember2024-06-
300001708527elut:StockOptionPlan2020Memberus-gaap:CommonClassAMember2023-06-080001708527us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001708527us-
gaap:EmployeeStockOptionMember2023-04-012023-06-300001708527us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001708527us-
gaap:RestrictedStockUnitsRSUMemberelut:StockOptionPlan2020Member2024-06-300001708527elut:RestrictedStockUnitsMarketConditionsMember2024-06-300001708527us-
gaap:RestrictedStockUnitsRSUMemberelut:StockOptionPlan2020Member2023-12-310001708527elut:RestrictedStockUnitsProductApprovalMember2024-01-012024-06-300001708527us-
gaap:RestrictedStockUnitsRSUMemberelut:StockOptionPlan2020Member2024-01-012024-06-300001708527srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-
300001708527srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001708527srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2024-01-012024-
06-300001708527srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001708527us-
gaap:CommonClassAMemberelut:RegisteredDirectOfferingOfCommonStockAndWarrantsMember2024-06-160001708527elut:LicenseAgreementWithCookBiotechMember2024-04-012024-06-
300001708527elut:LicenseAgreementWithCookBiotechMember2023-04-012023-06-300001708527elut:LicenseAgreementWithCookBiotechMember2023-01-012023-06-
300001708527srt:MinimumMemberus-gaap:OfficeEquipmentMember2024-06-300001708527srt:MinimumMemberelut:ProcessingAndResearchEquipmentMember2024-06-
300001708527srt:MaximumMemberus-gaap:OfficeEquipmentMember2024-06-300001708527srt:MaximumMemberelut:ProcessingAndResearchEquipmentMember2024-06-300001708527us-
gaap:ComputerEquipmentMember2024-06-300001708527elut:CommonStockWarrantMember2024-07-012024-07-
310001708527elut:PrefundedWarrants2024Memberelut:RegisteredDirectOfferingOfCommonStockAndWarrantsMember2023-09-212023-09-
210001708527elut:PrefundedWarrants2023Memberus-gaap:PrivatePlacementMember2023-09-212023-09-210001708527elut:SWKLoanFacilityMember2022-12-142022-12-
140001708527elut:SWKLoanFacilityMember2022-08-102022-08-100001708527us-gaap:CommonClassAMemberelut:RegisteredDirectOfferingOfCommonStockAndWarrantsMember2024-06-
162024-06-160001708527elut:RegisteredDirectOfferingOfCommonStockAndWarrantsMember2024-04-012024-06-
300001708527elut:RegisteredDirectOfferingOfCommonStockAndWarrantsMember2024-01-012024-06-300001708527us-gaap:CommonClassAMemberus-gaap:PrivatePlacementMember2023-
09-212023-09-210001708527elut:ViableBoneMatrixVbmProductLitigationMember2024-01-012024-06-300001708527elut:RegisteredDirectOfferingOfCommonStockAndWarrantsMember2024-
06-162024-06-160001708527elut:PrefundedWarrantsMemberelut:RegisteredDirectOfferingOfCommonStockAndWarrantsAndPrivatePlacementMember2024-04-012024-06-
300001708527elut:PrefundedWarrantsMemberelut:RegisteredDirectOfferingOfCommonStockAndWarrantsAndPrivatePlacementMember2024-01-012024-06-300001708527us-
gaap:PrivatePlacementMember2023-09-212023-09-210001708527us-gaap:RetainedEarningsMember2024-04-012024-06-300001708527us-gaap:RetainedEarningsMember2024-01-012024-06-
300001708527us-gaap:RetainedEarningsMember2023-04-012023-06-300001708527us-gaap:RetainedEarningsMember2023-01-012023-06-
300001708527elut:ViableBoneMatrixVbmProductLitigationFraudMember2024-06-300001708527elut:FiberCellLitigationProductLiabilityMember2021-09-012024-06-
300001708527elut:ViableBoneMatrixVbmProductLitigationMember2024-06-300001708527elut:FiberCellLitigationProductLiabilityMember2024-06-
300001708527elut:FiberCellLitigationProductLiabilityMember2022-08-012024-06-300001708527elut:NewAssetBasedRevolvingLoanFacilityMember2022-08-
100001708527elut:RevenueInterestObligationMember2024-04-012024-06-

registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15 (d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Yes Â No Â No Â A Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â32.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Yes Â No Â No Â A Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of Âlarge accelerated filer, Âaccelerated filer, Âsmaller reporting company, Âemerging growth companyÂ in RuleÂ 12b-2 of the Exchange Act.Â Large accelerated filer Â Accelerated filer Â Non-accelerated filer Â Smaller reporting company Â Emerging growth company Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to SectionÂ 13(a)Â of the Exchange Act. Â Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Yes Â No Â As of August 7, 2024, there were 29,746,935 shares of the registrant's Class A common stock and 4,313,406 shares of the registrant's Class B common stock outstanding.Â Table of Contents FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Quarterly Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report, including, without limitation, statements regarding our results of operations, financial position, and business strategy; expectations regarding our products and their targeted effects; plans for our sales and marketing growth; expectations regarding the potential payment of post-closing earnout payments from the sale of our Orthobiologics Business to Berkeley Biologics, LLC (the "Berkeley"); our anticipated expansion of our product development and research activities; increases in expenses and seasonality; expectations regarding our competitive advantages, and overall clinical and commercial success; expectations regarding the pending lawsuits and claims related to our recall of a single lot of Fiber Viable Bone Matrix (the "FiberCel") and viable bone matrix (the "VBM"), amounts recoverable under insurance, indemnity and contribution agreements and the impact of such lawsuits and claims on our future financial position; and our expectations and plans regarding pursuit of any strategic transactions are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Without limiting the foregoing, the words "aim," "believe," "expect," "may," "will," "should," "expect," "explore," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "could," "continue" or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These forward-looking statements are not a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements. These forward-looking statements are based on our management's beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits related to FiberCel and VBM and avoid a material adverse financial consequence; the continued and future acceptance of our products by the medical community; our ability to market and sell our newly approved EluProÂ antibacterial envelope device; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; 1 Table of Contents our ability to successfully realize the anticipated benefits of the sale of our Orthobiologics Business; a physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the U.S. Food and Drug Administration and comparable foreign authorities for our products and product candidates; and our ability to obtain, maintain and adequately protect our intellectual property rights. These and other important factors discussed in Part I, Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Part II, Item 1A, "Risk Factors" in this Quarterly Report, and in Part I, Item 1A, "Risk Factors" and Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "Annual Report") and in our other filings with the Securities and Exchange Commission (the "SEC"), each of which filings are accessible on the SEC's website at www.sec.gov and the Investor Relations page of our website at https://investors.Elutia.com/financials/sec-filings, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Quarterly Report. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. As used in this Quarterly Report, unless otherwise specified or the context otherwise requires, references to "we," "us," "our," "the Company" and "Elutia" refer to the operations of Elutia Inc. and its consolidated subsidiaries. WEBSITE DISCLOSURE We may use our website as a distribution channel of material information about the Company. Financial and other important information regarding the Company is routinely posted on and accessible through the Investor Relations sections of its website at www.Elutia.com. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the "Email Alerts" option under the IR Resources menu of the Investor Relations of our website at www.Elutia.com. The reference to our website address does not constitute incorporation by reference of the information contained on or available through our website, and you should not consider such information to be a part of this Quarterly Report. 2 Table of Contents TRADEMARKS, TRADE NAMES AND SERVICE MARKS This Quarterly Report includes our trademarks, trade names and service marks, including, without limitation, "Elutia," "CanGaroo," "EluPro," "CanGaroo," "ProxiCor," "Tyke," "VasCure," "SimpliDerm," "SimpliDerm Ellipse" and our logo, which are our property and are protected under applicable intellectual property laws. This Quarterly Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks may appear in this Quarterly Report without the "TM," "SM" and "SM" symbols, but such references are not intended to indicate, in any way, that we or the applicable owner forgo or will not assert, to the fullest extent permitted under applicable law, our rights or the rights of any applicable licensors to these trademarks, trade names and service marks. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. 3 INDUSTRY AND OTHER DATA Unless otherwise indicated, information contained in this Quarterly Report concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is based on our management's estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe the information from these third-party publications, research, surveys and studies included in this Quarterly Report is reliable. Management's estimates are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are subject to a high degree of uncertainty and risk due to a variety of factors, including those described in this Quarterly Report under "Forward-Looking Statements" and Part I, Item 1A, "Risk Factors" in our Annual Report which can be found at https://investors.Elutia.com/financials/sec-filings. These and other factors could cause our future performance to differ materially from our assumptions and estimates. 3 Table of Contents TABLE OF CONTENTS Page FORWARD-LOOKING STATEMENTS WEBSITE DISCLOSURE TRADEMARKS, TRADE NAMES AND SERVICE MARKS 3 INDUSTRY AND OTHER DATA 3 PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) 7 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Quantitative and Qualitative Disclosures About Market Risk 43 Item 4. Controls and Procedures 43 PART II "OTHER INFORMATION" Item 1. Legal Proceedings 44 Item 1A. Risk Factors 44 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 44 Item 4. Mine Safety Disclosures 44 Item 5. Other Information 44 Item 6. Exhibits 45 Signatures 47 Table of Contents PART I "FINANCIAL INFORMATION" Item 1. Financial Statements (Unaudited) 4 Cond

[illegible]

assumptions and estimates in determining an appropriate term, risk-free interest rate, volatility factor, dividend yield, and the fair value of common stock. Significant adjustments to the unobservable inputs would have a direct impact on the fair value of the warrant liability. Revenue Recognition The Company's revenue is generated from contracts with customers in accordance with ASC 606. The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, the Company enters into contracts to primarily sell and distribute products to healthcare providers or commercial partners. Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products to the Company's customers. For all product sales, the Company has no further performance obligations and revenue is recognized at the point control transfers which occurs either when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, in accordance with the terms of the agreement. A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and from inventory physically held by distributors and direct sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized. The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in sales and marketing costs. Contracts with customers state the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company's contracts vary; however, as a common business practice, payment terms are typically due in full within 30 to 60 days of delivery. The Company, at times, extends volume discounts to customers. The Company permits returns of its products in accordance with the terms of contractual agreements with customers. Allowances for returns are provided based upon analysis of the Company's historical patterns of returns matched against the revenues from which they originated. The Company records estimated returns as a reduction of revenue in the same period revenue is recognized. Stock-Based Compensation Plans The Company accounts for its stock-based compensation plans in accordance with ASC 718. Accounting for Stock Compensation. ASC 718 requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors, including employee stock options and restricted stock. Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the requisite service period of the entire award. 14 Table of Contents Research and Development Costs Research and development costs, which include mainly salaries, outside services and supplies, are expensed as incurred. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company's cash balances with the individual institutions may at times exceed the federally insured limits. There were two customers that represented 14% and 11%, respectively, of the Company's net sales for the six months ended June 30, 2024. Additionally, there were two customers that represented 26% and 12%, respectively, of the Company's accounts receivable as of June 30, 2024. Comprehensive Income (Loss) Comprehensive income (loss) comprises net income (loss) and other changes in equity that are excluded from net income (loss). For the three and six months ended June 30, 2024 and 2023, the Company's net loss equaled its comprehensive loss and accordingly, no additional disclosure is presented. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred income taxes are recorded to reflect the tax consequences on future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to amounts that are more likely than not to be realized. The Company is subject to income taxes in the federal and state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting for uncertainty in income taxes, the Company recognizes tax liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is more likely than not (greater than 50%) of being realized upon settlement. The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. Note 3. Recently Issued Accounting Standards In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the condensed consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements. 15 Table of Contents Note 4. Sale of Orthobiologics Business As described in Note 2, on November 8, 2023, the Company completed the sale of its Orthobiologics Business. Accordingly, the Orthobiologics Business is reported as discontinued operations in accordance with ASC 205-20 - Discontinued Operations and the amounts for the three and six months ended June 30, 2023 have been recast to conform to this discontinued operations presentation. In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. The following table shows the financial results of the discontinued operations for the three and six months ended June 30, 2023. Additionally, a gain of \$0.2 million was recognized in the second quarter of 2024 related to the final working capital adjustment received from Berkeley.

	Three Months Ended June 30, 2023	Six Months Ended June 30, 2023
Net sales	\$ 3,945	\$ 10,603
Cost of goods sold	\$ 5,678	\$ 9,378
Gross profit	(1,733)	(1,225)
Sales and marketing	\$ 596	\$ 1,262
General and administrative	\$ 1,438	\$ 3,048
Research and development	\$ 304	\$ 513
Total operating expenses	\$ 1,043	\$ 2,079
Interest expense	\$ 115	\$ 230
Net income	\$ (2,891)	\$ (1,084)
Total operating and investing cash flows of discontinued operations for the six months ended June 30, 2023 are comprised of the following:		
Six Months Ended June 30, 2023		
Significant non-cash reconciliation items		
Depreciation	\$ 117	
Stock-based compensation	\$ 65	
Changes in operating assets and liabilities:		
Accounts receivable	(607)	
Inventory	(183)	
Prepaid expenses and other	(557)	
Accounts payable and accrued expenses and other current liabilities	\$ 1,156	
Obligations to tissue suppliers	(228)	
Significant investing items		
Expenditures for property, plant and equipment	(224)	
Net cash provided for the granting of incentive and non-qualified stock options to employees, directors and consultants of the Company. On October 7, 2020, in connection with the Company's initial public offering (IPO), the Company adopted the Elutia Inc. 2020 Incentive Award Plan, and on June 8, 2023, the Company's stockholders approved the amendment and restatement of that plan (as amended and restated, the 2020 Plan), which authorizes the grant of incentive and non-qualified stock options, restricted stock, restricted stock units and stock appreciation rights to employees, directors and consultants. A Shares of Class A common stock totaling 1,636,000 were initially reserved for issuance pursuant to the 2020 Plan, and in June 2023, the number of shares of Class A common stock reserved for issuance under the 2020 Plan was increased by 2,000,000 shares. In addition, the shares reserved for issuance under the 2020 Plan also include shares reserved but not issued under the 2015 Plan as well as an annual increase as set forth in the 2020 Plan. As of June 30, 2024, the Company had 405,909 shares of Class A common stock available for issuance under the 2020 Plan. Stock Options The Company's policy is to grant stock options at an exercise price equal to 100% of the market value of a share of Class A common stock at closing on the date of the grant. The Company's stock options generally have contractual terms of ten years and vest over a period of either three or four years from the date of grant. A summary of stock option activity under the Company's 2015 Plan and 2020 Plan for the six months ended June 30, 2024 is as follows:		
Weighted-Average Exercise Price	\$ 6.80	\$ 6.80
Weighted-Average Remaining Term	6.08	6.08
Contractual Intrinsic Value	\$ 3.59	\$ 3.59
Number of Shares	53,433	10,855
Price (in thousands)	(53,433)	(10,855)
Outstanding, December 31, 2023	1,501,193	878
Granted	1,790,654	3,598
Forfeited	(53,433)	(10,855)
Outstanding, June 30, 2024	3,238,414	5,236
Vested and exercisable, June 30, 2024	1,138,985	6,808
The weighted average grant date fair value of options granted during the six months ended June 30, 2024 was \$2.38. As of June 30, 2024, there was approximately \$4.6 million of total unrecognized compensation expense related to unvested stock options. These costs are expected to be recognized over a weighted-average period of 2.1 years. The Company uses the Black-Scholes model to value its stock option grants that vest based on the passage of time or the achievement of certain performance criteria and expenses the related compensation cost using the straight-line method over the vesting period. The fair value of stock options is determined on the grant date using assumptions for the estimated fair value of the underlying common stock, expected term, expected volatility, dividend yield, and the risk-free interest rate. Before the completion of the Company's IPO, the Board of Directors determined the fair value of common stock considering the state of the business, input from management, third party valuations and other considerations. The Company uses the simplified method for estimating the expected term used to determine the fair value of options. The expected volatility of the Class A common stock is partially based on the historical volatility of comparable companies in the industry whose share prices are publicly available. The Company uses a zero-dividend yield assumption as the Company has not paid dividends since inception nor does it anticipate paying dividends in the future. The risk-free interest rate approximates recent U.S. Treasury note auction results with a similar life to that of the option. The period expense is then determined based on the valuation of the options and is recognized on a straight-line basis over the requisite service period for the entire award. The following weighted-average assumptions were used to determine the fair value of time-based options granted during the three and six months ended June 30, 2024 and 2023:		
Six Months Ended June 30, 2024		
Expected term (years)	5.9	6.0
Risk-free interest rate	3.3%	3.9%
Volatility factor	63.8%	63.8%
Dividend yield	0%	0%
During the six months ended June 30, 2024, the Company granted 397,640 options that vest on a defined date following the U.S. Food and Drug Administration's (FDA) clearance of the Company's EluPro (referred to as 17 Table of Contents CanGaroRM during development) product. With the FDA's approval of EluPro in June 2024, such vesting will occur in mid-August 2024. Consistent with the above, these performance vesting options have been valued using the Black-Scholes model. The Company also granted 162,500 stock options that vest in equal installments upon the achievement of certain share price thresholds for twenty consecutive days of trading at each respective threshold. For these stock options, the Company accounted for the awards as market condition awards and used an option pricing model, the Monte Carlo model, to determine the fair value of the respective equity instruments and an expense		

RateA is subject to a floor of 2.75%. The agreement governing the SWK Loan Facility also includes an exit fee equal to 6.5% of the aggregate principal amount funded prior to termination plus \$62,500 and prepayment penalties equal to: (i) if such prepayment occurs prior to the first anniversary of the Closing Date, 2% of A the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the loan or 19 Table of Contents(ii) if such prepayment occurs after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination. The weighted average interest rate on the SWK Loan Facility was 13.6% and 13.0% for the three months ended June 30, 2024 and 2023, respectively and 13.6% and 12.9% for the six months ended June 30, 2024 and 2023, respectively.

On August 10, 2022, the Company issued to SWK Funding LLC a warrant (the "Class A Warrant") to purchase, in the aggregate, up to 187,969 shares of Class A common stock of the Company, \$0.001 par value per share at an exercise price of \$6.65 per share. The Class A Warrant is immediately exercisable for up to 187,969 shares of Class A common stock from time to time on or after the Closing Date. A The exercise price and number of shares of Class A common stock issuable upon exercise of the Class A Warrant are subject to adjustment in the event of stock dividends, stock splits and certain other events affecting the Class A common stock. Unless earlier exercised or terminated in accordance with its terms, the Class A Warrant will expire on the seventh anniversary of the Closing Date. Upon issuance, the Company valued the Class A Warrant at approximately \$0.6 million using the Black-Scholes model. The recognition of the Class A Warrant as well as deferred financing costs of approximately \$0.5 million incurred in securing the SWK Loan Facility served to reduce the recorded value of the associated debt. The debt discount and deferred financing costs will be recognized as interest expense through the maturity of the loan.

The SWK Loan Facility Agreement requires certain mandatory prepayments, subject to certain exceptions, with: (1) 100% of any net casualty proceeds in excess of \$250,000 and (2) for non-ordinary course asset sales, an amount equal to the difference between (x) the proportion of divested gross profit (as defined in the SWK Loan Facility Agreement) to the Company's total gross profit (as defined in the SWK Loan Facility Agreement) multiplied by the outstanding loans under the SWK Loan Facility and (y) the difference between \$1,000,000 and the aggregate sale proceeds of any assets previously sold during the fiscal year. No such mandatory prepayments were required during the three and six months ended June 30, 2024 and 2023.

A Long-term debt was comprised of the following (in thousands):

	June 30, 2024	December 31, 2023
Term Loan Facility, net of unamortized discount and deferred financing costs	\$22,322	\$23,677
Current Portion	(3,449)	(3,321)
Long-Term Debt	\$18,873	\$20,356

The fair value of all debt instruments, which is based on inputs considered to be Level 2 under the fair value hierarchy, approximates the respective carrying values as of June 30, 2024 and December 31, 2023.

Note 8. Revenue Interest Obligation On May 31, 2017, the Company completed an asset purchase agreement with CorMatrix Cardiovascular, Inc. (the "CorMatrix Acquisition") and acquired all CorMatrix commercial assets and related intellectual property (the "CorMatrix Acquisition"). As part of the CorMatrix Acquisition, the Company assumed a restructured, long-term obligation (the "Revenue Interest Obligation") to Ligand Pharmaceuticals Incorporated (the "Ligand") with an estimated present value on the acquisition date of \$27.7 million. Subject to annual minimum payments of \$2.75 million per year, the terms of the Revenue Interest Obligation required Elutia to pay Ligand, 5% of future sales of the products Elutia acquired from CorMatrix, including CanGaroo, ProxiCor, Tyke and VasCure, as well as products substantially similar to those products, such as the recently-approved EluPro product. Furthermore, a \$5.0 million payment would be due to Ligand if cumulative sales of these products exceed \$100 million and a second \$5.0 million will be due if cumulative sales exceed \$300 million during the ten-year term of the agreement which expires on May 31, 2027. On January 10, 2024, the Company entered into an amendment to the Revenue Interest Obligation (the "Amended Revenue Interest Obligation"). Pursuant to the Amended Revenue Interest Obligation, the parties modified and restructured the Revenue Interest Obligation by revising the annual minimum payments for 2024 and each subsequent fiscal year during the term of the agreement from \$2.75 million to \$4.4 million. Such minimums are payable quarterly within 30 days after each quarter-end date. Additionally, the Company made payments totaling \$3.0 million (50% paid 20 Table of Contentsin January 2024 and 50% paid in April 2024) in satisfaction of all royalty obligations for the first three fiscal quarters of 2023 and made a payment in February 2024 of \$1.1 million in satisfaction of the royalty obligations for the fourth quarter of 2023. Furthermore, as part of the Amended Revenue Interest Obligation, Ligand waived the Company's obligation to make the \$5.0 million milestone payment that became due to Ligand in the second quarter of 2023. Total payments to Ligand during the six months ended June 30, 2024 were \$5.2 million comprised of the aforementioned 2023 amounts due and a 2024 quarterly minimum payment of \$1.1 million.

The Company records the present value of the estimated total future payments under both the Revenue Interest Obligation and Amended Revenue Interest Obligation as a long-term obligation, with the short-term portion being recorded as described below. At each reporting period, the value of the Revenue Interest Obligation is re-measured based on current estimates of future payments, with changes to be recorded in the condensed consolidated statements of operations using the catch-up method. The Amended Revenue Interest Obligation changed the timing and extent of future payments by the Company to Ligand and such change to the estimated future payments yielded a reduction to the total obligation of approximately \$1.4A million during the six months ended June 30, 2024. The resulting gain was recognized as other expense (income), net in the accompanying condensed consolidated statement of operations. A Interest expense relating to the Revenue Interest Obligation of approximately \$0.4 million and \$0.5 million was recorded for the three months ended June 30, 2024 and 2023, respectively and approximately \$0.9 million and \$1.1 million was recorded for the six months ended June 30, 2024 and 2023, respectively.

As of June 30, 2024, the short-term portion of the Amended Revenue Interest Obligation is comprised of the newly established annual minimum payments of \$4.4 million. As of December 31, 2023, the short-term portion of the Initial Revenue Interest Obligation is comprised of (i) the 2023 and 2024 minimum payments, (ii) the first \$5.0 million sales milestone payment noted above and (iii) the unpaid portion of the 2022 minimum payments.

A Note 9: Common Stock and Warrants Registered Direct Offering of Common Stock and Warrants On June 16, 2024, the Company sold, in a registered direct offering (the "Registered Offering") an aggregate of (i) 3,175,000 shares of the Company's Class A common stock and (ii) prefunded warrants (the "2024 Prefunded Warrants") to purchase up to an aggregate of 725,000 shares of Class A Common Stock. The public offering price for each share of Class A Common Stock was \$3.40, and the public offering price for each 2024 Prefunded Warrant was \$3.399, for aggregate gross proceeds of approximately \$13.3 million, before deducting offering expenses. The 2024 Prefunded Warrants have an exercise price of \$0.001 per share of Class A Common Stock, are exercisable immediately and will expire when exercised in full. The Company incurred transaction fees, including commissions and legal fees, of approximately \$1.4 million in connection with the Registered Offering, of which \$1.1 million were allocated to the issuance of the common stock.

Private Placement of Common Stock and Warrants On September 21, 2023, the Company sold, in a private offering (the "Private Offering") an aggregate of (i) 6,852,811 units (the "Common Units") each comprised of (a) one share of the Company's Class A common stock and (b) a warrant (the "Common Warrant") to purchase one and one half shares of Class A Common Stock, and (ii) 503,058 units (the "Prefunded Units"), each comprised of (a) a prefunded warrant (the "2023 Prefunded Warrant") to purchase one share of Class A Common Stock, and (b) a Common Warrant. The Common Units were sold at a purchase price of \$1.4275 per unit, and the Prefunded Units were sold at a purchase price of \$1.4265 per unit, for aggregate gross proceeds of approximately \$10.5 million, before deducting offering expenses. Each Common Warrant is exercisable at any time until the earlier of (a) 30 trading days after the clearance by the FDA of the Company's EluPro product or (b) five years from the date of the offering, at an exercise price per share of \$1.4275. Each 2023 Prefunded Warrant is exercisable at any time at a nominal exercise price per share of \$0.001 (with the remainder of the exercise price per share of Class A Common Stock having been prefunded to the Company). The Company incurred transaction fees, including commissions and legal fees, of approximately \$1.1 million in connection with the Private Offering, of which \$0.4 million were allocated to the issuance of the common stock.

21 Table of ContentsSee below for discussion of the accounting for the warrants and the allocation of the remainder of the transaction fees from both the Registered Offering and Private Offering.

Warrant Liabilities The Company has concluded that the 2024 Prefunded Warrants from the Registered Offering and the Common Warrants and the 2023 Prefunded Warrants from the Private Offering do not meet the equity contract scope exception under ASC 815-40 as in the event of a (i) fundamental transaction such as a merger and (ii) failure to timely delivery warrant shares upon exercise, certain provisions may require the Company to adjust the settlement value that is not consistent with a fixed-for-fixed option pricing model. As a result, with respect to the 2024 Prefunded Warrants, the Company allocated \$2.5 million of the gross proceeds from the Registered Offering to such warrants based on their fair value. Similarly, with respect to the Common Warrants and 2023 Prefunded Warrants, the Company allocated \$8.6 million of the gross proceeds from the Private Offering to such warrants based on their fair value. Additionally, the Company allocated a portion of the transaction fees from both the Registered Offering and the Private Offering to the respective warrants and expensed within other expense (income), net. Such expenses totaled \$0.3 million during the three and six months ended June 30, 2024. No such expenses were recognized in the three and six months ended June 30, 2023.

The liability associated with the 2024 Prefunded Warrants, Common Warrants and 2023 Prefunded Warrants is recorded as warrant liability in the accompanying condensed consolidated balance sheet as of June 30, 2024 and December 31, 2023. A summary of the warrant activity for the six months ended June 30, 2024 is as follows:

	June 30, 2024	December 31, 2023
Issued	725,000	-
Exercised	(1,366,025)	(261,470)
Outstanding, June 30, 2024	9,667,719	241,588
Total Outstanding, December 31, 2023	9,667,719	241,588

The valuation of the warrants is adjusted to fair value (Level 3) at each subsequent balance sheet date until the warrants are settled. The following table provides a rollforward of the aggregate fair value of the warrant liability for the six months ended June 30, 2024 (in thousands):

	June 30, 2024	December 31, 2023
Total Offering Warrants	\$11,670	\$11,670
Exercise	(1,366)	(261)
Change in Fair Value	25,670	1,172
Exercise	(1,326)	(27,974)
Change in Fair Value	(3,116)	(1,064)
Warrant Liability, June 30, 2024	\$34,224	\$1,198

The fair value adjustments, which include \$18.3 million recognized during the three months ended June 30, 2024, were driven mainly by increases in the Company's stock price since December 31, 2023 and have been recorded as other expense (income), net in the accompanying condensed consolidated statements of operations for the three and six months ended June 30, 2024.

The Company calculated the fair value of the Common Warrants as of June 30, 2024 using the Black-Scholes option pricing model with the following inputs as of June 30, 2024 and December 31, 2023:

	June 30, 2024	December 31, 2023
Stock Price	\$4.96	\$2.16
Dividend Yield	0%	0%
Volatility Factor	88.4%	107.3%
Expected Term (years)	0.18	0.74
Risk-free interest rate	5.5%	5.1%

The expected term of the Common Warrants was a significant unobservable input, which includes the Company's probability-weighted expectations relative to the timing of the clearance by the FDA of the Company's CanGarooR antibiotic-eluting biologic envelope.

With the FDA's approval of EluPro in June 2024, the last exercise date for the Common Warrants was July 31, 2024. All Common Warrants outstanding as of June 30, 2024 were exercised by such date yielding exercise proceeds of \$13.8 million in July 2024.

The Company has used the price of its Class A Common Stock to estimate the fair value of the 2024 Prefunded Warrants and 2023 Prefunded Warrants at each measurement date. The price of the Company's Class A Common Stock approximates fair value of the 2024 Prefunded Warrants and 2023 Prefunded Warrants due to the exercise price per share of \$0.001.

Note 10. Commitments and Conting

[illegible]

Surgical infections reported in several patients treated with the product, including some patients who tested positive for tuberculosis. Additionally, in July 2023, we announced a voluntary recall of a single lot of one of our viable bone matrix (“vBMB”) products and the market withdrawal of all of our VBM products produced after a specified date. Notice of the voluntary recall was issued to centers after we learned of post-surgical tuberculosis infections in two patients treated with product from a single donor lot of our VBM product. Both of these products were part of our Orthobiologics Business, which we have fully divested as described above. For information about legal proceedings in which we are involved and the possible future financial implications, see Note 10 to condensed consolidated financial statements included elsewhere in this Quarterly Report.**Impact of Inflation**Inflationary factors, such as increases in our cost of goods sold or other operating expenses, may adversely affect our operating results. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, we do not believe inflation had a material effect on our financial condition or results of operations during the three or six months ended June 30, 2024 and 2023. We cannot assure you, however, that we will be able to increase the selling prices of our products or reduce our operating expenses in an amount sufficient to offset the effects future inflationary pressures may have on our gross margin. Accordingly, we cannot assure you that our financial condition and results of operations will not be materially impacted by inflation in the future.Components of Our Results of OperationsNet SalesWe recognize revenue on the sale of our products. Our device protection products are sold to hospitals and other healthcare facilities primarily through our direct sales force, commercial partners or independent sales agents. Our cardiovascular products are sold domestically through a distribution agreement with LeMaitre Vascular and internationally through commercial partners. Our women’s health products are sold directly to hospitals and other healthcare facilities through independent sales agents or through our distribution agreement with Tiger Aesthetics Medical after their acquisition of the assets of Sientra in April 2024. ExpensesIn recent years, we have incurred significant costs in the operation of our business. We expect that our recurring operating costs will largely stabilize, or increase at modest rates, in the near future through the identification of efficiencies as we grow. We may, however, still experience more significant expense increases to the extent we expand our sales and marketing, product development and clinical and research activities. As a result, we will need to generate significant net sales in order to achieve profitability. Below is a breakdown of our main expense categories and the related expenses incurred in each category:

Cost of Goods Sold

Our cost of goods sold relate to purchased raw materials and the processing and conversion costs of such raw materials consisting primarily of salaries and benefits, supplies, quality control testing and the manufacturing overhead incurred at our processing facilities in Roswell, Georgia and our former Orthobiologics facility in Richmond, California. The Roswell facility has additional capacity, which if utilized, would further leverage our fixed overhead. Cost of goods sold also includes the amortization of intangibles generated from the CorMatrix Acquisition in 2017.Sales and MarketingExpensesSales and marketing expenses are primarily related to our direct sales force, consisting of salaries, commission compensation, fringe benefits, meals and other expenses. Auto and travel costs also contribute to sales and marketing expenses. Outside of our direct sales force, we incur significant expenses relating to commissions to our CanGaroo and SimpliDerm commercial partners and independent sales agents. Additionally, this expense category includes distribution costs as well as market research, trade show attendance, advertising and public relations related to our products, and customer service expenses. General and AdministrativeExpensesGeneral and administrative expenses consist primarily of compensation, consulting, legal, human resources, information technology, accounting, insurance and general business expenses. Our G&A expenses have increased as a result of operating as a public company, especially as a result of hiring additional personnel and incurring greater director and officer insurance premiums, greater investor relations costs, and additional costs associated with accounting, legal, tax-related and other services associated with maintaining compliance with exchange listing and SEC requirements.Research and DevelopmentExpensesResearch and development expenses consist primarily of salaries and fringe benefits, laboratory supplies, clinical studies and outside service costs. Over the last several years, our product development efforts have been primarily related to activities associated with the development of EluPro (referred to as CanGaroORM during development), our initial DEB product offering. See above for discussion of the June 2024 FDA approval of EluPro. Future development efforts are expected to focus on (i) expanding the EluPro offering with additional sizes and product features and (ii) developing new products within the DEB product portfolio. We also conduct clinical studies to validate the performance characteristics of our products and to capture patient data necessary to support our commercial efforts.FiberCel Litigation CostsFiberCel litigation costs consist primarily of legal fees and the estimated costs to resolve the outstanding FiberCel litigation cases off-set by the estimated and actual amounts recoverable under insurance, indemnity and contribution agreements for such costs.

The following table sets forth certain components of our income statement for the periods indicated below, presented both in thousands and percentages of total net sales.

(in thousands)	% of Net Sales
Total net sales	\$698.4 million
Cost of goods sold	\$349.2 million
Gross profit	\$349.2 million
Selling, general & administrative	\$183.7 million
Research & development	\$116.3 million
Interest expense	\$1.2 million
Other income	\$0.1 million
Income before taxes	\$26.0 million
Taxes	\$1.7 million
Net income	\$24.3 million

The following table sets forth certain components of our cash flow statement for the periods indicated below, presented both in thousands and percentages of total net sales.

(in thousands)	% of Net Sales
Cash provided by operating activities	\$183.7 million
Cash used in investing activities	\$116.3 million
Cash used in financing activities	\$116.3 million
Change in cash	\$51.1 million

We provide detailed discussions regarding our operating results and financial position throughout this report. Please refer to the “Management Discussion and Analysis” section of this report for a more complete understanding of our business and its risks.

accordance with U.S. generally accepted accounting principles (“GAAP”), has limitations as an analytical tool and should not be considered in isolation or as an alternative to our GAAP gross margin, gross profit or any other financial performance measure presented in accordance with GAAP. We present gross margin, excluding intangible asset amortization, because we believe that it provides meaningful supplemental information regarding our operating performance by removing the impact of amortization expense, which is not indicative of our overall operating performance. We believe this provides our management and investors with useful information to facilitate period-to-period comparisons of our operating results. Our management uses this metric in assessing the health of our business and our operating performance, and we believe investors’ understanding of our operating performance is similarly enhanced by our presentation of this metric. In addition, other companies, including companies in our industry, may use other measures to evaluate their performance, which could reduce the usefulness of this non-GAAP financial measure as a tool for comparison.

36 Table of ContentsThe following table presents a reconciliation of our gross margin, excluding intangible asset amortization, for the three and six months ended June 30, 2024 and 2023 to the most directly comparable GAAP financial measure, which is our GAAP gross margin (in thousands).

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	Three Months Ended June 30, 2023	Six Months Ended June 30, 2023
GAAP Gross Margin	\$6,291,185	\$12,985,465	\$6,291,185	\$12,985,465
Intangible asset amortization	(1,699,948)	(3,492,248)	(1,699,948)	(3,492,248)
Gross margin, excluding intangible asset amortization	\$4,591,237	\$9,493,217	\$4,591,237	\$9,493,217

Historically, we have experienced seasonality, with lower sales in our first and second quarters and higher sales in our fourth quarter, and we expect this trend to continue. We have experienced and may in the future experience, higher sales in the fourth quarter as a result of hospitals in the United States increasing their purchases of our products to coincide with the end of their budget cycles. Satisfaction of patient deductibles throughout the course of the year also results in increased sales later in the year, once patients have paid their annual insurance deductibles in full, which reduces their out-of-pocket costs. Conversely, our first quarter generally has lower sales than the preceding fourth quarter as patient deductibles are re-established with the new year, which increases their out-of-pocket costs.

Liquidity and Capital ResourcesAs of June 30, 2024, we had cash of approximately \$18.2 million. Since inception, we have financed our operations primarily through amounts borrowed under our credit facilities, proceeds from our initial public offering (“IPO”), sales of our products and more recently, the sale of our Orthobiologics Business and proceeds from a follow-on offering and private placements of our common stock and warrants. Our historical cash outflows have primarily been associated with acquisitions and integration, manufacturing and administrative costs, general and marketing, research and development, clinical activity, purchase of property and equipment used in our production activities, litigation costs and investing in our commercial infrastructure through our direct sales force and our commercial partners in order to expand our presence and to promote awareness and adoption of our products. As of June 30, 2024, our accumulated deficit was \$221.8 million.

On June 18, 2024, we sold, in a registered direct offering (“Registered Offering”) an aggregate of (i) 3,175,000 shares (“Common Shares”) of the Company’s Class A common stock and (ii) prefunded warrants (“2024 Prefunded Warrants”) to purchase up to an aggregate of 725,000 shares of Class A Common Stock. The public offering price for each share of Class A Common Stock was \$3.40, and the public offering price for each 2024 Prefunded Warrant was \$3.399, for aggregate gross proceeds of approximately \$13.3 million, before deducting offering expenses. The 2024 Prefunded Warrants have an exercise price of \$0.001 per share of Class A Common Stock, are exercisable immediately and will expire when exercised in full.

On September 21, 2023, we sold, in a private offering (“Private Offering”) an aggregate of (i) 6,852,811 units (“Common Units”), each comprised of (a) one share of our Class A common stock and (b) a warrant (“Common Warrant”) to purchase one and one half shares of Class A Common Stock, and (ii) 503,058 units of the (“Prefunded Units”), each comprised of (a) a prefunded warrant (“2023 Prefunded Warrant”) to purchase one share of Class A Common Stock, and (b) a Common Warrant. The Common Units were sold at a purchase price of \$1.4275 per unit, and the 2023 Prefunded Units were sold at a purchase price of \$1.4265 per unit, for aggregate gross proceeds of approximately \$10.5 million, before deducting offering expenses. Each Common Warrant is exercisable at any time until the earlier of (a) 30 trading days after the clearance by the FDA of our CanGarooRM antibiotic-eluting biologic envelope or (b) five years from the date of the offering, at an exercise price per share of \$1.4275. Each 2023 Prefunded Warrant is exercisable at any time at a nominal exercise price per share of \$0.001 (with the remainder of the exercise price per share of Class A Common Stock having been prefunded to us). With the FDA’s approval of EluPro in June 2024 (referred to as CanGarooRM during development), the last exercise date for the Common Warrants was July 31, 2024. All Common Warrants outstanding as of June 30, 2024 were exercised by such date yielding exercise proceeds of \$13.8 million in July 2024.

We expect our losses to continue for the foreseeable future and these losses will continue to have an adverse effect on our financial position. Because of the numerous risks and uncertainties associated with our commercialization and development efforts, including our ability to successfully commercialize our new EluPro product, we are unable to predict when we will become profitable, and we may never become profitable. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.

In order to mitigate the current and potential future liquidity issues caused by the matters noted above, we may seek to raise capital through the issuance of common stock, such as the Registered Offering and Private Offering described above, pursue asset sale or other transactions, such as the sale of the Orthobiologics Business described above. However, such transactions may not be successful, and we may not be able to raise additional equity, refinance our debt instruments, or sell assets on acceptable terms, or at all. As such, based on our current operating plans, we believe there is uncertainty as to whether our future cash flows along with our existing cash, issuances of additional equity and cash generated from expected future sales will be sufficient to meet our anticipated operating needs through twelve months from the financial statement issuance date. Due to these factors, there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the financial statements.

Cash Flows for the Six Months Ended June 30, 2024 and 2023

	Six Months Ended June 30, 2024	Six Months Ended June 30, 2023
Operating Activities	\$7.0 million	\$7.6 million
Investing Activities	\$(0.2 million)	\$(0.2 million)
Financing Activities	\$(0.1 million)	\$(0.1 million)

The year-over-year decrease was primarily due to a lower net loss (excluding non-cash items) as well as reductions in inventory held.

Cash Flows From Investing ActivitiesNet cash provided by investing activities for the six months ended June 30, 2024 was \$0.2 million compared to net cash used in investing activities of \$0.3 million for the six months ended June 30, 2023. The current year period reflects the receipt of \$0.2 million in the second quarter of 2024 from an adjustment payment related to the final working capital received by Berkeley at the sale date. The prior year period use of cash is related to the purchase of property and equipment for our production activities.

Cash Flows From Financing ActivitiesNet cash provided by financing activities for the six months ended June 30, 2024 was \$5.7 million compared to \$0.1 million for the six months ended June 30, 2023. The year-over-year increase was caused primarily by the Registered Offering and warrant exercises which yielded proceeds of \$14.1 million offset by repayments of long-term debt and 38 Table of Contentspayments on the revenue interest obligation which collectively totalled \$7.2 million. No such activity occurred in the 2023 period.

Credit FacilitiesGeneralOn August 10, 2022 (the “Closing Date”), we entered into a senior secured term loan facility with SWK Funding LLC (“SWK”), as agent, and other lenders party thereto (as amended and modified subsequent to the Closing Date, the “SWK Loan Facility”) for an aggregate principal amount of \$25 million. An initial draw of \$21 million was made on the Closing Date with the additional \$4 million drawn on December 14, 2022 upon satisfaction of the amended terms enabling such receipt. The SWK Loan Facility also allows for the establishment of a separate, new asset-based revolving loan facility of up to \$8 million, which has not been entered into to date. As of June 30, 2024, we had \$23.0 million of indebtedness outstanding under our SWK Loan Facility, with such balance being net of \$0.7 million of unamortized discount and deferred financing costs.

Interest RatesAll of the SWK Loan Facility borrowings take the form of Secured Overnight Financing Rate (“SOFR”) loans and bear interest at a rate per annum equal to the sum of an applicable margin of (i) 7.75% and the SOFR Rate (based upon an interest period of 3 months), or (ii) if we have elected the PIK Interest option (as defined below) 3.75% and the SOFR Rate. We may elect a portion of the interest due, to be paid in-kind at a rate per annum of 4.5% (“PIK Interest”), and such election may be made (x) until November 15, 2024 if certain conditions, as defined, have not been met, or (y) if such conditions have been satisfied, until November 17, 2025. The SOFR Rate is subject to a floor of 2.75%.

Mandatory PrepaymentsThe SWK Loan Facility Agreement requires certain mandatory prepayments, subject to certain exceptions, with: (1) 100% of any net casualty proceeds in excess of \$250,000 and (2) for non-ordinary course asset sales, an amount equal to the difference between (x) the proportion of divested gross profit (as defined in the SWK Loan Facility) to the Company’s total gross profit (as defined in the SWK Loan Facility) multiplied by the outstanding loans under the SWK Loan Facility, and (y) the difference between \$1,000,000 and the aggregate sale proceeds of any assets previously sold during the fiscal year. The closing of the sale of the Orthobiologics Business in November 2023 triggered the mandatory prepayment of \$4.0 million. Of such amount, \$2.0 million was paid shortly after closing of the divestiture of the Orthobiologics Business and the remainder was paid on February 15, 2024 based on mutual agreement between the parties. No such mandatory prepayments were required in the six months ended June 30, 2023.

Optional PrepaymentThe agreement, as amended, governing the SWK Loan Facility also includes an exit fee equal to 6.5% of the aggregate principal amount funded prior to termination plus \$62,500A and prepayment penalties equal to: (i) if such prepayment occurs prior to the first anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the loan or (ii) if such prepayment occurs after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination.

Amortization and Final MaturityThe SWK Loan Facility matures on August 10, 2027 and accrues interest, payable quarterly in arrears. Principal amortization of the SWK Loan Facility starts on November 15, 2024, which amortization may be extended to November 17, 2025 if the Extension Conditions (as defined in the SWK Loan Facility Agreement) have been satisfied. Principal payments during the amortization period will be limited based on revenue-based caps. As of June 30, 2024, quarterly principal payments are scheduled to begin on November 15, 2024, in an amount equal to 5% of the outstanding principal on such principal payment commencement date with the balance paid at maturity.

SecurityAll obligations under the SWK Loan Facility are, and any future guarantees of those obligations will be, secured by, among other things, and in each case subject to certain exceptions, a first priority lien on and security interest in, upon, and to all of our assets, whether now owned or hereafter acquired, wherever located.

Covenants and Other MattersThe SWK Loan Facility Agreement that governs the SWK Loan Facility contains a number of covenants that, among other things and subject to certain exceptions, restrict our ability to:—incur additional indebtedness;—incur certain liens;—pay dividends or make other distributions on equity interests;—redeem, repurchase or refinance subordinated indebtedness;—consolidate, merge or sell or otherwise dispose of assets;—make investments, loans, advances, guarantees and acquisitions;—enter into transactions with affiliates;—amend or modify our governing documents;—amend or modify certain material agreements; and—alter the business conducted by us and our subsidiaries. In addition, the SWK Loan Facility Agreement contains two financial covenants. The first covenant, which is measured quarterly, requires us to achieve a specified Minimum Aggregate Revenue (as defined in the SWK Loan Facility) for the preceding 12-month period or, alternatively, to maintain Consolidated Unencumbered Liquid Assets (as defined in the SWK Loan Facility) greater than either (i) the outstanding principal balance of the loan, or (ii) the aggregate operating cash burn (as defined in the SWK Loan Facility) for the preceding 12-month period. The second covenant requires us to maintain a minimum liquidity (as defined in the SWK Loan Facility) of the greater of (a) \$5.0 million and (b) the sum of the operating cash burn for the two prior consecutive fiscal quarters then ended (the “Liquidity Covenant”).

On March 27, 2024, we entered into an amendment to the SWK Loan Facility Agreement, which modified the Minimum Aggregate Revenue covenant under the SWK Facility to provide that as of the last business day of each fiscal quarter of the Company beginning with the first fiscal quarter of 2024, our required Minimum Aggregate Revenue (as defined in the SWK Facility) for the trailing twelve-month period must be equal to or greater than \$20.0 million.

The SWK Loan Facility Agreement contains events of default, including, most significantly, a failure to timely pay interest or principal, insolvency, or an action by the FDA or such other material adverse event impacting the operations of Elutia. As of June 30, 2024, we were in compliance with the financial covenants and all other covenants.

40 Table of ContentsFunding RequirementsWe expect to continue to incur significant expenses and operating losses for the foreseeable future as we expand our product development and clinical and research activities. In addition, we expect to continue to incur significant costs and expenses associated with operating as a public company. As of June 30, 2024, we had \$22.3 million of indebtedness outstanding, consisting of \$23.0 million outstanding under our SWK Loan Facility, net of \$0.7 million of unamortized discount and deferred financing costs. Such indebtedness currently has a principal payment commencement date of November 15, 2024, with quarterly principal payments in an amount equal to 5% of the outstanding principal. In addition, we are party to a royalty agreement with Ligand Pharmaceuticals Incorporated (“Ligand”) pursuant to a long-term obligation to Ligand (the “Revenue Interest Obligation”). The Revenue Interest Obligation, as amended in January 2024, requires us to pay Ligand 5.0% of

condensed consolidated financial statements and compliance with GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We have discussed the policies and estimates that we believe are critical and require the use of complex judgment in their application in our Annual Report, and, during the three and six months ended June 30, 2024, there were no material changes to those previously disclosed other than those outlined in Note 2.

Summary of Significant Accounting Policies.

Recent Accounting Pronouncements. Refer to Note 3.

Recently Issued Accounting Standards. As to our condensed consolidated financial statements included elsewhere in this Quarterly Report for information regarding recently issued accounting pronouncements:

JOB Section 107 of the JOBS Act permits us, as an emerging growth company, to take advantage of an extended transition period for adopting new or revised accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, as a result, so long as we remain an emerging growth company, unless we subsequently choose to affirmatively and irrevocably opt out of the extended transition period, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies.

Section 107 of the JOBS Act provides that we can elect to opt out of the extended transition period at any time, which election is irrevocable. We will remain an emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues are \$1.235 billion or more; (ii) the last day of 2025; (iii) the date that we become a large accelerated filer as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common equity held by non-affiliates is \$700 million or more as of the last business day of our most recently completed second 42 Table of Contentsfiscal quarter; or (iv) the date on which we have issued more than \$1.0 billion in non-convertible debt securities during the previous three years.

Item 3. Quantitative and Qualitative Disclosures About Market Risk. We are exposed to market risks in the ordinary course of our business, including risks relating to changes in interest rates, foreign currency and inflation. The following discussion provides additional information regarding these risks.

Interest Rate Risk. Our primary exposure to market risk relates to changes in interest rates. Borrowings under our SWK Loan Facility bear interest at variable rates, subject to an interest rate floor. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control. A hypothetical 10% relative change in interest rates on our variable rate indebtedness outstanding at June 30, 2024 would not have had a material effect on our financial statements. We do not currently engage in hedging transactions to manage our exposure to interest rate risk.

Credit Risks. As of June 30, 2024, our cash was maintained with two financial institutions in the United States. While our deposit accounts are insured up to the legal limit, the balances we maintain may, at times, exceed this insured limit. We believe these financial institutions have sufficient assets and liquidity to conduct their operations in the ordinary course of business with little or no credit risk to us.

Foreign Currency Risk. Our business is primarily conducted in U.S. dollars. Any transactions that may be conducted in foreign currencies are not expected to have a material effect on our financial condition, results of operations or cash flows. As we grow our operations, our exposure to foreign currency risk could become more significant.

Item 4. Controls and Procedures.

Limitations on Effectiveness of Controls and Procedures. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures. The Company's management has evaluated, with the participation of the Chief Executive Officer and the Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of June 30, 2024.

Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings. From time to time, we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. For information about legal proceedings in which we are involved, see Note 10 to condensed consolidated financial statements included elsewhere in this Quarterly Report.

Item 1A. Risk Factors. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described as risk factors, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. For a discussion of these potential risks and uncertainties, see Part I, Item 1A. **Risk Factors** of our Annual Report. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock. There have been no material changes in our risk factors to those included in our Annual Report.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures. Not applicable.

Item 5. Other Information. During the three months ended June 30, 2024, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K).

Table of Contents

Item 6. Exhibits.

Exhibit Number | **A Description** | **Form File No.** | **Exhibit Filing Date** | **Furnished Herewith**

8-K001-395774.16/18/2024 | **Second Amendment to Credit Agreement, dated March 27, 2024, by and among Elutia Inc., SWK Funding LLC, as Agent, and the Lenders from time to time party thereto.** | **8-K001-395771.14/1/2024** | **10.12a** | **Placement Agency Agreement, dated June 16, 2024, by and between Elutia Inc. and Lake Street Capital Markets, LLC.** | **8-K001-395771.16/18/2024** | **10.3a** | **Form of Securities Purchase Agreement.** | **8-K001-395771.10.26/18/2024** | **10.31** | **Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.** | **8-K001-395771.10.26/18/2024** | **10.31** | **Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.** | **8-K001-395771.10.26/18/2024** | **10.31** | **Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** | **8-K001-395771.10.26/18/2024** | **10.31** | **Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** | **8-K001-395771.10.26/18/2024** | **10.31** | **INS&E Online XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.** | **8-K001-395771.10.26/18/2024** | **10.31** | **SCH&E Online XBRL Taxonomy Extension Schema Document.** | **8-K001-395771.10.26/18/2024** | **10.31** | **CAL&E Online XBRL Taxonomy Extension Calculation Linkbase Document.** | **8-K001-395771.10.26/18/2024** | **10.31** | **DEF&E Online XBRL Taxonomy Extension Definition Linkbase Document.** | **8-K001-395771.10.26/18/2024** | **10.31** | **LAB&E Online XBRL Taxonomy Extension Label Linkbase Document.** | **8-K001-395771.10.26/18/2024** | **10.31** | **PRE&E Online XBRL Taxonomy Extension Presentation Linkbase Document.** | **8-K001-395771.10.26/18/2024** | **10.31** | **COVER Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).** | **8-K001-395771.10.26/18/2024** | **10.31** | **Filed herewith.** | **8-K001-395771.10.26/18/2024** | **10.31** | **Furnished herewith.** | **8-K001-395771.10.26/18/2024** | **10.31** | **Cover Contents** | **SIGNATURES** | **Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.** | **ELUTIA INC.** | **Date:** August 13, 2024 | **By:** /s/ C. Randal Mills, Ph.D. | **&C.** | **Randal Mills, Ph.D.** | **&C.** | **President and Chief Executive Officer** | **&C.** | **(principal executive officer)** | **Date:** August 13, 2024 | **By:** /s/ Matthew Ferguson | **&C.** | **Matthew Ferguson** | **&C.** | **Chief Financial Officer** | **&C.** | **(principal financial officer and principal accounting officer)** | **&C.** | **EX-31.2 elut-20240630ex31d1.htm EX-31.1 Exhibit 31.1a CERTIFICATION** | **&C.** | **C. Randal Mills, Ph.D., certify that:** | **&C.** | **I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 of Elutia Inc.;** | **&C.** | **2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;** | **&C.** | **3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;** | **&C.** | **4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:** | **&C.** | **(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;** | **&C.** | **(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;** | **&C.** | **(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and** | **&C.** | **(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and** | **&C.** | **5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):** | **&C.** | **(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record,**

Significant Accounting Policies - Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 99940204 - Disclosure - Summary of Significant Accounting Policies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 99940206 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 99940207 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit risk (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - Sale of Orthobiologics Business - Non-cash reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - Stock-Based Compensation - Option Valuation Assumption (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940505 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99940506 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Long-Term Debt - SWK Loan Facility (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Revenue Interest Obligation - (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Common Stock and Warrants - Registered Direct Offering of Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Common Stock and Warrants - Private Placement of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Common Stock and Warrants - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940904 - Disclosure - Common Stock and Warrants - Warrants fair value rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 99940905 - Disclosure - Common Stock and Warrants - Warrant pricing inputs (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Commitment and Contingencies - License and Supply (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Commitment and Contingencies - Legal Proceedings (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Net Loss Per Share - Anti-dilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Recently Issued Accounting Standards link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Sale of Orthobiologics Business link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Revenue Interest Obligation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Common Stock and Warrants link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99920302 - Disclosure - Recently Issued Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Sale of Orthobiologics Business (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99940205 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Segment Information - Reconciliation of segment gross profit (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 elut-20240630_cal.xml EX-101.CAL EX-101.DEF 8 elut-20240630_def.xml EX-101.DEF EX-101.LAB 9 elut-20240630_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Class A Common stock Class A Common stock Class B Common stock Document Information [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filter Category Entity Small Business Entity Emerging Growth Company Entity EX Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net Inventory, Net Inventory Total Loss Contingency, Receivable, Current Receivables of litigation costs Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Other Assets, Noncurrent Operating lease right-of-use assets and other Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity (Deficit) Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Represents the amount payables to tissue suppliers, classified as current. Payables to Tissue Suppliers, Current Payables to tissue suppliers Short-term Debt Current portion of long-term debt Amount of revenue interest obligation, classified as current. Revenue Interest Obligation, Current Current portion of revenue interest obligation Estimated Litigation Liability, Current Contingent liability for legal proceedings Other Liabilities, Current Current operating lease liabilities Liabilities, Current Total current liabilities Long-term Debt, Excluding Current Maturities Long-term debt Amount of revenue interest obligation, classified as noncurrent. Revenue Interest Obligation, Noncurrent Long-term revenue interest obligation Warrants and Rights Outstanding Warrant liability Warrant liability value Warrant liability Other Liabilities, Noncurrent Other long-term liabilities Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Common Stock and Warrants Stockholders' equity (deficit): Common Stock, Value, Issued Common stock Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Balance at the ending Balance at the beginning Total stockholders' deficit Liabilities and Equity Total liabilities and stockholders' deficit Common Stock, Par or Stated Value Per Share Common stock, par value (in dollar per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenue from Contract with Customer, Including Assessed Tax Net sales Total sales Cost of Goods and Services Sold Cost of goods sold Gross Profit Gross profit Gross profit Selling and Marketing Expense Sales and marketing Sales and marketing General and Administrative Expense General and administrative Research and development Research and Development Expense Research and development Research and development Legal Fees FiberCel litigation costs, net FiberCel litigation costs, net Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Interest Expense Interest expense Fair Value Adjustment of Warrants Fair value adjustment Change in fair value Loss on revaluation of warrant liability Other Nonoperating Income (Expense) Other expense (income), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before provision for income taxes Income Tax Expense (Benefit) Income tax expense (benefit) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net loss from continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (loss) from discontinued operations Net loss Net loss Net loss Income (Loss) from Continuing Operations, Per Basic Share Net loss from continuing operations per share - basic (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Net loss from continuing operations per share - diluted (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Net income (loss) from discontinued operations per share - basic (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Net income (loss) from discontinued operations per share - diluted (in dollars per share) Earnings Per Share, Basic Net loss per share - basic (in dollar per share) Earnings Per Share, Diluted Net loss per share - diluted (in dollar per share) Weighted Average Number of Shares Outstanding, Basic Weighted average common shares outstanding - basic (in shares) Weighted average number of common shares, basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average common shares outstanding - diluted (in shares) Weighted average number of common shares, diluted (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-in Capital Accumulated Deficit Increase (Decrease) in Stockholders' Equity (Roll Forward) Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, Outstanding Balance at the ending (in shares) Balance at the beginning (in shares) Stock Issued During Period, Value, Conversion of Convertible Securities Exercises of Common Warrants and Prefunded Warrants Stock Issued During Period, Shares, Conversion of Convertible Securities Exercises of Common Warrants and Prefunded Warrants (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under Employee Stock Purchase Plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under Employee Stock Purchase Plan (in shares) Shares issued under ESPP Stock Issued During Period, Value, Restricted Stock Award, Gross Vesting of restricted stock units, net of shares withheld and taxes paid Stock Issued During Period, Shares, Restricted Stock Award, Gross Vesting of restricted stock units, net of shares withheld and taxes paid (in shares) APIC, Share-based Payment Arrangement, Increase for Cost Recognition Stock-based compensation Stock Issued During Period, Value, New Issues Issuance of common stock in connection with registered direct offering, net of issuance costs of \$1.1 million (in shares) Sale of Stock [Axis] Sale of Stock [Domain] Information on Registered Direct Offering of Common Stock and Warrants. Registered Direct Offering of Common Stock and Warrants [Member] Registered Direct Offering of Common Stock and Warrants Payments of Stock Issuance Costs Issuance and offering costs Amount allocated to issuance of the common stock CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Gain (Loss) on Disposition of Business Gain on sale of Orthobiologics Business Gain on sale of Orthobiologics Business The amount of gain (loss) on revaluation of revenue interest obligation and other. Gain (Loss) On Revaluation Of Revenue Interest Obligation And Other Gain on revaluation of revenue interest obligation The amount of interest expense recorded as additional revenue interest obligation. Interest Expense Recorded As Additional Revenue Interest Obligation Interest expense recorded as additional revenue interest obligation or long-term debt Amortization of Debt Issuance Costs Amortization of deferred financing costs and debt discount Share-based Payment Arrangement, Noncash Expense Stock-based compensation Accounts Receivable, Credit Loss Expense (Reversal) Bad debt expense Amount of losses on product recall and market withdrawal. Losses on Product Recall and Market Withdrawal Losses associated with viable bone matrix recall and market withdrawal Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Insurance Settlements Receivable Receivables of litigation costs Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other Amount of increase (decrease) in accounts payable and accrued expenses and payables to tissue suppliers. Increase (Decrease) in Accounts Payable and Accrued Expenses and Payables to Tissue Suppliers Accounts payable and accrued expenses and payables to tissue suppliers Amount of increase (decrease) in contingent liability. Increase (Decrease) Contingent Liability Contingent liability for legal proceedings Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable and other liabilities. Increase (Decrease) in Contract with Customer, Liability And Other Liabilities Other liabilities Net Cash Provided by (Used in) Operating Activities Cash used in operating activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] INVESTING ACTIVITIES: Proceeds from Divestiture of Businesses Proceeds from sale of Orthobiologics Business Payments to Acquire Property, Plant, and Equipment Expenditures for property, plant and equipment Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] FINANCING ACTIVITIES: Proceeds from Issuance of Common Stock Gross proceeds allocated to common shares Proceeds from direct registered offering and warrants, net of offering costs Repayments of Long-term Debt Repayments of long-term debt Proceeds from Warrant Exercises Proceeds from exercises of Common Warrants and Prefunded Warrants The cash outflow on payments on revenue interest obligation. Payments On Revenue Interest Obligation Payments on revenue interest obligation Amount of cash outflow to repay insurance premium financings. Repayments of Insurance Premium Financings Repayments of insurance premium financings Payment, Tax Withholding, Share-Based Payment Arrangement Payments for taxes upon vesting of restricted stock units Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Proceeds from sales of common stock through Employee Stock Purchase Plan Payments of Financing Costs Deferred financing costs Deferred financing costs Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net decrease in cash and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest The amount of fair value of warrants issued. Fair Value of Warrants Issued Fair value of warrants issued The value of the operating lease right-of-use asset extensions executed not resulting in cash receipts or cash payments in the period. Operating Lease Right-of-Use Asset Extensions Operating lease right-of-use asset extensions executed The value of the common stock that warrants are being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Common Stock Issued Upon Conversion Warrants Conversion of Common Warrants and Prefunded Warrants to common stock Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Description of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Recently Issued Accounting Standards Accounting Standards Update and Change in Accounting Principle [Text Block] Recently Issued Accounting Standards Sale of Orthobiologics Business Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Sale of Orthobiologics Business Stock-Based Compensation Share-based Payment Arrangement [Text Block] Stock-Based Compensation Inventory Inventory Disclosure [Text Block] Inventory Long-Term Debt Debt Disclosure [Text Block] Long-Term Debt No definition available. Revenue Interest Obligation The entire disclosure on revenue interest obligation. Revenue Interest Obligation [Text Block] Revenue Interest Obligation Stockholders' Equity Note Disclosure [Text Block] Common Stock and Warrants Commitment and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitment and Contingencies Net Loss Per Share Earnings Per Share [Text Block] Net Loss Per Share Segment Information Segment Reporting Disclosure [Text Block] Segment Information Basis of Accounting, Policy [Policy Text Block] Basis of Presentation and Liquidity Use of Estimates, Policy [Policy Text Block] Use of Estimates Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Attributable to Common Stockholders Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Accounts Receivable [Policy Text Block] Accounts Receivable and Allowances Inventory, Policy [Policy Text Block] Inventories Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Lessee, Leases [Policy Text Block] Leases Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Long-Lived

Assets Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Share-based Payment Arrangement [Policy Text Block] Stock-Based Compensation Plans Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Standards The tabular disclosure of estimated useful lives of the assets. Schedule Of Estimated Useful Lives Of Assets [Table Text Block] Summary of estimated useful lives of the assets Disposal Groups, Including Discontinued Operations [Table Text Block] Schedules of assets and liabilities, financial results and cash flow reconciliation of the discontinued operations Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of stock options outstanding, exercisable and vested or expected to vest Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of weighted-average assumptions were used to determine the fair value of options Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] Schedule of RSU activity Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation expense recognized Schedule of Inventory, Current [Table Text Block] Summary of inventory Schedule of Debt [Table Text Block] Summary of PPP loan recorded within long-term debt Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Fair Value by Liability Class [Domain] Liability related to security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Warrant Liability [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Tabular disclosure of warrants. Warrants Activity [Table Text Block] Summary of the Offering Warrants activity Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of rollover of the aggregate fair value of the warranty liability Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Schedule of inputs used to calculate fair value of Common Warrants Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of net loss per share attributable to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potential common shares excluded from calculation, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of sales information Schedule reflecting accounting policies. Accounting Policies [Table] Disposal Group Name [Axis] Disposal Group Name [Domain] This member stands for Orthobiologics Business. Orthobiologics Business [Member] Divestiture of Orthobiologics Disposal Group Classification [Axis] Disposal Group Classification [Domain] Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] Discontinued Operations, Held-for-sale or Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Accounting Policies [Line Items] Amount of consideration receivable after closing in the form of earn-out payments to be received for the disposal of assets and liabilities, including discontinued operation. Disposal Group, Including Discontinued Operation, Consideration, Payable After Closing Purchase price due after closing in the form of earn-out payments The percent on actual revenue payable to the selling entity by the buying entity in the applicable year that is derived from sales of the Products defined as "Earn-Out Products" under the Purchase Agreement, Disposal Group, Including Discontinued Operation, Consideration, Payable After Closing, Earn-Out On Revenue, Percent Earn-out payments, as a percent actual revenue Discontinued Operation, Period of Continuing Involvement after Disposal Earn-out period Represents the amount of earn-out payments received during the reported period under the sale of entity's assets and business. Disposal Group Including Discontinued Operation, Earn Out Amount Earn-out payments received Represents the indemnity holdback amount to be held by buyer under the purchase agreement. Disposal Group Including Discontinued Operation, Indemnity Holdback Amount Indemnity holdback amount Represents the indemnity hold back retention period by buyer under the purchase agreement. Disposal Group Including Discontinued Operation, Indemnity Holdback Amount, Retainment Period Retainment Period Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Recognized a gain Schedule of Stock by Class [Table] Class of Stock [Line Items] Net Loss per Share Attributable to Common Stockholders Property, Plant and Equipment [Table] Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum Maximum Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Represents the information pertaining to processing and research equipment. Processing and research equipment Office equipment and furniture Computer hardware and software Property, Plant and Equipment [Line Items] Property, Plant and Equipment Property, Plant and Equipment, Useful Life Estimated useful lives Accounting Standards Update and Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Recently Issued Accounting Standards Operating lease right-of-use assets and other Right-of-use assets Operating Lease, Liability Lease liabilities Lessee, Operating Lease, Liability, Payment, Due [Abstract] Future minimum lease commitments under non-cancelable operating leases Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year For the six months ended December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Year ended December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Year ended December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Year ended December 31, 2027 Long-Lived Assets Impairment of Long-Lived Assets to be Disposed of Impairment losses Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue Represents the term for payment for contracts with customers. Revenue From Contract With Customer, Term of Payment Term of payment Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Revenues Accounts Receivable Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer concentration risk Customer [Axis] Customer [Domain] Represents one major customer of the entity. Customer One [Member] One Customer Represents another major customer of the entity. Customer Two [Member] Another customer Concentration Risk [Line Items] Number of major customers. Number Of Major Customers Number of major customer Concentration Risk, Percentage Concentration risk (as a percent) Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Sale of Orthobiologics Business Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Financial results Disposal Group, Including Discontinued Operation, Revenue Net sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Cost of goods sold Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Gross profit Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Sales and Marketing Expense Sales and marketing Disposal Group, Including Discontinued Operation, General and Administrative Expense General and administrative Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Research and Development Expense Research and development Disposal Group, Including Discontinued Operation, Operating Expense Total operating expenses Disposal Group, Including Discontinued Operation, Interest Expense Interest Expense Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Net income (loss) Net Cash Provided by (Used in) Discontinued Operations [Abstract] Significant operating non-cash reconciliation items: Depreciation and Amortization, Discontinued Operations Depreciation Amount of stock-based compensation attributable discontinued operations. Stock-based Compensation, Discontinued Operations Stock-based compensation No definition available. Changes in Operating Assets and Liabilities, Discontinued Operations [Abstract] Changes in operating assets and liabilities: The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services, attributable to discontinued operations. Increase (Decrease) in Accounts Receivable, Discontinued Operations Accounts receivable The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities, attributable to discontinued operations. Increase (Decrease) in Inventory, Discontinued Operations Inventory Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods, attributable to discontinued operations. Increase (Decrease) in Prepaid Expenses, Other, Discontinued Operations Prepaid expenses and other The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received, the amount of obligations and expenses incurred but not paid, and other current liabilities, attributable to discontinued operations. Increase (Decrease) in Accounts Payable, Accrued Liabilities and Other, Discontinued Operations Accounts payable and accrued expenses and other current liabilities The increase (decrease) during the reporting period in the amounts payable to tissue suppliers, attributable to discontinued operations. Increase (Decrease) in Obligations to Tissue Suppliers, Discontinued Operations Obligations to tissue suppliers Discontinued Operation, Alternative Cash Flow Information [Abstract] Significant investing items: Capital Expenditure, Discontinued Operations Expenditures for property, plant and equipment Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to 2020 plan. 2020 Plan Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-Based Compensation Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Grant of equity awards authorized Common stock reserved for future issuance Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease) Increase in number of shares reserve for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares available for grant Awards available for grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted Granted Options to purchase common stock Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time subject to specified product approval. Performance Based Options, Product Approval [Member] Options that vest 10th day after FDA's approval of CanGarooRM product Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time for meeting certain market conditions. Performance Based Options, Market Conditions [Member] Options that vest on achievements of price thresholds Represents the exercise price as a percentage of market value of share of common stock at closing on the date of the grant. Exercise Price As A Percentage Of Market Value Of Share Of Common Stock Exercise price as a percentage of market value of share of common stock at closing on the date of the grant Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Contractual term Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the end Outstanding at the beginning Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Vested and exercisable at the end Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end (in dollars per share) Outstanding at the beginning (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vested and exercisable at the end (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-Average Remaining Contractual Term (years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Vested and exercisable (in years) No definition available. Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Vested and exercisable at the end (in dollars) Share-based Payment Arrangement, Additional Disclosure [Abstract] Other Disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value of options granted Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted-average recognition period The period over which share price threshold is calculated for performance awards to vest, in 'PnYnMnDnThnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share Based Compensation, Performance Based, Share Price, Period Share price threshold period Expected expense recognition period of award under share-based payment arrangement, in 'PnYnMnDnThnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Expense Recognition Term Period to recognize costs Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted-average assumptions were used to determine the fair value of options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield assumption to estimate fair value Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility factor Restricted stock units Restricted stock units Share instrument which is convertible to stock or an equivalent amount of cash, after a specified product approval. Restricted Stock Units, Product Approval [Member] RSUs that vest 10th day after FDA's approval of CanGarooRM product Share instrument which is convertible to stock or an equivalent amount of cash, after a specified market conditions are met. Restricted Stock Units, Market Conditions [Member] RSUs that vest on achievements of price thresholds Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of Shares Underlying RSUs Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Outstanding at the end Unvested at the beginning Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unvested at the ending (in dollars per share) Unvested at the beginning (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Fair value of share-based awards granted. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value Total fair value of the restricted stock units granted Period over which share price must exceed pre-determined price by certain date as a vesting condition, in a share-based agreement, in 'PnYnMnDnThnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Share-based Payment Arrangement, Share Price Period for Vesting Period over which price must exceed \$10 for awards to vest Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation costs Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Employee Stock Purchase Plan Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock-Based Compensation The offering period of employee stock purchase plan, in 'PnYnMnDnThnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Employee Stock Purchase Plan, Offering Period Offering period Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Price of the common stock purchased as percentage of fair market value of common stock Income Statement Location [Axis] Income Statement Location [Domain] Sales and marketing General and administrative Research and development Cost of goods sold Share-based Payment Arrangement, Expense Stock-based compensation expense Inventory, Current [Table] Inventory [Line Items] Inventory Inventory, Raw Materials, Net of Reserves Raw materials

Inventory, Work in Process, Net of Reserves Work in process Inventory, Finished Goods, Net of Reserves Finished goods Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents term loan facility agreement with SWK Funding LLC. SWK Loan Facility Represents new asset-based revolving loan facility. New Asset-Based Revolving Loan Facility Debt Instrument [Line Items] Long-Term Debt Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Proceeds from Issuance of Debt Quarterly principal amortization as a percentage of the funded amount at the time of the closing of the loan facility agreement. Debt Quarterly Principal Amortization, As Percent To Funded Amount Quarterly principal amortization (percent) Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate Percentage points added to the reference rate to compute the in-kind variable rate on the debt instrument. Debt Instrument, Basis Spread on Variable Rate, In Kind Interest in-kind spread basis Interest rate in kind on debt instrument as an option for interest payment. Debt Instrument, Interest In Kind The fee, expressed as a percentage of the debt instrument, for exit. Debt Instrument, Exit Fee, Percent Exit fee (as a percent) The termination fee amount added to the exit fee percent of the aggregate principal amount funded prior to termination.transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Debt Instrument, Exit Fee, Percentage Plus Amount Exit fee termination plus The percentage of pre-payment penalties prior to first anniversary of the debt, as a percentage of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the debt. Debt Prepayment Penalties, Prior to First Anniversary Prepayment penalty prior to first anniversary (as a percent) The pre-payment penalty after first anniversary, expressed as a percentage of the outstanding principal amount of debt, Debt Prepayment Penalties, After First Anniversary Prepayment penalty after first anniversary (as a percent) Debt Instrument, Interest Rate During Period Weighted average interest rate Number of new warrants issued during the period. Warrants Issued During Period Warrants issued Warrants sold Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollar per share) The maximum number shares issuable in the exercise of warrants at the closing date of a financing. Maximum Issuable Shares For Warrants At Closing Of Financing Maximum shares issuable at closing Warrants Not Settled in Cash, Fair Value Disclosure Warrant value The percentage of mandatory redemption of term loan facility amount of any casualty proceeds in excess of \$250,000 with respect to assets upon which the lender or agent maintains a lien. Loan Facility Mandatory Prepayment Percentage Casualty Proceeds of Security Percentage of casualty proceeds in excess of \$250,000 to redeem loan balance The amount of threshold of casualty proceeds of assets upon which the lender or agent maintains a lien in excess of which is to redeem the loan balance Loan Facility Mandatory Prepayment Casualty Proceeds of Security Excess Casualty proceeds threshold amount in excess of which is used to redeem loan balance The threshold amount of non-ordinary course asset sales in excess of which is exempted from mandatory prepayment. Loan Agreement Covenant, Threshold Amount of Asset Sale, Mandatory Prepayment Threshold amount in excess of which exempted from mandatory prepayment Long-term Debt, Fiscal Year Maturity [Abstract] Contractual maturities of the long-term debt Long-term Debts Term Loan Facility, net of unamortized discount and deferred financing costs Long-term Debt, Current Maturities Current Portion Scenario [Axis] Scenario [Domain] Represents the scenario when cumulative sales of products exceed \$100.0. Cumulative sales of products exceed \$100M Represents the scenario when cumulative sales of products exceed \$300.0. Cumulative sales of products exceed \$300M Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to Ligand Pharmaceuticals. Ligand Pharmaceuticals Represents information pertaining to revenue interest obligation. Revenue Interest Obligation. Debt Instrument, Fair Value Disclosure Present value of future minimum payments of obligation The amount of minimum sales in revenue interest obligation agreement. Revenue Interest Obligation, Annual Minimum Sale Annual minimum sale Represents the percentage of future sales for revenue interest obligation. Revenue Interest Obligation, Percentage of Future Sales Percentage of future sales Represents the amount of payments due based on cumulative sales. Revenue Interest Obligation, Payments Due Based on Cumulative Sales Payments due based on cumulative sales The amount of cumulative sales as basis of the amount due in revenue interest obligation agreement. Revenue Interest Obligation, Cumulative Sales Cumulative sales Represents the term of agreement. Revenue Interest Obligation, Agreement Term Term of agreement Amount of payment agreed to pay upon satisfaction of all royalty obligations for the first three fiscal quarters of 2023. Revenue Interest Obligation, Payment Agreed upon Satisfaction of Royalty Obligations for First Three Quarters of 2023 Payment agreed upon satisfaction of royalty obligations for first three quarters Amount of payment agreed to pay upon satisfaction of all royalty obligations for the fourth quarter of 2023. Revenue Interest Obligation, Payment Agreed upon Satisfaction of Royalty Obligations for Fourth Quarter of 2023 Payment agreed upon satisfaction of royalty obligations for the fourth quarter Represents the percentage of payment made of the total amount paid for revenue interest obligation. Revenue Interest Obligation, Percentage of Payments Made Percentage of payment made Gains (Losses) on Restructuring of Debt Waiving of milestone payment under revenue interest obligation. Revenue Interest Obligation, Milestone Payment Waiver Amount Milestone payment waived amount Amount of payment under revenue interest obligation during the reported period. Revenue Interest Obligation, Payment In Period Total payments Amount of payment related to current fiscal period obligations under revenue interest obligation during the reported period. Revenue Interest Obligation, Payment For Current Period 2024 quarterly minimum payment Interest Expense, Debt Interest expense related to revenue interest obligation The current amount of revenue of interest obligation arising from the current period annual minimum payment obligation. Revenue Interest Obligation, Current from Current Year Short term revenue interest obligation from current period amendment Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] This member stands for prefunded stock warrant issued in 2024. Prefunded Warrants, 2024 [Member] 2024 Prefunded Warrants Subsidiary, Sale of Stock [Line Items] Private Placement of Common Stock Common Stock and Warrants Sale of Stock, Number of Shares Issued in Transaction Shares issued Shares sold (in shares) Sale of Stock, Price Per Share Price per share (in USD per share) Per share amount received for each share of warrant sold in the stock transaction. Warrant Price Per Share Price per warrant (in USD per share) Sale of Stock, Consideration Received on Transaction Proceeds from issuance of shares Payment of Financing and Stock Issuance Costs Private placement fees Transaction fees Warrant [Member] Warrants Outstanding Offering Warrants This member stands for common stock warrant. Common stock warrants Common stock warrants This member stands for prefunded stock warrant issued in 2023. Prefunded Warrants, 2023 [Member] 2023 Prefund Warrants This member stands for prefunded stock warrant. Prefunded Warrants [Member] Prefunded Warrants Private Placement [Member] Private Placement The number of common units sold during the reported period. Common Units Sold Aggregate Common units sold The number of common stocks for each common units old during the reported period. Common Units Sold Number Of Stock Each Unit Number of common stock per unit Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of common stock per warrant (in shares) The number of prefunded units sold during the reported period. Prefunded Units Sold Number of Prefunded Units to sell Amount paid per common units sold. Common Units Sold Price Per Share Common unit purchase price (in dollar per unit) Amount paid per prefunded units sold. Prefunded Units Sold Price Per Share Prefunded unit purchase price (in dollar per unit) Proceeds from Issuance of Private Placement Proceeds from private placement and warrants The number of trading days after the approval of a product to exercise warrants. Warrant Number Of Trading Days To Exercise After Approval Of Product Number of trading days after clearance by the U.S. Food & Drug Administration of the Company's CanGarooRM antibiotic-eluting biologic envelope to exercise warrant Warrants and Rights Outstanding, Term Warrants term Class of Warrant or Right [Table] Information on Registered Direct Offering of Common Stock and Warrants and Private Placements Registered Direct Offering of Common Stock and Warrants and Private Placement [Member] Registered Direct Offering of Common Stock and Warrants and Private Placement Class of Warrant or Right [Line Items] Warrants Class of Warrant or Right, Outstanding Outstanding Number of warrants or rights issued during the period. Class of Warrant or Right, Issued Issued Number of warrants or rights exercised during the period. Class of Warrant or Right, Exercised Exercised Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Fair value upon issuance Value of exercised derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price Warrants and Rights Exercised Exercised Fair Value Measurement Inputs and Valuation Techniques [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement input using common stock price. Measurement Input, Common Stock Price [Member] Common stock price Measurement Input, Expected Term [Member] Expected term (years) Measurement Input, Risk Free Interest Rate [Member] Risk-free interest rate Measurement Input, Price Volatility [Member] Volatility factor Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrant Liabilities Warrants and Rights Outstanding, Measurement Input Fair value calculation input Proceeds from Issuance of Warrants Proceeds from exercise of warrants Other Commitments [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents the information pertaining to license agreement with Cook Biotech. License agreement with Cook Biotech Other Commitments [Line Items] Cook Biotech License and Supply Agreements Represents the information pertaining to percentage of royalty o sales. Percentage of Royalty on Sales Percentage of royalty on sales Royalty Expense Royalty expense License fee payable annually per agreement. Payment of License Fee per Year License fee payments per year Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Domain] Represents lawsuits alleging that the plaintiffs were exposed to and/or contracted tuberculosis and/or suffered substantial symptoms and complications following the implantation of FiberCel during spinal fusion operations. FiberCel Litigation Product Liability [Member] FiberCel Litigation Product Liability Represents lawsuits related to viable bone matrix ("VBM") product. Viable Bone Matrix ("VBM")Product Litigation [Member] Viable Bone Matrix Litigation Represents lawsuits related to viable bone matrix ("VBM") product alleging fraudulent inducement. Viable Bone Matrix ("VBM")Product Litigation, Fraud [Member] Viable Bone Matrix Litigation, Fraudulent Inducement Represents lawsuits filed by the entity against Medtronic Sofamor Danek USA, Inc. (Medtronic) alleging breach of the 2019 Tissue Product Supply Agreement (the "Supply Agreement") between the entity and Medtronic. In particular, the complaint alleges that Medtronic did not honor its contractual obligations to obtain insurance coverage and to defend and indemnify the entity for over 100 lawsuits against the entity alleging claims arising from the use of FiberCel products distributed by Medtronic Lawsuit Against Medtronic Sofamor Danek USA, Inc. [Member] Medtronic Litigation Loss Contingencies [Line Items] Legal Proceedings Loss Contingency, New Claims Filed, Number Number of lawsuits filed or asserted Loss Contingency, Pending Claims, Number Number of active lawsuits or claims filed or asserted Number of patients affected from post-surgical mycobacterium tuberculosis (mtb) infections treated with vbm product. Number of Patients Affected from Post-Surgical Mycobacterium Tuberculosis (MTB) Infections Treated with VBM Product Number of patients affected from post-surgical mycobacterium tuberculosis (mtb) infections treated with vbm product Number of patients that received tissue from bone matrix ("VBM") product lot that was recalled. Number of Patients Received Tissue From Recalled VBM Product Number of individuals received tissue from the recalled VBM lot The number of lawsuits the entity alleges a counter party did not obtain insurance coverage from product usage per supply agreement with counter party. Litigation, Number of Lawsuit Lack of Insurance Coverage Number of lawsuits without insurance coverage Loss Contingency, Claims Settled, Number Number of cases settled Litigation Settlement, Amount Awarded to Other Party Total amount of settlements Loss Contingency Accrual Total estimated liability Loss Contingency, Receivable Receivable from litigation costs Payments for Legal Settlements Settlement amount Income Amounts Attributable to Parent, Disclosures [Abstract] Numerator: Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Net loss from continuing operations Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic Net income from discontinued operations Net Income (Loss) Available to Common Stockholders, Basic Net loss No definition available. Earnings Per Share, Basic and Diluted, Other Disclosure 1 [Abstract] Denominator: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] This member stands for class A common stock warrant. Class A Common Stock Warrants [Member] Class A Warrants Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Schedule of Segment Reporting Information, by Segment [Table] Product and Service [Axis] Product and Service [Domain] Represents the information pertaining to device protection. Device Protection [Member] Device Protection Represents the information pertaining to Women's Health. Women's Health [Member] Women's Health Represents the information pertaining to Cardiovascular. Cardiovascular Segment Reporting Information [Line Items] Number of Operating Segments Number of operating segments Aggregate revenue less cost of goods and services sold or operating expenses, excluding intangible asset amortization, directly attributable to the revenue generation activity. Gross Profit, Before Intangible Asset Amortization Gross profit, excluding intangible asset amortization Amortization of Intangible Assets Intangible asset amortization expense Intangible asset amortization expense Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of segment gross profit to the consolidated loss from operations Segment Reporting, Other Significant Reconciling Item, Consolidated [Abstract] Adjustments: EX-101.PRE 10 elut-20240630 prg.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 07, 2024 Document Information [Line Items] A Document Type 10-Q A Document Quarterly Report true A Document Transition Report false A Document Period End Date Jun. 30, 2024 A Entity File Number 001-39577 A Entity Registrant Name Elutia Inc. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 47-4790334 A Entity Address, Address Line One 12510 Prosperity Drive A Entity Address, Address Line Two SuiteA 370 A Entity Address, City or Town Silver Spring A Entity Address State Or Province MD A Entity Address, Postal Zip Code 20904 A City Area Code 240 A Local Phone Number 247-1170 A Title of 12(b) Security Class A Common Stock, par value \$0.001 per share A Trading Symbol ELUT A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company true A Entity Exit Transition Period false A Entity Shell Company false A Entity Central Index Key 0001708527 A Current Fiscal Year End Date -12-31 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q2 A Amendment Flag false A Class A Common stock A A Document Information [Line Items] A A Entity Common Stock, Shares Outstanding A 29,746,935 Class B Common stock A A Document Information [Line Items] A A Entity Common Stock, Shares Outstanding A 4,313,406 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei AmendmentFlag Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:yearItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei DocumentInformationLineItems Namespace Prefix: dei Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei DocumentQuarterlyReport Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei DocumentTransitionReport Namespace Prefix: dei Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei DocumentType Namespace Prefix: dei Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine1 Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei EntityAddressAddressLine2 Namespace Prefix: dei Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name:

dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:> dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:shareItem Type Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:> dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: [http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItem Type Balance Type: na Period Type: duration X - DefinitionTitle of a 12\(b\) registered security. + ReferencesReference 1:">http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1:">http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R2.htm IDEA: XBRL DOCUMENT v.3.24.2.u1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD \(\\$\) in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: A Cash and cash equivalents \\$1,188 \\$1,197,276 Accounts receivable, net 3,518 3,263 Inventory 3,115 3,853 Receivables of litigation costs 4,421 2,696 Prepaid expenses and other current assets 1,109 2,165 Total current assets 30,351 31,253 Property and equipment, net 159 172 Intangible assets, net 9,972 11,671 Operating lease right-of-use assets and other 1,422 332 Total liabilities: A Accounts payable 3,140 2,285 Accrued expenses 7,335 9,485 Payables to tissue suppliers 798 906 Current portion of long-term debt 3,449 3,321 Current portion of revenue interest obligation 4,400 11,741 Contingent liability for legal proceedings 20,198 15,024 Current operating lease liabilities 488 275 Total current liabilities 39,808 43,037 Long-term debt 18,873 20,356 Long-term revenue interest obligation 6,972 5,360 Warrant liability 39,018 12,760 Other long-term liabilities 1,571 515 Total liabilities 106,242 82,028 Commitments and contingencies Stockholders' equity \(deficit\): A Additional paid-in capital 157,452 137,021 Accumulated deficit \(221,818\) \(175,644\) Total stockholders' deficit \(64,338\) \(38,600\) Total liabilities and stockholders' deficit 41,904 43,428 Class A Common stock A Stockholders' equity \(deficit\): A Common stock 24 19 Class B Common stock A Stockholders' equity \(deficit\): A Common stock \\$ 4 \\$ 4 X - DefinitionRepresents the amount payables to tissue suppliers, classified as current. + ReferencesNo definition available. + Details Name: elut_PayablesToTissueSuppliersCurrent Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of revenue interest obligation, classified as current. + ReferencesNo definition available. + Details Name: elut_RevenueInterestObligationCurrent Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of revenue interest obligation, classified as noncurrent. + ReferencesNo definition available. + Details Name: elut_RevenueInterestObligationNoncurrent Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred \(and for which invoices have typically been received\) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + ReferencesReference 1: \[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(19\\)\\(a\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:\]\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:\) <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2:> \[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(20\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital \\(APIC\\) for common and preferred stock. + ReferencesReference 1:">http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2:">http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.6-04\\(18\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3:">http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(30\\)\\(a\\)\\(1\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1:">http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2:">http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3:">http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\(i\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-10Reference 4:">http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \\(ee\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5:">http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \\(d\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6:">http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7:">http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \\(bb\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8:">http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9:">http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.4-08\\(g\\)\\(1\\)\\(ii\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10:">http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11:">http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12:">http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13:">http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14:">http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.7-03\\(a\\)\\(12\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15:">http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.6-04\\(8\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16:">http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.5-02\\(18\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18:">http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(ii\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19:">http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iii\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iii\\)\\(A\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(5\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iii\\)\\(A\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27:">http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(5\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28:">http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29:">http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30:">http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.9-03\\(11\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities \(due within one year or within the normal operating cycle if longer\). + ReferencesReference 1:\)](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1:)

Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1:

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483076/450-20-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LitigationReserveCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482425/460-10-50-3> + Details Name: us-gaap_LossContingencyReceivableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10> + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: [http](http://www.xbrl.org/2009/role/commonPracticeRef)

2024 Dec. 31, 2023 Class A Common stock \$ A Common stock, par value (in dollar per share) \$ 0.001 \$ 0.001 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issued 23,963,101 18,884,196 Common stock, shares outstanding 23,963,101 18,884,196 Class B Common stock \$ A Common stock, par value (in dollar per share) \$ 0.001 \$ 0.001 Common stock, shares authorized 20,000,000 20,000,000 Common stock, shares issued 4,313,406 4,313,406 Common stock, shares outstanding 4,313,406 4,313,406 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> -Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\)](https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\)](https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\)](https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\)](https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\)](https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS A A A Net sales \$ 6,291 \$ 6,351 \$ 12,985 \$ 12,743 Cost of goods sold 3,492 3,637 7,343 6,655 Gross profit 2,799 2,714 5,642 6,088 Sales and marketing 3,330 3,022 6,639 7,713 General and administrative 4,689 3,861 9,745 7,381 Research and development 1,001 869 2,173 2,460 FiberCel litigation costs, net 2,289 1,271 4,074 3,182 Total operating expenses 11,309 9,023 22,631 20,736 Loss from operations (8,510) (6,309) (16,989) (14,648) Interest expense 1,267 1,409 2,580 2,839 Loss on revaluation of warrant liability 18,337 27,974 Other expense (income), net 257 A (1,186) A Loss before provision for income taxes (28,371) (7,718) (46,357) (17,487) Income tax expense (benefit) (11) 12 (3) 24 Net loss from continuing operations (28,360) (7,730) (46,354) (17,511) Income (loss) from discontinued operations 180 (2,891) 180 (1,084) Net loss \$ (28,180) \$ (10,621) \$ (46,174) \$ (18,595) Net loss from continuing operations per share - basic (in dollars per share) \$ (1.14) \$ (0.48) \$ (1.90) \$ (1.08) Net loss from continuing operations per share - diluted (in dollars per share) (1.14) (0.48) A A Net income (loss) from discontinued operations per share - basic (in dollars per share) 0.01 (0.18) A A Net income (loss) from discontinued operations per share - diluted (in dollars per share) 0.01 (0.18) 0.01 (0.07) Net loss per share - basic (in dollar per share) (1.13) (0.65) \$ (1.89) \$ (1.15) Net loss per share - diluted (in dollar per share) \$ (1.13) \$ (0.65) A A Weighted average common shares outstanding - basic (in shares) 24,900,167 16,223,919 24,408,651 16,208,905 Weighted average common shares outstanding - diluted (in shares) 24,900,167 16,223,919 24,408,651 16,208,905 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\(d\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\(a\)\)](https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\)](https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479941/924-10-S99-1> + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\)\(3\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g)(3) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\)](https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\)](https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\)](https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI](https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\)](https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\)](https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27))) -Publisher FASB -URI [https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\)](https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap_FairValueAdjustmentOfW

[Paragraph 2 - SubParagraph \(SX 210.5-03\(2\)\)](#) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.5-03(1)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 235 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.4-08(g)(1)(ii)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 323 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Subparagraph (c) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 825 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 28 - Subparagraph (f) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(i)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(iv)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(5)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(i)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(A)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iii)(B)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(iv)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 470 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 1B - Subparagraph (SX 210.13-02(a)(4)(v)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: <http://www.xbrl.org/2003/role/exampleRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 31 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap GrossProfit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 22 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: <http://www.xbrl.org/2003/role/exampleRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 55 - Paragraph 48 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 32 - Subparagraph (g) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 30 - Subparagraph (b) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 270 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph (i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 32 - Subparagraph (ee) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 32 - Subparagraph (c) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 944 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.7-04(11)) - Publisher FASB - URI https://asc.fasb.org/1943274/214777250/944-220-S99-1Reference 9: <http://www.xbrl.org/2003/role/exampleRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 31 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 942 - SubTopic 235 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.9-05(b)(2)) - Publisher FASB - URI https://asc.fasb.org/1943274/214777314/942-235-S99-1Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.5-03(10)) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 942 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.9-04(15)) - Publisher FASB - URI https://asc.fasb.org/1943274/214748524/942-220-S99-1 + Details Name: us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Topic 810 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 19 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> - Topic 280 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 22 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: [http://www.xbrl.org/2009/role](http://www.xbrl.org/2009/role/commonPracticeRef)

-Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10:

-Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition)Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition)Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Definition)The aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-45-10)

Section S99 - Paragraph 1A - Subparagraph (SX 210.13-01(a)(4)(i)) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23:

Jun. 30, 2024 Jun. 30, 2023 OPERATING ACTIVITIES: $\dot{A}$ $\dot{A}$ Net loss $\dot{x}$ (46,174) $\dot{x}$ (18,951) Adjustments to reconcile net loss to net cash used in operating activities: $\dot{A}$ $\dot{A}$ Depreciation and amortization 1,726 1,901 Gain on sale of Orthobiologics Business (180) $\dot{A}$ Loss on revaluation of warrant liability 27,974 $\dot{A}$ Gain on revaluation of revenue interest obligation (1,443) $\dot{A}$ Interest expense recorded as additional revenue interest obligation or long-term debt 1,450 1,619 Amortization of deferred financing costs and debt discount 108 107 Stock-based compensation 4,908 1,371 Bad debt expense $\dot{A}$ 834 Losses associated with viable bone matrix recall and market withdrawal $\dot{A}$ 1,984 Changes in operating assets and liabilities: $\dot{A}$ $\dot{A}$ Accounts receivable (255) (321) Inventory 738 (1,206) Receivables of litigation costs (1,725) 4,937 Prepaid expenses and other 1,345 652 Accounts payable and accrued expenses and payables to tissue suppliers (751) 1,828 Contingent liability for legal proceedings 5,174 (2,890) Other liabilities 132 224 Net cash used in operating activities (6,973) (7,555) INVESTING ACTIVITIES: $\dot{A}$ $\dot{A}$ Proceeds from sale of Orthobiologics Business 180 $\dot{A}$ Expenditures for property, plant and equipment (13) (267) Net cash provided by (used in) investing activities 167 (267) FINANCING ACTIVITIES: $\dot{A}$ $\dot{A}$ Proceeds from direct registered offering and warrants, net of offering costs 12,390 $\dot{A}$ Repayments of long-term debt (2,000) $\dot{A}$ Proceeds from exercises of Common Warrants and Prefunded Warrants 1,928 $\dot{A}$ Payments on revenue interest obligation (5,200) $\dot{A}$ Repayments of insurance premium financings (1,148) $\dot{A}$ Payments for taxes upon vesting of restricted stock units (322) (19) Proceeds from sales of common stock through Employee Stock Purchase Plan 70 148 Net cash provided by financing activities 5,718 129 Net decrease in cash and restricted cash (1,088) (7,693) Cash and cash equivalents, beginning of period 19,276 16,989 Cash and cash equivalents, end of period 18,188 9,296 Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: $\dot{A}$ $\dot{A}$ Cash paid for interest 3,492 $\dot{x}$ 1,100 Fair value of warrants issued 2,464 $\dot{A}$ Operating lease right-of-use asset extensions executed 1,379 $\dot{A}$ Conversion of Common Warrants and Prefunded Warrants to common stock $\dot{x}$ 4,180 $\dot{A}$ $\dot{X}$ - DefinitionThe value of the common stock that warrants are being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: elut_CommonStockIssuedUponConversionWarrants Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of fair value of warrants issued. + ReferencesNo definition available. + Details Name: elut_FairValueOfWarrantsIssued Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of gain (loss) on revaluation of revenue interest obligation and other. + ReferencesNo definition available. + Details Name: elut_GainLossOnRevaluationOfRevenueInterestObligationAndOther Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in contingent liability. + ReferencesNo definition available. + Details Name: elut_IncreaseDecreaseContingentLiability Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accounts payable and accrued expenses and payables to tissue suppliers. + ReferencesNo definition available. + Details Name: elut_IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndPayablesToTissueSuppliers Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable and other liabilities. + ReferencesNo definition available. + Details Name: elut_IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of interest expense recorded as additional revenue interest obligation. + ReferencesNo definition available. + Details Name: elut_IncreaseDecreaseInRevenueInterestObligation Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of losses on product recall and market withdrawal. + ReferencesNo definition available. + Details Name: elut_LossesOnProductRecallAndMarketWithdrawal Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe value of the operating lease right-of-use asset extensions executed not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: elut_OperatingLeaseRightOfUseAssetExtensions Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow on payments on revenue interest obligation. + ReferencesNo definition available. + Details Name: elut_PaymentsOnRevenueInterestObligation Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to repay insurance premium financings. + ReferencesNo definition available. + Details Name: elut_RepaymentsOfInsurancePremiumFinancings Namespace Prefix: elut_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt issuance costs. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 3: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 4: <http://www.xbrli.org/2009/role/commonPracticeRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3> + Details Name: us-gaap_AmortizationOfFinancingCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B) + Details Name: us-gaap_GainLossOnSaleOfBusiness Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrli.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for

resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details) Name: us-gaap PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details) Name: us-gaap ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details) Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details) Name: us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details) Name: us-gaap ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details</p><p>Name: us-gaap ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: <a href=) Name: us-gaap ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details) Name: us-gaap RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details) Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT 33.24.2.u1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Registered Direct Offering of Common Stock and Warrants A Issuance and offering costs \$ 1.1 \$ 1.1 X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details> Name: us-gaap PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap SubsidiarySaleOfStockAxis=elut RegisteredDirectOfferingOfCommonStockAndWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 20 R9.htm IDEA: XBRL DOCUMENT 33.24.2.u1 Organization and Description of Business 6 Months Ended Jun. 30, 2024 Organization and Description of Business A Organization and Description of Business ELUTIA INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)Note 1. Organization and Description of BusinessElutiaA Inc. (together with its consolidated subsidiaries, "ElutiaA or the aœœCompanyaœœ") is a commercial-stage company leveraging its unique understanding of biologics to improve the interaction between implanted medical devices and patients by reducing complications associated with these surgeries. The Company has developed a portfolio of products using both human and porcine tissue that are designed to be as close to natural biological material as possible. ElutiaAaœœ's portfolio of products spans the Device Protection, Womenaœœ's Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details> Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT 33.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies A Summary of Significant Accounting PoliciesNote 2. Summary of Significant Accounting PoliciesBasis of Presentation and LiquidityThe unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (aœœGAAPaœœ) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Companyaœœ's condensed consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (aœœAnnual Reportaœœ) for the fiscal year ended December 31, 2023. The financial information as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. A The condensed consolidated balance sheet data as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Companyaœœ's operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.aœœThe condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. A aœœOn November 8, 2023, the Company completed the sale of substantially all of the assets relating to its Orthobiologics segment (the aœœOrthobiologics Businessaœœ) to Berkeley Biologics, LLC (aœœBerkeleyaœœ). The Orthobiologics Business was comprised of assets relating to researching, developing, administering, insuring, operating, commercializing, manufacturing, selling and marketing the Companyaœœ's Orthobiologics products, and the business of contract manufacturing of particulate bone, precision milled bone, cellular bone matrix, acellular dermis, soft tissue and other products. The assets sold represent the entirety of the Companyaœœ's Orthobiologics segment. In the sale, the Company received approximately \$14.6 million, and the Company may earn up to an additional \$20 million, in the aggregate, in the form of earn-out payments. The earn-out payments are equal to 10% of the actual revenue earned by Berkeley in each of the five years after the closing of the sale from sales of specified Orthobiologics products under the purchase agreement (including improvements, modifications, derivatives and enhancements related to those products). There were no earn-out payments earned or paid in the three or six months ended June 30, 2024. Additionally, the purchase agreement provides for a customary indemnity holdback in the amount of \$1.5 million to be retained by Berkeley for 24 months after close. The Company recognized a gain of approximately \$6.0 million on the sale of the Orthobiologics Business in the fourth quarter of 2023 and an additional gain of \$0.2 million in the second quarter of 2024 from an adjustment payment related to the final working capital received by Berkeley at the sale date. The indemnity holdback is available as a source of recovery for Berkeley for claims of indemnification under the purchase agreement, and some or all of the holdback may be retained by Berkeley if Berkeley is successful in asserting a

claim or claims for indemnification against the Company. Should the Company receive incremental proceeds in the future through an earn-out payment or payment of the holdback amount, an additional gain will be recorded upon the receipt of such amounts. See Note 4 for further discussion of the sale of the Orthobiologics Business and the presentation of such business as discontinued operations for the three and six months ended June 30, 2023. Unless indicated otherwise, the information in the notes to condensed consolidated financial statements for the three and six months ended June 30, 2023 relates to continuing operations. In accordance with Accounting Standards Update (ASU) 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. For the six months ended June 30, 2024, the Company incurred a net loss of \$46.2 million, and as of June 30, 2024, the Company had an accumulated deficit of \$221.8 million. In addition, during the six months ended June 30, 2024, the Company used \$7.0 million of cash in operating activities and expects to continue to incur cash outflows in 2024. Because of the numerous risks and uncertainties associated with the Company's commercialization and development efforts, the Company is unable to predict when it will become profitable, and it may never become profitable. The Company's inability to achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash flows. Furthermore, even if the Company does achieve profitability, it may not be able to sustain or increase profitability on an ongoing basis, or, in general, be able to satisfy its obligations, including those related to the FiberCel Litigation and VBM Litigation described in Note 10, when they become due. In order to mitigate the current and potential future liquidity issues caused by the matters noted above, we may seek to raise capital through the issuance of common stock or pursue asset sales or other transactions, such as the sale of the Orthobiologics Business described above. A However, such transactions may not be successful, and we may not be able to raise additional equity, refinance our debt instruments, or sell assets on acceptable terms, or at all. As such, based on our current operating plans, we believe there is uncertainty as to whether our future cash flows along with our existing cash, issuances of additional equity and cash generated from expected future sales will be sufficient to meet our anticipated operating needs through twelve months from the condensed consolidated financial statement issuance date. Due to these factors, there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the condensed consolidated financial statements. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. That is, the accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions relating to inventories, receivables, long-lived assets, the valuation of stock-based awards, the valuation of the revenue interest obligation, the valuation of the warrant liability, the contingent liabilities for legal proceedings and deferred income taxes are made at the end of each financial reporting period by management. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates. Net Loss per Share Attributable to Common StockholdersOur common stock has a dual class structure, consisting of Class A common stock, \$0.001 par value per share (the Class A common stock) and Class B common stock, \$0.001 par value per share (the Class B common stock). Other than voting rights, the Class B common stock has the same rights as the Class A common stock, and therefore both are treated as the same class of stock for purposes of the earnings per share calculation. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average shares outstanding during the period. For purposes of the diluted net income (loss) per share attributable to common stockholders calculation, stock options, restricted stock units (RSUs) and warrants are considered to be common stock equivalents. All common stock equivalents have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for both periods presented. Fair Value of Financial InstrumentsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value: Level 1 Valuations based on quoted prices for identical assets and liabilities in active markets. Level 2 Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3 Valuations based on unobservable inputs reflecting the Company's own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment. The estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information and appropriate valuation methodologies. The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. Cash and Cash EquivalentsThe Company maintains its cash balances at banks and financial institutions. The balances are insured up to the legal limit. The Company maintains cash balances that may, at times, exceed this insured limit. The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. Accounts Receivable and AllowancesAccounts receivable in the accompanying balance sheets are presented net of allowances for credit losses. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables. The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowance for doubtful accounts is recorded to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowance for credit losses is recorded based on factors including the length of time the receivables are past due, the current business environment and the Company's historical experience. Provisions to the allowance for doubtful accounts are recorded to general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. InventoryInventory, consisting of purchased materials, direct labor and manufacturing overhead, is stated at the lower of cost or net realizable value, with cost determined generally using the average cost method. At each balance sheet date, the Company also evaluates inventory for excess quantities, obsolescence or shelf-life expiration. This evaluation includes analysis of the Company's current and future strategic plans, historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions and a review of the shelf-life expiration dates for products. To the extent that management determines there is excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. Property and EquipmentProperty and equipment are stated at cost less accumulated depreciation. Depreciation is computed on the straight-line method over the following estimated useful lives of the assets: Processing and research equipment 5 to 10 years Office equipment and furniture 3 to 5 years Computer hardware and software 3 years Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance costs are expensed as incurred. LeasesIn February 2016, the Financial Accounting Standards Board (FASB) issued ASU No 2016-02, Leases to increase the transparency and comparability about leases among entities. ASU 2016-02 and certain additional ASUs are now codified as ASC 842, Leases. ASC 842 supersedes the lease accounting guidance in ASC 840 and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. The Company determines if an arrangement contains a lease at inception. Right-of-use (ROU) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company combines lease and non-lease elements for office leases. During the six months ended June 30, 2024, the Company entered into lease extensions in Silver Spring, Maryland and Roswell, Georgia and entered into a new lease in San Diego, California, which collectively resulted in operating lease right-to-use assets and liabilities of \$1.4 million. Such new leases will result in future cash obligations of \$0.3 million for the six months ended December 31, 2024 and \$0.6 million, \$0.7 million and \$0.1 million for the years ended December 31, 2025, 2026 and 2027, respectively. Long-Lived AssetsPurchased intangible assets with finite lives are carried at acquired fair value, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets. The Company periodically evaluates the period of depreciation or amortization for long-lived assets to determine whether current circumstances warrant revised estimates of useful lives. The Company reviews its property and equipment and intangible assets for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment exists when the carrying value of the Company's asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset. If impairment exists, the carrying value of that asset is adjusted to its fair value. A discounted cash flow analysis is used to estimate an asset's fair value, using assumptions that market participants would apply. The results of impairment tests are subject to management's estimates and assumptions of projected cash flows and operating results. Changes in assumptions or market conditions could result in a change in estimated future cash flows and could result in a lower fair value and therefore an impairment, which could impact reported results. There were no impairment losses for the three and six months ended June 30, 2024 or 2023. Warrant LiabilityThe Company accounts for its warrants in accordance with ASC 815, Derivatives and Hedging Contracts in Entity's Own Equity, as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Prefunded and Common Warrants issued in connection with the September 2023 private placement (see Note 9) are classified as liabilities and are recorded at fair value. The warrants are subject to re-measurement at each settlement date and at each balance sheet date and any change in fair value is recognized in other expense (income), net in the condensed consolidated statements of operations. The Company estimates the fair value of the warrant liability using a Black-Scholes pricing model. We are required to make assumptions and estimates in determining an appropriate term, risk-free interest rate, volatility factor, dividend yield, and the fair value of common stock. Any significant adjustments to the unobservable inputs would have a direct impact on the fair value of the warrant liability. Revenue RecognitionThe Company's revenue is generated from contracts with customers in accordance with ASC 606. The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, the Company enters into contracts to primarily sell and distribute products to healthcare providers or commercial partners. Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products to the Company's customers. For all product sales, the Company has no further performance obligations and revenue is recognized at the point control transfers which occurs either when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, in accordance with the terms of the agreement. A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and from inventory physically held by distributors and direct sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized. The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in sales and marketing costs. Contracts with customers state the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company's contracts vary; however, as a common business practice, payment terms are typically due in full within 30 to 60 days of delivery. The Company, at times, extends volume discounts to customers. The Company permits returns of its products in accordance with the terms of contractual agreements with customers. Allowances for returns are provided based upon analysis of the Company's historical patterns of returns matched against the revenues from which they originated. The Company records estimated returns as a reduction of revenue in the same period revenue is recognized. Stock-Based Compensation PlansThe Company accounts for its stock-based compensation plans in accordance with ASC 718, Accounting for Stock Compensation. ASC 718 requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors, including employee stock options and restricted stock. Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the requisite service period of the entire award. Research and Development CostsResearch and development costs, which include mainly salaries, outside services and supplies, are expensed as incurred. Concentration of Credit RiskFinancial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company's cash balances with the individual institutions may at times exceed the federally insured limits. There were two customers that represented 14% and 11%, respectively, of the Company's net sales for the six months ended June 30, 2024. Additionally, there were two customers that represented 26% and 12%, respectively, of the Company's accounts receivable as of June 30, 2024. Comprehensive Income (Loss)Comprehensive income (loss) comprises net income (loss) and other changes in equity that are excluded from net income (loss). For the three and six months ended June 30, 2024 and 2023, the Company's net loss equalled its comprehensive loss and accordingly, no additional disclosure is presented. Income TaxesThe Company uses the asset and liability method of accounting for income taxes. Deferred income taxes are recorded to reflect the tax consequences on future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to amounts that are more likely than not to be realized. The Company is subject to income taxes in the federal and state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting for uncertainty in income taxes, the Company recognizes tax liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is more likely than not (greater than 50%) of being realized upon settlement. The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI http://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI http://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Recently Issued Accounting Standards 6 Months Ended Jun 30, 2024 Recently Issued Accounting Standards A Recently Issued Accounting Standards Note 3. Recently Issued Accounting StandardsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the condensed consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements,

anally provided enhanced transparency and disclosure usefulness disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 280 - SubTopic 10 -Name Accounting Standards Codification -Section 65- Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org/250/tableOfContentReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 + Details Name: us-gaap NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT V3.24.2.u1 Sale of Orthobiologics Business 6 Months Ended Jun. 30, 2024 Sale of Orthobiologics Business A sale of Orthobiologics Business As described in Note 2, on November 8, 2023, the Company completed the sale of its Orthobiologics Business. Accordingly, the Orthobiologics Business is reported as discontinued operations in accordance with ASC 205-20 - Discontinued Operations and the amounts for the three and six months ended June 30, 2023 have been recast to conform to this discontinued operations presentation.â€In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. The following table shows the financial results of the discontinued operations for the three and six months ended June 30, 2023. Additionally, a gain of \$0.2 million was recognized in the second quarter of 2024 related to the final working capital adjustment received from Berkeley.â€â€â€â€â€â€Three Months Ended â€â€Six Months Endedâ€â€June 30, 2023â€â€June 30, 2023â€â€Net sales\$ 3,945â€â€\$ 10,603Cost of goods sold\$ 5,678â€â€\$ 9,378Gross profit\$ (1,733)â€â€\$ 1,225Sales and marketing\$ 596â€â€\$ 1,262General and administrative\$ 143â€â€\$ 304Research and development\$ 304â€â€\$ 513Total operating expense\$ 1,043â€â€\$ 2,079Interest expense\$ 115â€â€\$ 230Net income\$ (2,891)â€â€\$ (1,084)â€â€â€â€â€â€Total operating and investing cash flows of discontinued operations for the six months ended June 30, 2023 are comprised of the following:â€â€â€â€â€Six Months Endedâ€â€June 30, 2023â€â€Significant operating non-cash reconciliation itemsâ€â€Depreciation\$ 117Stock-based compensation\$ 65Changes in operating assets and liabilities:â€â€Accounts receivable\$ (607)Inventory\$ (183)Prepaid expenses and other\$ (557)Accounts payable and accrued expenses and other current liabilitiesâ€â€\$ 1,156Obligations to tissue suppliersâ€â€\$ (228)â€â€â€â€Significant investing itemsâ€â€Expenditures for property, plant and equipmentâ€â€\$ 224â€â€X - ReferencesNo definition available. + Details Name: us-gaap DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL

https://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory 6 Months Ended Jun. 30, 2024 Inventory A Inventory Note 6. InventoryInventory was comprised of the following (in thousands):

Raw materials	\$341.6
Work in process	\$498.6
Finished goods	\$2,276.6
Total	\$3,115.6

 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Long-Term Debt 6 Months Ended Jun. 30, 2024 Long-Term Debt A Long-Term Debt Note 7. Long-Term DebtOn August 10, 2022, the Company entered into a senior secured term loan facility with SWK Funding LLC, as agent, and other lenders party thereto for an aggregate principal amount of \$25 million, and the Company amended the facility on May 12, 2023 (as amended, the *SWK Loan Facility*). An initial draw of \$21 million was made in August 2022, with the additional \$4 million drawn on December 14, 2022 upon satisfaction of the amended terms enabling such receipt. The SWK Loan Facility also allows for the establishment of a separate, new asset-based revolving loan facility of up to \$8 million, which has not been entered into to date. The SWK Loan Facility matures on August 10, 2027 and accrues interest, payable quarterly in arrears. Principal amortization of the SWK Loan Facility starts on November 15, 2024, which amortization may be extended to November 17, 2025 if certain conditions have been satisfied. Principal payments during the amortization period will be limited based on revenue-based caps. As of June 30, 2024, quarterly principal payments are scheduled to begin on November 15, 2024, in an amount equal to 5% of the aggregate principal amount funded with the balance paid at maturity. The SWK Loan Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by all assets of the Company, subject to certain customary exceptions. As of June 30, 2024, Elutia was in compliance with its financial covenants under the agreement governing the SWK Loan Facility (the *SWK Loan Facility Agreement*). All of the SWK Loan Facility borrowings take the form of Secured Overnight Financing Rate (the *SOFRA*) loans and bear interest at a rate per annum equal to the sum of an applicable margin of (i) 7.75% and the *SOFRA* Rate (based upon an interest period of 3 months), or (ii) if the Company has elected the *PIK* Interest option (as defined below), 3.75% and the *SOFRA* Rate. The Company may elect a portion of the interest due, to be paid in-kind at a rate per annum of 4.5% (the *PIK Interest*), and such election may be made (x) until November 15, 2024 if certain conditions, as defined, have not been met, or (y) if such conditions have been satisfied, until November 17, 2025. The *SOFRA* Rate is subject to a floor of 2.75%. The agreement governing the SWK Loan Facility also includes an exit fee equal to 6.5% of the aggregate principal amount funded prior to termination plus \$62,500 and prepayment penalties equal to: (i) if such prepayment occurs prior to the first anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the loan or (ii) if such prepayment occurs after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date, 2% of the aggregate principal amount funded prior to the termination. The weighted average interest rate on the SWK Loan Facility was 13.6% and 13.0% for the three months ended June 30, 2024 and 2023, respectively and 13.6% and 12.9% for the six months ended June 30, 2024 and 2023, respectively. On August 10, 2022, the Company issued to SWK Funding LLC a warrant (the *Class A Warrant*) to purchase, in the aggregate, up to 187,969 shares of Class A common stock of the Company, \$0.001 par value per share at an exercise price of \$6.65 per share. The Class A Warrant is immediately exercisable for up to 187,969 shares of Class A common stock from time to time on or after the Closing Date. The exercise price and number of shares of Class A common stock issuable upon exercise of the Class A Warrant are subject to adjustment in the event of stock dividends, stock splits and certain other events affecting the Class A common stock. Unless earlier exercised or terminated in accordance with its terms, the Class A Warrant will expire on the seventh anniversary of the Closing Date. Upon issuance, the Company valued the Class A Warrant at approximately \$0.6 million using the Black-Scholes model. The recognition of the Class A Warrant as well as deferred financing costs of approximately \$0.5 million incurred in securing the SWK Loan Facility served to reduce the recorded value of the associated debt. The debt discount and deferred financing costs will be recognized as interest expense through the maturity of the loan. The SWK Loan Facility Agreement requires certain mandatory prepayments, subject to certain exceptions, with: (1) 100% of any net casualty proceeds in excess of \$250,000 and (2) for non-ordinary course asset sales, an amount equal to the difference between (x) the proportion of divested gross profit (as defined in the SWK Loan Facility Agreement) to the Company's total gross profit (as defined in the SWK Loan Facility Agreement) multiplied by the outstanding loans under the SWK Loan Facility and (y) the difference between \$1,000,000 and the aggregate sale proceeds of any assets previously sold during the fiscal year. No such mandatory prepayments were required during the three and six months ended June 30, 2024 and 2023. A long-term debt was comprised of the following (in thousands):

Current Portion	\$23,677
Long-Term Debt	\$18,873.3
Total	\$42,550.3

 The fair value of all debt instruments, which is based on inputs considered to be Level 2 under the fair value hierarchy, approximates the respective carrying values as of June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role

may require the Company to adjust the settlement value that is not consistent with a fixed-for-fixed option pricing model. As a result, with respect to the 2024 Prefunded Warrants, the Company allocated \$2.5 million of the gross proceeds from the Registered Offering to such warrants based on their fair value. Similarly, with respect to the Common Warrants and 2023 Prefunded Warrants, the Company allocated \$8.6 million of the gross proceeds from the Private Offering to such warrants based on their fair value. Additionally, the Company allocated a portion of the transaction fees from both the Registered Offering and the Private Offering to the respective warrants and expensed within other expense (income), net. Such expenses totaled \$0.3 million during the three and six months ended June 30, 2024. No such expenses were recognized in the three and six months ended June 30, 2023. The liability associated with the 2024 Prefunded Warrants, Common Warrants and 2023 Prefunded Warrants is recorded as warrant liability in the accompanying condensed consolidated balance sheet as of June 30, 2024 and December 31, 2023. A summary of the warrant activity for the six months ended June 30, 2024 is as follows:

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985	1984	1983	1982	1981	1980	1979	1978	1977	1976	1975	1974	1973	1972	1971	1970	1969	1968	1967	1966	1965	1964	1963	1962	1961	1960	1959	1958	1957	1956	1955	1954	1953	1952	1951	1950	1949	1948	1947	1946	1945	1944	1943	1942	1941	1940	1939	1938	1937	1936	1935	1934	1933	1932	1931	1930	1929	1928	1927	1926	1925	1924	1923	1922	1921	1920	1919	1918	1917	1916	1915	1914	1913	1912	1911	1910	1909	1908	1907	1906	1905	1904	1903	1902	1901	1900	1899	1898	1897	1896	1895	1894	1893	1892	1891	1890	1889	1888	1887	1886	1885	1884	1883	1882	1881	1880	1879	1878	1877	1876	1875	1874	1873	1872	1871	1870	1869	1868	1867	1866	1865	1864	1863	1862	1861	1860	1859	1858	1857	1856	1855	1854	1853	1852	1851	1850	1849	1848	1847	1846	1845	1844	1843	1842	1841	1840	1839	1838	1837	1836	1835	1834	1833	1832	1831	1830	1829	1828	1827	1826	1825	1824	1823	1822	1821	1820	1819	1818	1817	1816	1815	1814	1813	1812	1811	1810	1809	1808	1807	1806	1805	1804	1803	1802	1801	1800	1799	1798	1797	1796	1795	1794	1793	1792	1791	1790	1789	1788	1787	1786	1785	1784	1783	1782	1781	1780	1779	1778	1777	1776	1775	1774	1773	1772	1771	1770	1769	1768	1767	1766	1765	1764	1763	1762	1761	1760	1759	1758	1757	1756	1755	1754	1753	1752	1751	1750	1749	1748	1747	1746	1745	1744	1743	1742	1741	1740	1739	1738	1737	1736	1735	1734	1733	1732	1731	1730	1729	1728	1727	1726	1725	1724	1723	1722	1721	1720	1719	1718	1717	1716	1715	1714	1713	1712	1711	1710	1709	1708	1707	1706	1705	1704	1703	1702	1701	1700	1699	1698	1697	1696	1695	1694	1693	1692	1691	1690	1689	1688	1687	1686	1685	1684	1683	1682	1681	1680	1679	1678	1677	1676	1675	1674	1673	1672	1671	1670	1669	1668	1667	1666	1665	1664	1663	1662	1661	1660	1659	1658	1657	1656	1655	1654	1653	1652	1651	1650	1649	1648	1647	1646	1645	1644	1643	1642	1641	1640	1639	1638	1637	1636	1635	1634	1633	1632	1631	1630	1629	1628	1627	1626	1625	1624	1623	1622	1621	1620	1619	1618	1617	1616	1615	1614	1613	1612	1611	1610	1609	1608	1607	1606	1605	1604	1603	1602	1601	1600	1599	1598	1597	1596	1595	1594	1593	1592	1591	1590	1589	1588	1587	1586	1585	1584	1583	1582	1581	1580	1579	1578	1577	1576	1575	1574	1573	1572	1571	1570	1569	1568	1567	1566	1565	1564	1563	1562	1561	1560	1559	1558	1557	1556	1555	1554	1553	1552	1551	1550	1549	1548	1547	1546	1545	1544	1543	1542	1541	1540	1539	1538	1537	1536	1535	1534	1533	1532	1531	1530	1529	1528	1527	1526	1525	1524	1523	1522	1521	1520	1519	1518	1517	1516	1515	1514	1513	1512	1511	1510	1509	1508	1507	1506	1505	1504	1503	1502	1501	1500	1499	1498	1497	1496	1495	1494	1493	1492	1491	1490	1489	1488	1487	1486	1485	1484	1483	1482	1481	1480	1479	1478	1477	1476	1475	1474	1473	1472	1471	1470	1469	1468	1467	1466	1465	1464	1463	1462	1461	1460	1459	1458	1457	1456	1455	1454	1453	1452	1451	1450	1449	1448	1447	1446	1445	1444	1443	1442	1441	1440	1439	1438	1437	1436	1435	1434	1433	1432	1431	1430	1429	1428	1427	1426	1425	1424	1423	1422	1421	1420	1419	1418	1417	1416	1415	1414	1413	1412	1411	1410	1409	1408	1407	1406	1405	1404	1403	1402	1401	1400	1399	1398	1397	1396	1395	1394	1393	1392	1391	1390	1389	1388	1387	1386	1385	1384	1383	1382	1381	1380	1379	1378	1377	1376	1375	1374	1373	1372	1371	1370	1369	1368	1367	1366	1365	1364	1363	1362	1361	1360	1359	1358	1357	1356	1355	1354	1353	1352	1351	1350	1349	1348	1347	1346	1345	1344	1343	1342	1341	1340	1339	1338	1337	1336	1335	1334	1333	1332	1331	1330	1329	1328	1327	1326	1325	1324	1323	1322	1321	1320	1319	1318	1317	1316	1315	1314	1313	1312	1311	1310	1309	1308	1307	1306	1305	1304	1303	1302	1301	1300	1299	1298	1297	1296	1295	1294	1293	1292	1291	1290	1289	1288	1287	1286	1285	1284	1283	1282	1281	1280	1279	1278	1277	1276	1275	1274	1273	1272	1271	1270	1269	1268	1267	1266	1265	1264	1263	1262	1261	1260	1259	1258	1257	1256	1255	1254	1253	1252	1251	1250	1249	1248	1247	1246	1245	1244	1243	1242	1241	1240	1239	1238	1237	1236	1235	1234	1233	1232	1231	1230	1229	1228	1227	1226	1225	1224	1223	1222	1221	1220	1219	1218	1217	1216	1215	1214	1213	1212	1211	1210	1209	1208	1207	1206	1205	1204	1203	1202	1201	1200	1199	1198	1197	1196	1195	1194	1193	1192	1191	1190	1189	1188	1187	1186	1185	1184	1183	1182	1181	1180	1179	1178	1177	1176	1175	1174	1173	1172	1171	1170	1169	1168	1167	1166	1165	1164	1163	1162	1161	1160	1159	1158	1157	1156	1155	1154	1153	1152	1151	1150	1149	1148	1147	1146	1145	1144	1143	1142	1141	1140	1139	1138	1137	1136	1135	1134	1133	1132	1131	1130	1129	1128	1127	1126	1125	1124	1123	1122	1121	1120	1119	1118	1117	1116	1115	1114	1113	1112	1111	1110	1109	1108	1107	1106	1105	1104	1103	1102	1101	1100	1099	1098	1097	1096	1095	1094	1093	1092	1091	1090	1089	1088	1087	1086	1085	1084	1083	1082	1081	1080	1079	1078	1077	1076	1075	1074	1073	1072	1071	1070	1069	1068	1067	1066	1065	1064	1063	1062	1061	1060	1059	1058	1057	1056	1055	1054	1053	1052	1051	1050	1049	1048	1047	1046	1045	1044	1043	1042	1041	1040	1039	1038	1037	1036	1035	1034	1033	1032	1031	1030	1029	1028	1027	1026	1025	1024	1023	1022	1021	1020	1019	1018	1017	1016	1015	1014	1013	1012	1011	1010	1009	1008	1007	1006	1005	1004	1003	1002	1001	1000	999	998	997	996	995	994	993	992	991	990	989	988	987	986	985	984	983	982	981	980	979	978	977	976	975	974	973	972	971	970	969	968	967	966	965	964	963	962	961	960	959	958	957	956	955	954	953	952	951	950	949	948	947	946	945	944	943	942	941	940	939	938	937	936	935	934	933	932	931	930	929	928	927	926	925	924	923	922	921	920	919	918	917	916	915	914	913	912	911	910	909	908	907	906	905	904	903	902	901	900	899	898	897	896	895	894	893	892	891	890	889	888	887	886	885	884	883	882	881	880	879	878	877	876	875	874	873	872	871	870	869	868	867	866	865	864	863	862	861	860	859	858	857	856	855	854	853	852	851	850	849	848	847	846	845	844	843	842	841	840	839	838	837	836	835	834	833	832	831	830	829	828	827	826	825	824	823	822	821	820	819	818	817	816	815	814	813	812	811	810	809	808	807	806	805	804	803	802	801	800	799	798	797	796	795	794	793	792	791	790	789	788	787	786	785	784	783	782	781	780	779	778	777	776	775	774	773	772	771	770	769	768	767	766	765	764	763	762	761	760	759	758	757	756	755	754	753	752	751	750	749	748	747	746	745	744	743	742	741	740	739	738	737	736	735	734	733	732	731	730	729	728	727	726	725	724	723	722	721	720	719	718	717	716	715	714	713	712	711	710	709	708	707	706	705	704	703	702	701	700	699	698	697	696	695	694	693	692	691	690	689	688	687	686	685	684	683	682	681	680	679	678	677	676	675	674	673	672	671	670	669	668	667	666	665	664	663	662	661	660	659	658	657	656	655	654	653	652	651	650	649	648	647	646	6
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	---

various potential indemnity and/or contributions rights against third party sources with respect to certain product liability losses. When settlements are reached and/or amounts are recorded in the related Contingent Liability for Legal Proceedings, the Company calculates amounts due to be reimbursed pursuant to the terms of the coverage and related agreements, and pursuant to other indemnity or contribution claims, in respect of product liability losses and related defense costs. The amounts probable of reimbursement or recovery from this calculation are recorded as receivables. The determination that the recorded receivables are probable of collection is based on the terms of agreements reached in respect of indemnity and contribution claims as well as the advice of the Company's outside legal counsel. These receivables at June 30, 2024 totaled \$4.4 million, with \$0.4 million relating to the FiberCel Litigation and \$4.0 million related to the VBM Litigation, and are recorded as Receivables of Litigation Costs in the accompanying condensed consolidated balance sheets.

At June 30, 2024, the Company continues to pursue additional amounts in respect of such indemnity and contribution claims which have not been reflected as part of this receivable. The Company will vigorously pursue its position with respect to these amounts.

As of both June 30, 2024 and 2023, the Company was not a party to, or aware of, any legal matters or claims with material financial exposure, except for the FiberCel Litigation, VBM Litigation and Medtronic matter. X - References No definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450-tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share 6 Months Ended Jun. 30, 2024 Net Loss Per Share A Net Loss Per Share Total 11. Net Loss Per Share

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z		
Share	(28,360)	(7,730)	(46,354)	(17,511)	Income (loss) from discontinued operations	\$ 180a	(2,891)	\$ 180a	(1,084)	Net loss	(28,180)	(10,621)	(46,174)	(18,595)	Denominator	A	A	A	A	A	A	A	A	A	A	A	A	
Weighted average number of common shares - basic and diluted	24,900	16,7a	16,223	91,9a	24,408	651a	16,208	905a	Net loss from continuing operations per share - basic and diluted	(1.14)	(0.48)	(1.90)	(1.08)	Net income (loss) from discontinued operations per share - basic and diluted	\$ 0.01a	(0.18)	(0.01a)	(0.07)	Net loss per share - basic and diluted	(1.13)	(0.65)	(1.89)	(1.15)	Net loss per share - basic and diluted	(1.13)	(0.65)	(1.89)	(1.15)

The Company's potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders:

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z																																																																																																																																											
Options to purchase common stock	3,238	414a	1,666	549a	Restricted stock units	2,218	216a	303	935a	Class A common stock warrants	187	969a	Common Warrants	9,667	779a	2023 Prefunded Warrants	241	588a	2024 Prefunded Warrants	725	000a	Total	16,278	966a	2,158	453a	X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260-tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information 6 Months Ended Jun. 30, 2024 Segment Information A Segment Information With the sale of the Orthobiologics Business, the Company now operates in three segments. These segments are based on financial information that is utilized by the Company's chief operating decision maker to assess performance and allocate resources. The Company determined its operating and reportable segments to be consistent with its major product groupings: Device Protection, Women's Health and Cardiovascular. The Company's net sales disaggregated by segment were as follows (in thousands): <table border="1"><thead><tr><th></th><th>A</th><th>B</th><th>C</th><th>D</th><th>E</th><th>F</th><th>G</th><th>H</th><th>I</th><th>J</th><th>K</th><th>L</th><th>M</th><th>N</th><th>O</th><th>P</th><th>Q</th><th>R</th><th>S</th><th>T</th><th>U</th><th>V</th><th>W</th><th>X</th><th>Y</th><th>Z</th></tr></thead><tbody><tr><td>Three Months Ended</td><td>2,639a</td><td>(2,221a)</td><td>4,996a</td><td>4,571</td><td>Women's health</td><td>2,571a</td><td>2,400a</td><td>6,138a</td><td>4,695</td><td>Cardiovascular</td><td>1,081a</td><td>1,730a</td><td>1,851a</td><td>3,477</td><td>Total net sales</td><td>6,291a</td><td>6,351a</td><td>12,985a</td><td>12,743a</td><td>The Company's gross profit disaggregated by segment were as follows (in thousands):</td><td>2,639a</td><td>(2,221a)</td><td>4,996a</td><td>4,571</td><td>Women's health</td><td>2,571a</td><td>2,400a</td><td>6,138a</td><td>4,695</td><td>Cardiovascular</td><td>1,081a</td><td>1,730a</td><td>1,851a</td><td>3,477</td><td>Total gross profit</td><td>6,291a</td><td>6,351a</td><td>12,985a</td><td>12,743a</td><td>The Company's gross profit disaggregated by segment were as follows (in thousands):</td><td>2,639a</td><td>(2,221a)</td><td>4,996a</td><td>4,571</td><td>Women's health</td><td>2,571a</td><td>2,400a</td><td>6,138a</td><td>4,695</td><td>Cardiovascular</td><td>1,081a</td><td>1,730a</td><td>1,851a</td><td>3,477</td><td>Total gross profit</td><td>6,291a</td><td>6,351a</td><td>12,985a</td><td>12,743a</td><td>The Company's gross profit disaggregated by segment were as follows (in thousands):</td><td>2,639a</td><td>(2,221a)</td><td>4,996a</td><td>4,571</td><td>Women's health</td><td>2,571a</td><td>2,400a</td><td>6,138a</td><td>4,695</td><td>Cardiovascular</td><td>1,081a</td><td>1,730a</td><td>1,851a</td><td>3,477</td><td>Total gross profit</td><td>6,291a</td><td>6,351a</td><td>12,985a</td><td>12,743a</td><td>The Company's gross profit disaggregated by segment were as follows (in thousands):</td><td>2,639a</td><td>(2,221a)</td><td>4,996a</td><td>4,571</td><td>Women's health</td><td>2,571a</td><td>2,400a</td><td>6,138a</td><td>4,695</td><td>Cardiovascular</td><td>1,081a</td><td>1,730a</td><td>1,851a</td><td>3,477</td><td>Total gross profit</td><td>6,291a</td><td>6,351a</td><td>12,985a</td><td>12,743a</td><td>The Company's gross profit disaggregated by segment were as follows (in thousands):</td><td>2,639a</td><td>(2,221a)</td><td>4,996a</td><td>4,571</td><td>Women's health</td><td>2,571a</td><td>2,400a</td><td>6,138a</td><td>4,695</td><td>Cardiovascular</td></tr></tbody></table>		A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	Three Months Ended	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total net sales	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular
	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z																																																																																																																																											
Three Months Ended	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total net sales	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular	1,081a	1,730a	1,851a	3,477	Total gross profit	6,291a	6,351a	12,985a	12,743a	The Company's gross profit disaggregated by segment were as follows (in thousands):	2,639a	(2,221a)	4,996a	4,571	Women's health	2,571a	2,400a	6,138a	4,695	Cardiovascular																																																							

Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/21474780097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/21474782689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/21474783499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/21474782740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/21474782790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/21474782790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrTrmtdFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd TradingArrByIndTable Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies A Basis of Presentation and Liquidity Basis of Presentation and LiquidityThe unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Companyâ€™s condensed consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (â€œAnnual Reportâ€) for the fiscal year ended December 31, 2023. The financial information as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023 is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. A The condensed consolidated balance sheet data as of December 31, 2023 was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Companyâ€™s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.â€¢The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. A â€¢On November 8, 2023, the Company completed the sale of substantially all of the assets relating to its Orthobiologics segment (the â€œOrthobiologics Businessâ€) to Berkeley Biologics, LLC (â€œBerkeleyâ€). The Orthobiologics Business was comprised of assets relating to researching, developing, administering, insuring, operating, commercializing, manufacturing, selling and marketing the Companyâ€™s Orthobiologics products, and the business of contract manufacturing of particulate bone, precision milled bone, cellular bone matrix, acellular dermis, soft tissue and other products. The assets sold represent the entirety of the Companyâ€™s Orthobiologics segment. In the sale, the Company received approximately \$14.6 million, and the Company may earn up to an additional \$20 million, in the aggregate, in the form of earn-out payments. The earn-out payments are equal to 10% of the actual revenue earned by Berkeley in each of the five years after the closing of the sale from sales of specified Orthobiologics products under the purchase agreement (including improvements, modifications, derivatives and enhancements related to those products). There were no earn-out payments earned or paid in the three or six months ended June 30, 2024. Additionally, the purchase agreement provides for a customary indemnity holdback in the amount of \$1.5 million to be retained by Berkeley for 24 months after closing. The Company recognized a gain of approximately \$6.0 million on the sale of the Orthobiologics Business in the fourth quarter of 2023 and an additional gain of \$0.2 million in the second quarter of 2024 from an adjustment payment related to the final working capital received by Berkeley at the sale date. The indemnity holdback is available as a source of recovery for Berkeley for claims of indemnification under the purchase agreement, and some or all of the holdback may be retained by Berkeley if Berkeley is successful in asserting a claim or claims for indemnification against the Company. Should the Company receive incremental proceeds in the future through an earn-out payment or payment of the holdback amount, an additional gain will be recorded upon the receipt of such amounts. See Note 4 for further discussion of the sale of the Orthobiologics Business and the presentation of such business as discontinued operations for the three and six months ended June 30, 2023. Unless indicated otherwise, the information in the notes to condensed consolidated financial statements for the three and six months ended June 30, 2023 relates to continuing operations.â€¢In accordance with Accounting Standards Update (â€œASUâ€) 2014-15, Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. For the six months ended June 30, 2024, the Company incurred a net loss of \$46.2 million, and as of June 30, 2024, the Company had an accumulated deficit of \$221.8 million. In addition, during the six months ended June 30, 2024, the Company used \$7.0 million of cash in operating activities and expects to continue to incur cash outflows in 2024. Because of the numerous risks and uncertainties associated with the Companyâ€™s commercialization and development efforts, the Company is unable to predict when it will become profitable, and it may never become profitable. The Companyâ€™s inability to achieve and then maintain profitability would negatively affect its business, financial condition, results of operations and cash flows. Furthermore, even if the Company does achieve profitability, it may not be able to sustain or increase profitability on an ongoing basis, or, in general, be able to satisfy its obligations, including those related to the FiberCel Litigation and VBM Litigation described in Note 10, when they become due. â€¢In order to mitigate the current and potential future liquidity issues caused by the matters noted above, we may seek to raise capital through the issuance of common stock or pursue asset sales or other transactions, such as the sale of the Orthobiologics Business described above. A However, such transactions may not be successful, and we may not be able to raise additional equity, refinance our debt instruments, or sell assets on acceptable terms, or at all. As such, based on our current operating plans, we believe there is uncertainty as to whether our future cash flows along with our existing cash, issuances of additional equity and cash generated from expected future sales will be sufficient to meet our anticipated operating needs through twelve months from the condensed consolidated financial statement issuance date. Due to these factors, there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the condensed consolidated financial statements. A The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. That is, the accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates and assumptions relating to inventories, receivables, long-lived assets, the valuation of stock-based awards, the valuation of the revenue interest obligation, the valuation of the warrant liability, the contingent liabilities for legal proceedings and deferred income taxes are made at the end of each financial reporting period by management. Management continually re-evaluates its estimates, judgments and assumptions, and management's evaluation could change. Actual results could differ from those estimates. Net Loss per Share Attributable to Common Stockholders Net Loss per Share Attributable to Common StockholdersOur common stock has a dual class structure, consisting of Class A common stock, \$0.001 par value per share (the â€œClass A common stockâ€) and Class B common stock, \$0.001 par value per share (the â€œClass B common stockâ€). Other than voting rights, the Class B common stock has the same rights as the Class A common stock, and therefore both are treated as the same class of stock for purposes of the earnings per share calculation. Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average shares outstanding during the period. For purposes of the diluted net income (loss) per share attributable to common stockholders calculation, stock options, restricted stock units (â€œRSUsâ€) and warrants are considered to be common stock equivalents. All common stock equivalents have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for both periods presented. Fair Value of Financial Instruments Fair Value of Financial InstrumentsFair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measures, the following hierarchy prioritizes the inputs to valuation methodologies used to measure fair value:Level 1â€‰%â€‰%Valuations based on quoted prices for identical assets and liabilities in active markets.Level 2â€‰%â€‰%Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.Level 3â€‰%â€‰%Valuations based on unobservable inputs reflecting the Companyâ€™s own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.The estimated fair value of financial instruments disclosed in the financial statements has been determined by using available market information and appropriate valuation methodologies. The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. Cash and Cash Equivalents Cash and Cash EquivalentsThe Company maintains its cash balances at banks and financial institutions. The balances are insured up to the legal limit. The Company maintains cash balances that may, at times, exceed this insured limit. The Company considers cash on hand, demand deposits in a bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. Accounts Receivable and Allowances Accounts Receivable and AllowancesAccounts receivable in the accompanying balance sheets are presented net of allowances for credit losses. The Company grants credit to customers in the normal course of business, but generally does not require collateral or any other security to support its receivables.The Company evaluates the collectability of accounts receivable based on a combination of factors. In circumstances where a specific customer is unable to meet its financial obligations to the Company, a provision to the allowance for doubtful accounts is recorded to reduce the net recognized receivable to the amount that is reasonably expected to be collected. For all other customers, a provision to the allowance for credit losses is recorded based on factors including the length of time the receivables are past due, the current business environment and the Companyâ€™s historical experience. Provisions to the allowance for doubtful accounts are recorded to general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. Inventories Inventory Property and Equipment Inventory, consisting of purchased materials, direct labor and manufacturing overhead, is stated at the lower of cost or net realizable value, with cost determined generally using the average cost method. At each balance sheet date, the Company also evaluates inventory for excess quantities, obsolescence or shelf-life expiration. This evaluation includes analysis of the Companyâ€™s current and future strategic plans, historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions and a review of the shelf-life expiration dates for products. To the extent that management determines there is excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.Property and EquipmentProperty and equipment are stated at cost less accumulated depreciation. Depreciation is computed on the straight-line method over the following estimated useful lives of the assets:â€¢â€¢â€¢â€¢Processing and research equipmentA A A 5 to 10 yearsOffice equipment and furnitureA 3 to 5 yearsComputer hardware and softwareA 3 yearsâ€¢Leasehold improvements are amortized on the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Repairs and maintenance costs are expensed as incurred. Leases LeasesIn February 2016, the Financial Accounting Standards Board (â€œFASBâ€) issued ASU No 2016-02, Leases to increase the transparency and comparability about leases among entities. ASU 2016-02 and certain additional ASUs are now codified as ASC 842, Leases. ASC 842 supersedes the lease accounting guidance in ASC 840 and requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. The Company determines if an arrangement contains a lease at inception. Right-of-use (â€œROUâ€) assets represent the Companyâ€™s right to use an underlying asset for the lease term and lease liabilities represent the Companyâ€™s obligation to make lease payments arising from that lease. For leases with a term greater than 12 months, ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The lease term includes the option to extend the lease when it is reasonably certain the Company will exercise

that option. When available, the Company uses the rate implicit in the lease to discount lease payments to present value. In the case the implicit rate is not available, the Company uses its incremental borrowing rate based on information available at the lease commencement date, including publicly available data for instruments with similar characteristics, to determine the present value of lease payments. The Company combines lease and non-lease elements for office leases. During the six months ended June 30, 2024, the Company entered into lease extensions in Silver Spring, Maryland and Roswell, Georgia and entered into a new lease in San Diego, California, which collectively resulted in operating lease right-to-use assets and liabilities of \$1.4 million. Such new leases will result in future cash obligations of \$0.3 million for the six months ended December 31, 2024 and \$0.6 million, \$0.7 million and \$0.1 million for the years ended December 31, 2025, 2026 and 2027, respectively. Long-Lived Assets Long-Lived Assets Purchased intangible assets with finite lives are carried at acquired fair value, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets. The Company periodically evaluates the period of depreciation or amortization for long-lived assets to determine whether current circumstances warrant revised estimates of useful lives. The Company reviews its property and equipment and intangible assets for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment exists when the carrying value of the company's asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset. If impairment exists, the carrying value of that asset is adjusted to its fair value. A discounted cash flow analysis is used to estimate an asset's fair value, using assumptions that market participants would apply. The results of impairment tests are subject to management's estimates and assumptions of projected cash flows and operating results. Changes in assumptions or market conditions could result in a change in estimated future cash flows and could result in a lower fair value and therefore an impairment, which could impact reported results. There were no impairment losses for the three and six months ended June 30, 2024 or 2023. Warrant Liability The Company accounts for its warrants in accordance with ASC 815, Derivatives and Hedging - Contracts in Entity's Own Equity, as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Prefunded and Common Warrants issued in connection with the September 2023 private placement (see Note 9) are classified as liabilities and are recorded at fair value. The warrants are subject to re-measurement at each settlement date and at each balance sheet date and any change in fair value is recognized in other expense (income), net in the condensed consolidated statements of operations. The Company estimates the fair value of the warrant liability using a Black-Scholes pricing model. We are required to make assumptions and estimates in determining an appropriate term, risk-free interest rate, volatility factor, dividend yield, and the fair value of common stock. Any significant adjustments to the unobservable inputs would have a direct impact on the fair value of the warrant liability. Revenue Recognition Revenue Recognition The Company's revenue is generated from contracts with customers in accordance with ASC 606. The core principle of ASC 606 is that the Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The ASC 606 revenue recognition model consists of the following five steps: (1) identify the contracts with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. As noted above, the Company enters into contracts to primarily sell and distribute products to healthcare providers or commercial partners. Revenue is recognized when the Company has met its performance obligations pursuant to its contracts with its customers in an amount that the Company expects to be entitled to in exchange for the transfer of control of the products to the Company's customers. For all product sales, the Company has no further performance obligations and revenue is recognized at the point control transfers which occurs either when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, in accordance with the terms of the agreement. A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and from inventory physically held by distributors and direct sales representatives. For these types of products sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized. The Company elected to account for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. The related shipping and freight charges incurred by the Company are included in sales and marketing costs. Contracts with customers state the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company's contracts vary; however, as a common business practice, payment terms are typically due in full within 30 to 60 days of delivery. The Company, at times, extends volume discounts to customers. The Company permits returns of its products in accordance with the terms of contractual agreements with customers. Allowances for returns are provided based upon analysis of the Company's historical patterns of returns matched against the revenues from which they originated. The Company records estimated returns as a reduction of revenue in the same period revenue is recognized. Stock-Based Compensation Plans Stock-Based Compensation Plans The Company accounts for its stock-based compensation plans in accordance with ASC 718, Accounting for Stock Compensation. ASC 718 requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors, including employee stock options and restricted stock. Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight-line basis over the requisite service period of the entire award. Research and Development Costs Research and Development Costs Research and development costs, which include mainly salaries, outside services and supplies, are expensed as incurred. Concentration of Credit Risk Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company's cash balances with the individual institutions may at times exceed the federally insured limits. There were two customers that represented 14% and 11%, respectively, of the Company's net sales for the six months ended June 30, 2024. Additionally, there were two customers that represented 26% and 12%, respectively, of the Company's accounts receivable as of June 30, 2024. Comprehensive Income (Loss) Comprehensive Income (Loss) Comprehensive income (loss) comprises net income (loss) and other changes in equity that are excluded from net income (loss). For the three and six months ended June 30, 2024 and 2023, the Company's net loss equalled its comprehensive loss and accordingly, no additional disclosure is presented. Income Taxes Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred income taxes are recorded to reflect the tax consequences on future years for differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to amounts that are more likely than not to be realized. The Company is subject to income taxes in the federal and state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting for uncertainty in income taxes, the Company recognizes tax liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is more likely than not (greater than 50%) of being realized upon settlement. The Company's policy is to recognize interest and/or penalties related to income tax matters in income tax expense. X - References No definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + References No definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.9-03\(1\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.9-03(1)(a))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478546/942-210-50-1> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-1> + Details Name: us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for comprehensive income. + References No definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for credit risk. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 942-SubTopic 825-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478898/942-825-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for determining the fair value of financial instruments. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 825-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-1> + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(SAB Topic 5.CC\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480091/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (SAB Topic 5.CC)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480091/360-10-50-1) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 05-Paragraph 4-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482338/360-10-50-4> + Details Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-20> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-19> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-25> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(SX 210.6-03\(b\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (SX 210.6-03(b)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-50-3) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17) Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-9> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-28> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-1> + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.5-02\(6\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.5-02(6)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-50-1) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 330-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483080/330-10-50-1> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483489/210-10-50-1> Reference 4: [http://www.xbrl.org/2003/role/exampleRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 912-SubTopic 330-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478411/912-330-50-1> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 330-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/330/tableOfContentReference 7> <http://www.xbrl.org/2003/role/disclosureRef-Topic 330-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483080/330-10-50-4> Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 6-Subparagraph \(a\)-SubTopic 10-Topic 270-Publisher FASB-URI https://asc.fasb.org/1943274/2147482989/270-10-45-6](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 6-Subparagraph (a)-SubTopic 10-Topic 270-Publisher FASB-URI https://asc.fasb.org/1943274/2147482989/270-10-45-6) + Details Name: us-gaap_InventoryPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for leasing arrangement entered into by lessee. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-1) + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (SX 210.7-03(a)(8)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-50-1) Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 6-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-6> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1) + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Definition Disclosure of accounting policy for costs that has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge

[a plan or design for a new product or process or for a significant improvement to an existing product or process.](#) + [ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 730 - SubTopic 10 - Name Accounting Standards Codification - Section 05 - Paragraph 1 - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer.](#) + [ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 17 - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 18 - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 18 - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 20 - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 20 - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 20 - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef - Topic 606 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 20 - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef - Name Accounting Standards Codification - Section 50 - Paragraph 4 - Subparagraph \(e\) - SubTopic 10 - Topic 235 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification - Topic 606 - Publisher FASB - URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.](#) + [ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(f\)\(1\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(f\)\(2\)\(i\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(f\)\(2\)\(ii\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(f\)\(2\)\(v\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SAB Topic 14.D.3.C\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479830/718-10-599-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SAB Topic 14.D.1.Q5\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479830/718-10-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 599 - Paragraph 1 - Subparagraph \(SAB Topic 14.D.2.Q6\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147479830/718-10-599-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - Name Accounting Standards Codification - Publisher FASB - URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(f\)\(2\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable.](#) + [ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef - Topic 310 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 6 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481962/310-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 310 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 310 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481962/310-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef - Topic 310 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481569/310-20-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef - Topic 310 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 15 - Subparagraph \(d\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481962/310-10-50-15Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef - Topic 310 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 11B - Subparagraph \(b\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.](#) + [ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification - Topic 275 - SubTopic 10 - Section 50 - Paragraph 9 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification - Topic 275 - SubTopic 10 - Section 50 - Paragraph 4 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph \(b\) - SubTopic 10 - Topic 275 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph \(c\) - SubTopic 10 - Topic 275 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification - Section 50 - Paragraph 11 - SubTopic 10 - Topic 275 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Name Accounting Standards Codification - Section 50 - Paragraph 12 - SubTopic 10 - Topic 275 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification - Topic 275 - SubTopic 10 - Section 50 - Paragraph 8 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Recently Issued Accounting Standards \(Policies\) 6 Months Ended Jun. 30, 2024 Recently Issued Accounting Standards A Recently Issued Accounting Standards In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting \(Topic 280\): Improvements to Reportable Segment Disclosures. This update improves reportable segment disclosure requirements, primarily through enhanced disclosures of significant segment expenses. The amendments in this update should be applied retrospectively to all prior periods presented in the condensed consolidated financial statements and are effective for fiscal years beginning after December 31, 2023 and interim periods within fiscal years beginning after December 31, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements. â€In December 2023, the FASB issued ASU No. 2023-09, Income Taxes \(Topic 740\): Improvement to Income Tax Disclosures. This update improves income tax disclosure requirements, primarily through enhanced transparency and decision usefulness of disclosures. The amendments in this update should be applied prospectively with the option to apply retrospectively and are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact of this guidance on its condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies \(Tables\) 6 Months Ended Jun. 30, 2024 Summary of Significant Accounting Policies A Summary of estimated useful lives of the assets â€â€â€](#)

[illegible]

Balance Type: na Period Type: duration X - DefinitionAmount of consideration receivable after closing in the form of earn-out payments to be received for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: elut DisposalGroupIncludingDiscontinuedOperationConsiderationPayableAfterClosing Namespace Prefix: elut Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe percent on actual revenue payable to the selling entity in the applicable year that is derived from sales of the Products defined as "Earn-Out Products" under the Purchase Agreement, + ReferencesNo definition available. + Details Name: elut DisposalGroupIncludingDiscontinuedOperationConsiderationPayableAfterClosingEarnOutOnRevenuePercent Namespace Prefix: elut Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRepresents the amount of earn-out payments received during the reported period under the sale of entity's assets and business. + ReferencesNo definition available. + Details Name: elut DisposalGroupIncludingDiscontinuedOperationEarnOutAmount Namespace Prefix: elut Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the indemnity holdback amount to be held by buyer under the purchase agreement. + ReferencesNo definition available. + Details Name: elut DisposalGroupIncludingDiscontinuedOperationIndemnityHoldbackAmount Namespace Prefix: elut Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the indemnity hold back retention period by buyer under the purchase agreement. + ReferencesNo definition available. + Details Name: elut DisposalGroupIncludingDiscontinuedOperationIndemnityHoldbackAmountRetentionPeriod Namespace Prefix: elut Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3> + Details Name: us-gaap DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPeriod of expected continuing involvement with a discontinued operation after the disposal date, in "PnYnMndTnHnMns" format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B) + Details Name: us-gaap DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147486667/40-323-65-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147486667/40-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrli.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrli.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrli.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrli.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrli.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrli.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrli.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrli.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrli.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrli.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrli.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrli.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrli.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrli.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrli.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrli.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 45 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12) + Details Name: us-gaap ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrli.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(2\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrli.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=elut OrthobiologicsBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DisposalGroupClassificationAxis=us-gaap DiscontinuedOperationsDisposedOffBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Net Loss per Share (Details) - \$ / shares Jun. 30, 2024 Dec. 31, 2023 Class A Common stock Ã A Net Loss per Share Attributable to Common Stockholders Ã A Common stock, par value (in dollar per share) \$ 0.001 \$ 0.001 Class B Common stock Ã A Net Loss per Share Attributable to Common Stockholders Ã A Common stock, par value (in dollar per share) \$ 0.001 \$ 0.001 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Property and Equipment (Details) Jun. 30, 2024 Computer hardware and software Á Property, Plant and Equipment Á Estimated useful lives 3 years Minimum | Processing and research equipment Á Property, Plant and Equipment Á Estimated useful lives 5 years Minimum | Office equipment and furniture Á Property, Plant and Equipment Á Estimated useful lives 3 years Maximum | Processing and research equipment Á Property, Plant and Equipment Á Estimated useful lives 10 years Maximum | Office equipment and furniture Á Property, Plant and Equipment Á Estimated useful lives 5 years X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMndTnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=elut_ProcessingAndResearchEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.RangeAxis=srt.MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Leases (Details) \$ in Millions Jun. 30, 2024 USD (\$) Summary of Significant Accounting Policies Á Right-of-use assets \$ 1.4 Lease liabilities 1.4 Future minimum lease commitments under non-cancelable operating leases Á For the six months ended December 31, 2024 0.3 Year ended December 31, 2025 0.6 Year ended December 31, 2026 0.7 Year ended December 31, 2027 0.1 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Long-Lived Assets (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Long-Lived Assets Á Á Á Impairment losses \$ 0 \$ 0 \$ 0 \$ 0 X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TangibleAssetImpairmentChargesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Revenue Recognition (Details) 6 Months Ended Jun. 30, 2024 Minimum Á Disaggregation of Revenue Á Term of payment 30 days Maximum Á Disaggregation of Revenue Á Term of payment 60 days X - DefinitionRepresents the term for payment for contracts with customers. + ReferencesNo definition available. + Details Name: elut_RevenueFromContractWithCustomerTermOfPayment Namespace Prefix: elut_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: srt.RangeAxis=srt.MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.RangeAxis=srt.MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Concentration of Credit risk (Details) - Customer concentration risk 6 Months Ended Jun. 30, 2024 customer Revenues Á Concentration Risk [Line Items] Á Number of major customer 2 Revenues | One Customer Á Concentration Risk [Line Items] Á Concentration risk (as a percent) 14.00% Revenues | Another customer Á Concentration Risk [Line Items] Á Concentration risk (as a percent) 11.00% Accounts Receivable Á Concentration Risk [Line Items] Á Number of major customer 2 Accounts Receivable | One Customer Á Concentration Risk [Line Items] Á Concentration risk (as a percent) 26.00% Accounts Receivable | Another customer Á Concentration Risk [Line Items] Á Concentration risk (as a percent) 12.00% X - DefinitionNumber of major customers. + ReferencesNo definition available. + Details Name: elut_NumberOfMajorCustomers Namespace Prefix: elut_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.MajorCustomersAxis=elut.CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt.MajorCustomersAxis=elut.CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CustomersReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Sale of Orthobiologics Business - Financial results (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Sale of Orthobiologics Business Á Á Á Gain on sale of Orthobiologics Business Á Á \$ 180 Á Divestiture of Orthobiologics | Discontinued Operations, Disposed of by Sale Á Á Á Sale of Orthobiologics Business Á Á Á Gain on sale of Orthobiologics Business \$ 200 Á Á Financial results Á Á Á Á Net sales \$ 3,945 Á \$ 10,603 Cost of goods sold \$ 5,678 Á 9,378 Gross profit Á (1,733) Á 1,225 Sales and marketing Á 596 Á 1,262 General and administrative Á 143 Á 304 Research and development Á 304 Á 513 Total operating expenses Á 1,043 Á 2,079 Interest Expense Á 115 Á 230 Net income (loss) Á \$ (2,891) Á \$ (1,084) X - DefinitionAmount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: elut_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense Namespace Prefix: elut_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesNo definition available. + Details Name: elut_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense Namespace Prefix: elut_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of gross profit attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B + Details Name: us-

gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense attributable to disposal group, including, but not limited to, discontinued operation. + ReferencesReference 1:

Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionOther than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=elut_StockOptionPlan2020Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Stock Options Activity (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Number of Shares A Outstanding at the beginning 1,501,193 A Granted 1,790,654 A Forfeited (53,433) A Outstanding at the end 3,238,414 1,501,193 Vested and exercisable at the end 1,138,985 A Weighted-Average Exercise Price A A Outstanding at the beginning (in dollars per share) \$ 8.37 A Granted (in dollars per share) 3.59 A Forfeited (in dollars per share) 10.85 A Outstanding at the end (in dollars per share) 5.23 \$ 8.37 Vested and exercisable at the end (in dollars per share) \$ 6.80 A Weighted-Average Remaining Contractual Term (years) A A Outstanding (in years) 7 years 9 months 18 days 7 years 9 months 18 days Vested and exercisable (in years) 8 years A Aggregate Intrinsic Value A A Aggregate Intrinsic Value (in dollars) \$ 3,034 A Vested and exercisable at the end (in dollars) \$ 776 A Other Disclosures A A Weighted average grant date fair value of options granted \$ 2.38 A Employee Stock Option A A Stock-Based Compensation A A Exercise price as a percentage of market value of share of common stock at closing on the date of the grant 100.00% A Contractual term 10 years A Other Disclosures A A Total unrecognized compensation expense \$ 4,600 A Weighted-average recognition period 2 years 1 month 6 days A Employee Stock Option I Minimum A A Stock-Based Compensation A A Vesting period 3 years A Employee Stock Option I Maximum A A Stock-Based Compensation A A Vesting period 4 years A Options that vest 10th day after FDA's approval of CanGarooRM product A A Number of Shares A A Granted 397,640 A Options that vest on achievements of price thresholds A A Number of Shares A A Granted 162,500 A Outstanding at the end 345,011 A Other Disclosures A A Share price threshold period 20 days A Period to recognize costs 3 years A X - DefinitionRepresents the exercise price as a percentage of market value of share of common stock at closing on the date of the grant. + ReferencesNo definition available. + Details Name: elut_ExercisePriceAsPercentageOfMarketValueOfShareOfCommonStock Namespace Prefix: elut_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionExpected expense recognition period of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExpenseRecognitionTerm Namespace Prefix: elut_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract Namespace Prefix: elut_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe period over which share price threshold is calculated for performance awards to vest, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: elut_ShareBasedCompensationPerformanceBasedSharePricePeriod Namespace Prefix: elut_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if

forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(e\)\(1\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=elut_PerformanceBasedOptionsProductApprovalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=elut_PerformanceBasedOptionsMarketConditionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=elut_PerformanceBasedOptionsMarketConditionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Option Valuation Assumption (Details) - Employee Stock Option 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Weighted-average assumptions were used to determine the fair value of options $\text{\$} \text{ } \text{\$}$ Dividend yield assumption to estimate fair value 0.00% 0.00% 0.00% 0.00% Expected term (years) $\text{\$}$ $\text{\$}$ 5 years 10 months 24 days 6 years Risk-free interest rate $\text{\$}$ $\text{\$}$ 3.30% 3.90% Volatility factor $\text{\$}$ $\text{\$}$ 100.90% 63.80% Dividend yield 0.00% 0.00% 0.00% 0.00% X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(f\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Restricted Stock Units (Details) $\text{\$}$ / shares in Units, $\text{\$}$ in Millions 6 Months Ended Jun. 30, 2024 USD ($\text{\$}$) $\text{\$}$ / shares shares Restricted stock units $\text{\$}$ Weighted-Average Grant Date Fair Value $\text{\$}$ Total fair value of the restricted stock units granted | $\text{\$}$ 8.2 Unrecognized compensation costs | $\text{\$}$ 5.9 Weighted-average recognition period 2 years 2 months 12 days Restricted stock units | Minimum $\text{\$}$ Weighted-Average Grant Date Fair Value $\text{\$}$ Vesting period 3 years Restricted stock units | Maximum $\text{\$}$ Weighted-Average Grant Date Fair Value $\text{\$}$ Vesting period 4 years Restricted stock units | 2020 Plan $\text{\$}$ Number of Shares Underlying RSUs $\text{\$}$ Unvested at the beginning 335,608 Granted 2,267,500 Vested (303,844) Forfeited (81,048) Outstanding at the end 2,218,216 Weighted-Average Grant Date Fair Value $\text{\$}$ Unvested at the beginning (in dollars per share) | $\text{\$}$ / shares $\text{\$}$ 3.64 Granted (in dollars per share) | $\text{\$}$ / shares $\text{\$}$ 3.59 Vested (in dollars per share) | $\text{\$}$ / shares $\text{\$}$ 3.93 Forfeited (in dollars per share) | $\text{\$}$ / shares $\text{\$}$ 2.72 Unvested at the ending (in dollars per share) | $\text{\$}$ / shares $\text{\$}$ 3.59 RSUs that vest 10th day after FDA's approval of CanGarooRM product $\text{\$}$ Number of Shares Underlying RSUs $\text{\$}$ Granted 560,625 RSUs that vest on achievements of price thresholds $\text{\$}$ Number of Shares Underlying RSUs $\text{\$}$ Granted 162,500 Outstanding at the end 252,394 Weighted-Average Grant Date Fair Value $\text{\$}$ Period over which price must exceed $\text{\$}$ 10 for awards to vest 20 days Period to recognize costs 3 years X - DefinitionFair value of share-based awards granted. + ReferencesNo definition available. + Details Name: elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionExpected expense recognition period of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExpenseRecognitionTerm Namespace Prefix: elut_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionPeriod over which share price must exceed pre-determined price by certain date as a vesting condition, in a share-based agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: elut_ShareBasedPaymentArrangementSharePricePeriodForVesting Namespace Prefix: elut_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2:

-Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod WeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSU Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=elut_StockOptionPlan2020 Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=elut_RestrictedStockUnitsProductApprovalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=elut_RestrictedStockUnitsMarketConditionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan 3 Months Ended 6 Months Ended Jun. 30, 2024 shares Jun. 30, 2024 shares Stock-Based Compensation A A Offering period A 6 months Price of the common stock purchased as percentage of fair market value of common stock A 85.00% Grant of equity awards authorized 774,341 774,341 Awards available for grant 502,325 502,325 Shares issued under ESPP 65,459 65,459 X - DefinitionThe offering period of employee stock purchase plan, in "PnYnMdTnHnMnS" format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: elut_EmployeeStockPurchasePlanOfferingPeriod Namespace Prefix: elut_Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-2-Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD (\$) in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Stock-Based Compensation A A A Stock-based compensation expense \$ 2,711 \$ 679 \$ 4,908 \$ 1,355 Stock-based compensation A A A 65 Sales and marketing A A A Stock-Based Compensation A A A Stock-based compensation expense 485 158 933 301 General and administrative A A A Stock-Based Compensation A A A Stock-based compensation expense 1,778 440 3,201 893 Research and development A A A Stock-Based Compensation A A A Stock-based compensation expense 356 39 610 79 Cost of goods sold A A A Stock-Based Compensation A A A Stock-based compensation expense \$ 92 \$ 42 \$ 164 \$ 82 X - DefinitionAmount of stock-based compensation attributable discontinued operations. + ReferencesNo definition available. + Details Name: elut_StockBasedCompensationDiscontinuedOperations Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventory (Details) - USD (\$) in Thousands Jun. 30, 2024 Dec. 31, 2023 Inventory A A Raw materials \$ 341 \$ 242 Work in process 498 286 Finished goods 2,276 3,325 Total \$ 3,115 \$ 3,853 X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrli.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: <http://www.xbrli.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: elut_DebtInstrumentBasisSpreadOnVariableRateInKind Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe fee, expressed as a percentage of the debt instrument, for exit. + ReferencesNo definition available. + Details Name: elut_DebtInstrumentExitFeePercent Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe termination fee amount added to the exit fee percent of the aggregate principal amount funded prior to termination transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesNo definition available. + Details Name: elut_DebtInstrumentExitFeePercentagePlusAmount Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionInterest rate in kind on debt instrument as an option for interest payment. + ReferencesNo definition available. + Details Name: elut_DebtInstrumentInterestInKind Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionThe pre-payment penalty after first anniversary, expressed as a percentage of the outstanding principal amount of debt. + ReferencesNo definition available. + Details Name: elut_DebtPrepaymentPenaltiesAfterFirstAnniversary Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionThe percentage of pre-payment penalties prior to first anniversary of the debt, as a percentage of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the debt. + ReferencesNo definition available. + Details Name: elut_DebtPrepaymentPenaltiesPriorToFirstAnniversary Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionQuarterly principal amortization as a percentage of the funded amount at the time of the closing of the loan facility agreement. + ReferencesNo definition available. + Details Name: elut_DebtQuarterlyPrincipalAmortizationAsPercentToFundedAmount Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionThe threshold amount of non-ordinary course asset sales in excess of which is exempted from mandatory prepayment. + ReferencesNo definition available. + Details Name: elut_LoanAgreementCovenantThresholdAmountOfAssetSaleMandatoryPrepayment Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe amount of threshold of casualty proceeds of assets upon which the lender or agent maintains a lien in excess of which is to redeem the loan balance + ReferencesNo definition available. + Details Name: elut_LoanFacilityMandatoryPrepaymentCasualtyProceedsOfSecurityExcess Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe percentage of mandatory redemption of term loan facility amount of any casualty proceeds in excess of \$250,000 with respect to assets upon which the lender or agent maintains a lien. + ReferencesNo definition available. + Details Name: elut_LoanFacilityMandatoryPrepaymentPercentageCasualtyProceedsOfSecurity Namespace Prefix: elut_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number shares issuable in the exercise of warrants at the closing date of a financing. + ReferencesNo definition available. + Details Name: elut_MaximumIssuableSharesForWarrantsAtClosingOffFinancing Namespace Prefix: elut_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of new warrants issued during the period. + ReferencesNo definition available. + Details Name: elut_WarrantsIssuedDuringPeriod Namespace Prefix: elut_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. +

Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1:

DefinitionRepresents the percentage of payment made of the total amount paid for revenue interest obligation. + ReferencesNo definition available. + Details Name: elut_RevenueInterestObligationPercentageOfPaymentsMade Namespace Prefix: elut_Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 - SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - DefinitionFor a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 60 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1 + Details Name: us-gaap_GainsLossesOnRestructuringOfDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - Details Name: us-gaap_FairValueByLiabilityClassAxis=elut_RevenueInterestObligationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=elut_LigandPharmaceuticalsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=elut_WhenCumulativeSalesOfProductsExceed300OMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=elut_WhenCumulativeSalesOfProductsExceed100OMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: DOCUMENT v3.24.2.u1 Common Stock and Warrants - Registered Direct Offering of Common Stock and Warrants (Details) - USD (\$) / shares in Units, \$ in Millions 3 Months Ended 6 Months Ended Jun. 24, 2024 Jun. 30, 2024 Jun. 30, 2024 2024 Prefund Warrants Á Á Á Common Stock and Warrants Á Á Á Exercise price (in dollar per share) Á \$ 0.001 \$ 0.001 Registered Direct Offering of Common Stock and Warrants Á Á Á Common Stock and Warrants Á Á Á Proceeds from issuance of shares \$ 13.3 Á Á Transaction fees \$ 1.4 Á Á Amount allocated to issuance of the common stock Á \$ 1.1 \$ 1.1 Registered Direct Offering of Common Stock and Warrants | 2024 Prefund Warrants Á Á Á Common Stock and Warrants Á Á Á Warrants sold 725,000 Á Á Price per warrant (in USD per share) \$ 3.399 Á Á Exercise price (in dollar per share) \$ 0.001 Á Á Registered Direct Offering of Common Stock and Warrants | Class A Common stock Á Á Á Common Stock and Warrants Á Á Á Shares sold (in shares) 3,175,000 Á Á Price per share (in USD per share) \$ 3.40 Á Á Amount allocated to issuance of the common stock \$ 1.1 Á Á X - DefinitionPer share amount received for each share of warrant sold in the stock transaction. + ReferencesNo definition available. + Details Name: elut_WarrantPricePerShare Namespace Prefix: elut_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionNumber of new warrants issued during the period. + ReferencesNo definition available. + Details Name: elut_WarrantsIssuedDuringPeriod Namespace Prefix: elut_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidarySaleOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemBalance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=elut_RegisteredDirectOfferingOfCommonStockAndWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock and Warrants - Private Placement of Common Stock (Details) \$ / shares in Units, \$ in Millions Sep. 21, 2023 USD (\$) \$ / shares shares Jun. 30, 2024 \$ / shares Dec. 31, 2023 \$ / shares Private Placement Á Á Á Private Placement of Common Stock Á Á Á Aggregate Common units sold | shares 6,852,811 Á Á Number of Prefund Units to sell | shares 503,058 Á Á Common unit purchase price (in dollar per unit) \$ 1.4275 Á Á Prefund unit purchase price (in dollar per unit) \$ 1.4265 Á Á Proceeds from private placement and warrants | \$ 10.5 Á Á Private placement fees | \$ 1.1 Á Á Class A Common stock Á Á Á Private Placement of Common Stock Á Á Á Common stock, par value (in dollar per share) Á \$ 0.001 \$ 0.001 Class A Common stock | Private Placement Á Á Á Private Placement of Common Stock Á Á Á Number of common stock per warrant (in shares) | shares 1.5 Á Á Amount allocated to issuance of the common stock | \$ 0.4 Á Á Common stock warrants | Private Placement Á Á Á Private Placement of Common Stock Á Á Á Number of common stock per unit | shares 1 Á Á Number of trading days after clearance by the U.S. Food & Drug Administration of the Company's CanGarooRM antibiotic-eluting biologic envelope to exercise warrant | D 30 Á Á Warrants term 5 years Á Á Exercise price (in dollar per share) \$ 1.4275 Á Á 2023 Prefund Warrants Á Á Á Private Placement of Common Stock Á Á Á Exercise price (in dollar per share) Á \$ 0.001 Á 2023 Prefund Warrants | Private Placement Á Á Á Private Placement of Common Stock Á Á Á Proceeds from private placement and warrants | \$ 8.6 Á Á Prefund Warrants | Private Placement Á Á Á Private Placement of Common Stock Á Á Á Number of common stock per warrant (in shares) | shares 1 Á Á Exercise price (in dollar per share) \$ 0.001 Á Á X - DefinitionThe number of common units sold during the reported period. + ReferencesNo definition available. + Details Name: elut_CommonUnitsSold Namespace Prefix: elut_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionThe number of common stocks for each common units old during the reported period. + ReferencesNo definition available. + Details Name: elut_CommonUnitsSoldNumberOfStockEachUnit Namespace Prefix: elut_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionAmount paid per common units sold. + ReferencesNo definition available. + Details Name: elut_CommonUnitsSoldPricePerShare Namespace Prefix: elut_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe number of prefund units sold during the reported period. + ReferencesNo definition available. + Details Name: elut_PrefundUnitsSold Namespace Prefix: elut_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionAmount paid per prefund units sold. + ReferencesNo definition available. + Details Name: elut_PrefundUnitsSoldPricePerShare Namespace Prefix: elut_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe number of trading days after the approval of a product to exercise warrants. + ReferencesNo definition available. + Details Name: elut_WarrantNumberOfTradingDaysToExerciseAfterApprovalOfProduct Namespace Prefix: elut_Data Type: xbrli:integerItemBalance Type: na Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each

warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <https://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1> + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidarySaleOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_CommonStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundedWarrants2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock and Warrants - Warrant Activity (Details) - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Jun. 16, 2024 Sep. 21, 2023 Jun. 30, 2024 Jun. 30, 2024 Common stock warrants A A A Warrants A A A Outstanding A A A 11,033,804 Exercised A A A (1,366,025) Outstanding A A A 9,667,779 9,667,779 2024 Prefunded Warrants A A A Warrants A A A Issued A A A 725,000 Outstanding A A A 725,000 725,000 2023 Prefund Warrants A A A Warrants A A A Outstanding A A A 503,058 Exercised A A A (261,470) Outstanding A A A 241,588 241,588 Registered Direct Offering of Common Stock and Warrants and Private Placement | Prefunded Warrants A A A Warrants A A A Transaction fees A A A 0.3 0.3 Registered Direct Offering of Common Stock and Warrants A A A Warrants A A A Transaction fees \$ 1.4 A A A Registered Direct Offering of Common Stock and Warrants | 2024 Prefunded Warrants A A A Warrants A A A Proceeds from private placement and warrants A A A \$ 2.5 A A A Private Placement A A A Warrants A A A Proceeds from private placement and warrants A A A \$ 8.6 A A X - DefinitionNumber of warrants or rights exercised during the period. + ReferencesNo definition available. + Details Name: elut_ClassOfWarrantOrRightExercised Namespace Prefix: elut_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights issued during the period. + ReferencesNo definition available. + Details Name: elut_ClassOfWarrantOrRightIssued Namespace Prefix: elut_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15> + Details Name: us-gaap_PaymentOfFinancingAndStockIssuanceCosts Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidarySaleOfStockAxis=elut_CommonStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundedWarrants2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=elut_RegisteredDirectOfferingOfCommonStockAndWarrantsAndPrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_RegisteredDirectOfferingOfCommonStockAndWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=elut_RegisteredDirectOfferingOfCommonStockAndWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock and Warrants - Warrants fair value rolloffwand (Details) - USD (\$) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2024 Warrants A A Warrant liability A A \$ 12,760 Fair value adjustment \$ (18,337) (27,974) Warrant liability 39,018 39,018 Offering Warrants A A Warrants A A Warrant liability A A 12,760 Fair value upon issuance A A 2,464 Fair value adjustment 18,300 (27,974) Exercised A (4,180) Warrant liability 39,018 39,018 Common stock warrants A A Warrants A A Warrant liability A A 11,670 Fair value adjustment A (25,670) Exercised A (3,116) Warrant liability 34,224 34,224 2023 Prefund Warrants A A Warrants A A Warrant liability A A 1,090 Fair value adjustment A (1,172) Exercised A (1,064) Warrant liability 1,198 1,198 2024 Prefunded Warrants A A Warrants A A Fair value upon issuance A A 2,464 Fair value adjustment A (1,132) Warrant liability \$ 3,596 3,596 X - DefinitionValue of exercised derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price + ReferencesNo definition available. + Details Name: elut_WarrantsAndRightsExercised Namespace Prefix: elut_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionValue of preferred stock and warrants for common stock issued. + ReferencesNo definition available. + Details Name: us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_CommonStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundedWarrants2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=elut_PrefundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Common Stock and Warrants - Warrant pricing inputs (Details) \$ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Sep. 21, 2023 USD (\$) \$ / shares Jul. 31, 2024 USD (\$) Jun. 30, 2024 USD (\$) Y \$ / shares Jun. 30, 2024 USD (\$) Y \$ / shares Dec. 31, 2023 USD (\$) Y \$ / shares Warrant Liabilities A A A Gross proceeds allocated to common shares A A A \$ 12,390 A Warrant liability value A A \$ 39,018 39,018 \$ 12,760 Change in fair value A A (18,300) 27,974 A Common stock warrants A A A Warrant Liabilities A A A Warrant liability value A A \$ 34,224 34,224 \$ 11,670 Change in fair value A A \$ 25,670 A Proceeds from exercise of warrants A A \$ 13,800 A A Common stock warrants | Common stock price A A A A Warrant Liabilities A A A Fair value calculation input | \$ / shares A A 4.96 4.96 2.16 Common stock warrants | Expected term (years) A A A A Warrant Liabilities A A A Fair value calculation input | Y A A 0.1 0.1 0.7 Common stock warrants | Risk-free interest rate A A A A Warrant Liabilities A A A Fair value calculation input A A 5.5 5.5 5.1 Common stock warrants | Volatility factor A A A A Warrant Liabilities A A A Fair value calculation input A A 88.4 88.4 107.3 2023 Prefund Warrants A A A A Warrant Liabilities A A A A Warrant liability value A A \$ 1,198 \$ 1,198 \$ 1,090 Change in fair value A A \$ 1,172 A Exercise price (in dollar per share) | \$ / shares A A \$ 0.001 \$ 0.001 A 2024 Prefunded Warrants A A A A Warrant Liabilities A A A A Warrant liability value A A \$ 3,596 3,596 A Change in fair value A A \$ 1,132 A Exercise price (in dollar per share) | \$ / shares A A \$ 0.001 \$ 0.001 A Private Placement A A A A Warrant Liabilities A A A A Proceeds from Issuance of Private Placement A A \$ 10,500 A A A Private Placement | Common stock warrants A A A A Warrant Liabilities A A A A Exercise price (in dollar per share) | \$ / shares A A 1.4275 A A A Private Placement | Prefunded Warrants A A A A Warrant Liabilities A A A A Exercise price (in dollar per share) | \$ / shares A A 0.001 A A A Private Placement | 2023 Prefund Warrants A A A A Warrant Liabilities A A A A Proceeds from Issuance of Private Placement \$ 8,600 A A A X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/214748112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482078/820-10-55-103>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 14: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 15: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 16: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 17: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 22: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI [https://asc](https://asc.fasb.org/1943274/2147482106/820-10-50-2)

[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap WarrantsAndRightsOutstanding Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap Data Type: xbrli:decimalItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap ClassOfWarrantOrRightAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=elut CommonStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=elut MeasurementInputCommonStockPriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap MeasurementInputTypeAxis=us-gaap MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=elut PrefundedWarrants2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=elut PrefundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=us-gaap PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=elut PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap Commitment and Contingencies - License and Supply (Details) - License agreement with Cook Biotech - USD (\$) \$ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Cook Biotech License and Supply Agreements A A A Percentage of royalty on sales A A 3.00% A Royalty expense \$ 0.0 \$ 0.0 \$ 0.0 \$ 0.0 License fee payments per year \$ 0.1 A \$ 0.1 X - DefinitionLicense fee payable annually per agreement. + ReferencesNo definition available. + Details Name: elut PaymentOfLicenseFeePerYear Namespace Prefix: elut Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionRepresents the information pertaining to percentage of royalty o sales. + ReferencesNo definition available. + Details Name: elut PercentageOfRoyaltyOnSales Namespace Prefix: elut Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap OtherCommitmentsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap RoyaltyExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap TypeOfArrangementAxis=elut LicenseAgreementWithCookBiotechMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitment and Contingencies - Legal Proceedings (Details) \$ in Millions 3 Months Ended 6 Months Ended 8 Months Ended 23 Months Ended 34 Months Ended Jun. 30, 2024 USD (\$) lawsuit item Sep. 30, 2023 person Jun. 30, 2024 USD (\$) lawsuit Jun. 30, 2024 USD (\$) person lawsuit Jun. 30, 2024 USD (\$) lawsuit Jun. 30, 2024 USD (\$) lawsuit Legal Proceedings A A A A Number of active lawsuits or claims filed or asserted | lawsuit 81 A 81 81 81 81 Receivable from litigation costs \$ 4.4 A \$ 4.4 A \$ 4.4 A \$ 4.4 A 4.4 FiberCel Litigation Product Liability A A A A Legal Proceedings A A A A Number of lawsuits filed or asserted | lawsuit A A A A 110 Number of active lawsuits or claims filed or asserted | lawsuit 81 A 81 81 81 81 Number of cases settled | lawsuit A A A A 29 A Total amount of settlements A A A \$ 9.1 A Total estimated liability \$ 16.4 A \$ 16.4 A 16.4 16.4 \$ 16.4 Receivable from litigation costs 0.4 A 0.4 \$ 0.4 0.4 0.4 Viable Bone Matrix Litigation A A A A Legal Proceedings A A A A Number of lawsuits filed or asserted | lawsuit A A A 21 A Number of patients affected from post-surgical mycobacterium tuberculosis (mtb) infections treated with vbm product | person A 2 A A A Number of individuals received tissue from the recalled VBM lot | person A A 36 A Total estimated liability 3.8 A 3.8 \$ 3.8 3.8 3.8 Receivable from litigation costs \$ 4.0 A 4.0 \$ 4.0 4.0 4.0 Settlement amount A \$ 0.0 A A Viable Bone Matrix Litigation, Fraudulent Inducement A A A A Legal Proceedings A A A A Number of active lawsuits or claims filed or asserted | lawsuit 1 A 1 1 1 1 Medtronic Litigation | Minimum A A A A Legal Proceedings A A A A Number of lawsuits without insurance coverage | item 100 A A A X - DefinitionThe number of lawsuits the entity alleges a counter party did not obtain insurance coverage from product usage per supply agreement with counter party. + ReferencesNo definition available. + Details Name: elut LitigationNumberOfLawsuitLackOfInsuranceCoverage Namespace Prefix: elut Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionNumber of patients affected from post-surgical mycobacterium tuberculosis (mtb) infections treated with vbm product. + ReferencesNo definition available. + Details Name: elut_NumberOfPatientsAffectedFromPostSurgicalMycobacteriumTuberculosisMtbInfectionsTreatedWithVbmProduct Namespace Prefix: elut Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionNumber of patients that received tissue from bone matrix ("VBM") product lot that was recalled. + ReferencesNo definition available. + Details Name: elut_NumberOfPatientsReceivedTissueFromRecalledVbmProduct Namespace Prefix: elut Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1> + Details Name: us-gaap LossContingenciesLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1>Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10> + Details Name: us-gaap LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionNumber of claims settled. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9) + Details Name: us-gaap LossContingencyClaimsSettledNumber Namespace Prefix: us-gaap Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionThe total number of new claims filed pertaining to a loss contingency during the period. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9) + Details Name: us-gaap LossContingencyPendingClaimsNumber Namespace Prefix: us-gaap Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionAmount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3> + Details Name: us-gaap LossContingencyReceivable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe amount of cash paid for the settlement of litigation or for other legal issues during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap PaymentsForLegalSettlements Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - Details Name: srt LitigationCaseAxis=elut FiberCellLitigationProductLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt LitigationCaseAxis=elut ViableBoneMatrixVbmProductLitigationFraudMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt LitigationCaseAxis=elut LawsuitAgainstMedtronicSofamorDanekUsaInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share (Details) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Numerator: A A A Net loss from continuing operations \$ (28,360) \$ (7,730) \$ (46,354) \$ (17,511) Net income from discontinued operations 180 (2,891) 180 (1,084) Net loss \$ (28,180) \$ (10,621) \$ (46,174) \$ (18,595) Denominator: A A A Weighted average number of common shares, basic (in shares) 24,900,167 16,223,919 24,408,651 16,208,905 Weighted average number of common shares, diluted (in shares) 24,900,167 16,223,919 24,408,651 16,208,905 Net loss from continuing operations per share - basic (in dollars per share) \$ (1.14) \$ (0.48) \$ (1.90) \$ (1.08) Net loss from continuing operations per share - diluted (in dollars per share) (1.14) (0.48) A Net income (loss) from discontinued operations per share - basic (in dollars per share) 0.01 (0.18) A Net income (loss) from discontinued operations per share - diluted (in dollars per share) 0.01 (0.18) 0.01 (0.07) Net loss per share - basic (in dollar per share) (1.13) (0.65) \$ (1.89) \$ (1.15) Net loss per share - diluted (in dollar per share) \$ (1.13) \$ (0.65) A A X - ReferencesNo definition available. + Details Name: elut_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract Namespace Prefix: elut Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/944-220-S99-1)

https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncomeAmountsAttributableToReportingEntityDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap IncomeLossFromContinuingOperationsPerBasicShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to

gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders. + ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16> + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Loss Per Share - Anti-dilutive securities (Details) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 16,278,966 2,158,453 Options to purchase common stock A A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 3,238,414 1,666,549 Restricted stock units A A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 2,218,216 303,935 Class A Warrants A A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 187,969 187,969 Common stock warrants A A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 9,667,779 A 2023 Prefunded Warrants A A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 241,588 A 2024 Prefunded Warrants A A Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] A A Anti-dilutive securities (in shares) 725,000 A X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=elut_ClassCommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=elut_CommonStockWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=elut_PrefundedWarrants2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=elut_PrefundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information - Disaggregation (Details) \$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 USD (\$ Jun. 30, 2023 USD (\$ Jun. 30, 2024 USD (\$) segment Jun. 30, 2023 USD (\$) Segment Reporting Information [Line Items] A A A Number of operating segments | segment A A A Total sales \$ 6,291 \$ 6,351 \$ 12,985 \$ 12,743 Gross profit, excluding intangible asset amortization 3,648 3,563 7,341 7,787 Intangible asset amortization expense 849 849 1,699 1,699 Gross profit 2,799 2,714 5,642 6,088 Device Protection A A A Segment Reporting Information [Line Items] A A A Total sales 2,639 2,221 4,996 4,571 Gross profit, excluding intangible asset amortization 1,571 1,499 3,200 3,294 Women's Health A A A Segment Reporting Information [Line Items] A A A Total sales 2,521 2,400 6,138 6,495 Gross profit, excluding intangible asset amortization 1,410 907 2,976 1,959 Cardiovascular A A A Segment Reporting Information [Line Items] A A A Total sales 1,081 1,730 1,851 3,477 Gross profit, excluding intangible asset amortization \$ 667 \$ 1,157 \$ 1,165 \$ 2,534 X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses, excluding intangible asset amortization, directly attributable to the revenue generation activity. + ReferencesNo definition available. + Details Name: elut_GrossProfitBeforeIntangibleAssetAmortization Namespace Prefix: elut_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\) \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)) (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 23: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18> + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItem Type Balance Type: na Period Type: duration X - DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4) + Details Name: us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=elut_DeviceProtectionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=elut_WomenSHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information - Reconciliation of segment gross profit (Details) - USD Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information - Reconciliation of segment gross profit (Details) - USD

\$ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024, Jun. 30, 2023, Jun. 30, 2023, Jun. 30, 2023 Reconciliation of segment gross profit to the consolidated loss from operations A A A A Gross Profit, Before Intangible Asset Amortization \$ 3,648 \$ 3,563 \$ 7,341 \$ 7,787 Adjustments: A A A A Intangible asset amortization expense (849) (849) (1,699) (1,699) Sales and marketing (3,330) (3,022) (6,639) (7,713) General and administrative (4,689) (3,861) (9,745) (7,381) Research and development (1,001) (869) (2,173) (2,460) FiberCell litigation costs, net (2,289) (1,271) (4,074) (3,182) Loss from operations (8,510) (6,309) (16,989) (14,648) Interest expense 1,267 1,409 2,580 2,839 Loss on revaluation of warrant liability 18,337 24,974 27,974 27,974 Gain on revaluation of revenue interest obligation A (1,443) A Other expense (income), net 257 A (1,186) A Loss before provision for income taxes \$ (28,371) \$ (7,718) \$ (46,357) \$ (17,487) X - DefinitionThe amount of gain (loss) on revaluation of revenue interest obligation and other. + ReferencesNo definition available. + Details Name: elut. GainLossOnRevaluationOfRevenueInterestObligationAndOther Namespace Prefix: elut. Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses, excluding intangible asset amortization, directly attributable to the revenue generation activity. + ReferencesNo definition available. + Details Name: elut. GrossProfitBeforeIntangibleAssetAmortization Namespace Prefix: elut. Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1> + Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 7: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 9: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477314/942-235-S99-1>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB

[illegible]

[illegible]

```

CLE":":N[N]Z#H#0#M>6<:10?-W *Z#H QM;F&P#< M JJ: 55SRK&90BMJK"(TE;701:|DBJ95J|:OTKW_JG+U+U<9_TJ;72_M%9VQJMDH X)&R+YE#QL_I"EDY F%
<0,0>MSJ0A|E,9_$J$K<=N-EAS/YZJ| MUP9P0KI-N;:<1@7HV?E3?E3HCFTM7S"-KZ86+<K1;:&Q<=|;")PD:(/ M2MK"H)JER|,O+WH?Y'L;2'&M;C#<6E:50K*+?
6F0+<0J0A|ECCVO1I, MP,6@U"Y10I?<=BV+LS<)<|K|J"U|U7#KJ,6S|D|R">?O15H+<64D|V0?P21 M$TQ<=|;W_P|_ OJ5#<#44HJ|D4S|<0DCC%41/1'<2&S|TIW|H0>R4 U<3M%2W:
M3;?<1> U>G&1EAP5E+YX+YIAD>B<@F;Z,H1D1&2G: 2;C:=-;)<)>GNQ$ M[A|D4A_<FV>=>+<3KIEWX#MBB9-0L|<+6$CNY<|<R-L|< QZ19Y#W$S$E+N M|]ZSA3".
<TGTGTBFN(PC|_U,9,<L%R MH?>|J,(X&V;+<# 8ZPG0)<@BSH +1,1=<0 7D?:<# N5H2A1V>=>+E9%G80R&C| MN72|KNY<:(00NM& )_JUVOO.L?
@6N$S,CQFOP)<=+JZ<_<KJ$HP72M>;>U>=> M'0 RG-L9'1OJ|<X>X'AM%<+131: MU-5;?QB5?<U4G7|M4&B9V|8TP>NG/G'<C>5#64EPI|SKLCS|CY6ULZ>?Z"
M@S"S<DK1I1G;1C/LPZ@<#5B,L2 R??A|J|SVV?O&G9'VQ|V|<VJN|B_ 0@<3 MBG 893BF2ZOX31<+1+GZ|,WP*9P5|O G11VE_I#<#<VDZ2"(63/YU/L+2,2BNRAF<=<#DZ9[K:
]>3Z?M%|@9<=V&K M1*$<6?GWPB|GOMSV17X@<9Y|G_N7P6Y2|<VJN2|?O1C4? FJ9#>+|J3I-?T0: ML:K|PUOX_0|<+15/J;X=A-@?<G@<Z;HAX3C|+1+ P04 "<12@U9 M|H(V-|,% (%0
0'<AL+W=O|<1-MWZ?F51F(XDN2=>E)?>T>+5N1(CH-MG7) MTB<+<V|<CNBX|W7|Q>+>4?G13E;4|FRR56A|U|S|;THK(|ZB>+PLN'B<@J4H M|G(E#<D-
455;<|>JIA5A|61V:?"78G;?<@UGRFEX?)|N|<(N+G9|0?<C9M$?<T1DG2' C|K>D%<+40-<3XNN4Y241J|PO|WCOM+8S08
M,B>2V@<R,05|FR233?<#Z0U14><+>4VW|H2:7|9+<7|1U|7UG G&#JEXM24E M#216M_ D9NN"DBRC&|;G&A|U:0T?<(%461V*Q@<#<BT-W|2>=50@W*LU|D&Y
M4@<#<=IV14MP,4?O;G: (G3J<?<K&_OM;9E,$S_<S2.M_P|_<=E2V3P_Y|E>Q>7&|, MGDT@<R45;S|97|WB1L|) RH&G8K10P2|<+<#3-YS1=<#G|I|9+<2F21+<+|SW
M|Z&6?<YXRNO6273>2">5S10_<U2M2V+<=E 9RET0125B->P?>FQ:S>01 K0$ ML|LU(H*+BL|E->+<U3.<#<F|L+<_1|"%F$2-SB7|I|CSV|U|T|25XU|),J6 M<ZV|LEE=0%UES-
1|:Z|O|H(C|<B7BPB#<#<S|BDB<=(U*6)_JH4Y|(WHB,M|FV M54400U Z|9|P|G|<+NN?)<D7G9,PI$S2Q<+<+0?<P|<L>=FKBB7|A_<#<M)E.H$<Q9 2).C|N"7|U|PRTNA00!->
R|,K|<6EGY&M2"N'E$<0D3_<C|K M2B|<G?<H,1D14>|L|>@<X,<L?>?W>?<W&|<?<JZ|<M|=|S=<#P<+<+<F|<JL>_<Y:P|IRFT6=QFZ|<+<M|E$39,<H|V_60$
M#7=<1M0>2<3D8B<9BW$Q|<(<N#<@<Q|<@<#N(87)<(<+<L>=<+M|J9+V$0=<0=K<R M070 G230<Q?<?Z2YQ3415ZB8A_<|<1V7S+<)<YU?<SZT<+Y#>=>AVD:6_M8Z<7
MZ&=<=I&K&6#BCM,V=6)<+<5Q9#?<P_1|1%<16W8N<D-K- HMHD, &J$P(WJ3 ME4VNSRM6*U(73)|5<BA4B1P=K(OV)|<2P%XY+W+1<CY|B,6|G|U M1PTPK|N|980K
P2$|L3-Y%GBDYR4+ M">+I<H?H%U|A;B_<B3<+<1YFE9RD+F6:UVL1?<E, <S0P?<6+|D|<1.BM+MB%X<7NQ@<1|K|V<1#EU;=&&" MPPE,XL8>|XRT|F73 MM?<H-$8)
+*Y$<(<4+<C40EDLKV7N<Z+|T8Y|H<+<H_<S'<9P<2S|J|X'<G4 MLPP,<|<1>1-<TD<CMVA_V<274>+0|<UVE|<V|I|<C>C<P N3$<DCN0|2|D
M|VG<N|J|<H$S|<7|EY4ZOVH;|<X|<S|J0?<K30T|H$W?<1$%<@<P|T|L0)<(<X;XG"<#1 MOKNU<157Y|JUVS17BE?FSD3?<G0B|_<H+<R+<#E+<=<X<?<L7U|+ P04 "<1J M2@U9V|<A.X4"<#<#P|<#0
'<AL+W=OED6A3<8Q53?<VSR;Y|<A>G=E-|_<J M1F+H05 M8GQ?<Z=<|GL=<WMZB1+<K8R|IGR45)<#<M%<M"LM"<D|<R|<R|P|<#71+<G#BR0H6((U2Z<C|Q8""3KLB3B:0H%WTPC?<F90%
<(<R<?<R<ETD<@<XN|Z7|K<=<2|W1,<#<|J| M|O|<W|O|D|M2M<?<J&|<X'<F|<V6DZ1+<+DWB|L_<@M_<#ERU8G2|DK|F3|Q|8_M.P|O)<8?<OSG<@<0-@<MM%F7DGMTKH7|I?<Q?<EZ0|<26:
"OCF6 DJH3 LN:P'H%<W=>N<CXZ 0=<M(06#Y<K>=<@<K|<M;N<C?<CK3V:R(BE_<V)|<@U|_<#|<0=<?7Z?<8F@<ISSA8QZ?
R:NYN$5|O5K<@GS'<OKQ0C?<1U8DR>>Z4HEB|<X'<Q?<E@<Q?<+<9J=<MYLX<|<1|<O/?<OZ_<MZ,<S<G>D|U<?<4?73>KHE84291 491Y|Z8B1F<1&|<17MB?>+|J"<M,<?Z?
|FYV|<AH5|O|<5|02P,<#< @4H-61?<|S!<@<B@<8 ID|X M'<1|<W|<W|<M|<UGL95+<YLP%<#<BL6D|<6|0<#ZV|<#2 M;M-2|J5-4=MNS@R|<U=U<C-
DG|<|U<=<PK|H5|>P#<W|JQK4?<#<|<F|<L2@<_<7BK& M5>+56M<+<WU=9?<156|U5<=<T|<R2|NLS5060|G&Z?<N"2:03$S<TRYE|9N;2|3 M6#2<40X;B51355B+K"KH">0*-<
0?<|<EA|EAM<M<#<M>X<Q?<0?<J_-<#<_<I01: 5=4 M<C'0A3|SE+<+<VW|<O?<7|<09V,D|U2S|G|<O|<X56|<ADVA?<P|N>WA>ABS<(*Q MNV<Z_98V71|<1J5M9B=<ECIG6"<#<%EXGWPS<(<=<
TQOQ>=<#<=5+<2|33+<DK M.K2QT470'<+ITYG'08SOF$<L$<L(G7>|D;|<C#5.8RD.2-IH M0|<#5ZK+<G*4VY?<RJ?<5Y2DV>+3M?<F>E|<Q|<0QH;Q 2RDQ>+<_<WR$HN <A4$X&<+!%?<F1
MXT47?>?<Q$<@5|3FA.X1?<3|5W4+<G9R'VN|FH6|<0>+<9?<T.IW<70G|WG@<#<M|<I0G0?<D|B
```

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~*L+#+&.CWW <>PG MR<=>1WXZCX8#1T4C/7',_1/YW\$ 02A'X &KJ[V9H-?>B-VU/VEDE/IT?>=MQCN H965TORM55' G5C1UQ7QC+&\$Y.EGP.MV^~+:15 M4L,&1)59%K(G'CB8?2 MFKUAS'W' %E04S'#!1!0 (+ U+M\$52*23.K%0 @" @9 ->F=PO=VJR M-W.H965TORM55' G5C1UQ7QC+&\$Y.EGP.MV^~+:15 M4L,&1)59%K(G'CB8?2 8'>=>GD904!>X\$K!L3:PG4RG7+769G/8-0A2B)U' M\XAY@(<0!A8(S'BY?>P-U'NHW1|KJ&ORA)1U^F7, ^7X7B5F<IJ>(>26&B)J3< MR-5? L(G)G9%BF>KREZPVLQ'X'DGCF6T.HP69R'L0?J\$S\$X5<.N)L#;FEWU!Bt M.A,W?B(YH<XUH=&E261Y&XT1N+76'P5>+J,Y/LHLP'<=&AG?%XYGY#M7 MBN=&D,0?>J]" [U,>#>JQTL-X@WE68;H08 ;D2N9FH-I 91%GPJ4F\$%?'(%7!<* M\$H(1N8&X4\$KDYF6& ?B,>LBE@4S_ MLRJJE5^~?J-LJ1WK)8_ AM(TE935!;_+NC1.PJQTN^XW+?A?ZY+8J.B)GQ"R M?>JG-H'2NN>ZAR/19(S;_& K=FAEWG9XMY-;ZC8#8)XYIJ+KNI!X3Q!/>7 M'>%HPVF/H;#DD00S8%13R'5HBUF-.0YGDTC8X9,8^R451N-.16HDNM110 MDT>=0.8*>L.V3E'1!+4W9(=1@<?>7)2YHSXYV<_>B#>KJRXABBI6|31578B, M-1'>S/Q=4-.HJBYHJIDFG4)-.H)8W(6QJ9TU^7)51YVOVG5F.F7918VGP M?JZSTX ^X'>#8NAJY5CO_>28&68ZDKF=H [A5725W?Y#Y7, <&R,S&Y\&IMY; M5?>2?FEIJL?N257)S M4-TUW(%#F'R4)CM>C^>LWIJ>=N?C7_12;8VNJLAE^EX>F>OX>Z_OS'~>EJ MF0>V:08ALPQ^009I9-Q|C|H>E>E4O1P'~>1(S MY%|2^<?>CTNR@8G>T)C9MG6JAVZ4+>6&=&1QN'X7|>[->1!>HX0;=W5G@] ?8 M? ^A3)V+|KOCN[_Q/]IBPP;6V<<608=C0/[5F1+ 0[Z.FI42_W%\$|8>: M%-9M(TG,TJA(=XOW67|NZR/=..0J4X331KI'E/TGD#1 5[IL';.#LG&#<=(W(C_3IT4P! MX,4@&\$A#E+V->G(T&)&W+P+;UDH;|EC9'@<O(5<C_PVW&P_5]1,5KV;| M?Z|F(MQ7CAVT-5UULQ5=M|JLV\XKA#H4'<=&9I-Z5V@>2=,4ZK'F09,M_KN(M MH1'I'D52<?1+>)5N67,?S@> +1 (HG>?WGN>=<[S92?>=4YYP;1570J'DD64J|M>?>[F#&K>_>E38SA4P+>WPUGZ65A' M'NKT^E-6L|A1|J|I9W&7|>+>5Y.1F7SNQ [*(HUI7FOFU_YU168'1+> MW3|19L.M'>0VVJLA^PP(D)J|>_ZC<_Y NY6P&U=Q>X9:E!^988N9D&N+>+M MLQ^MJZTT'>N'91'HW' #FSN(-S_UUJ>C>ZY0YH4QO<+&PQ?7&.&K &@6; MIEME- YTRJPUPE(HBAAJ|V|M)K3GBZ_>Z;)>5'>AN3#>'81C' 17WQ M'>67-25'KJ/YVZQWB2LD'SDN80C26'H MJZ '.1N>?>7'100'>KJ>Z,Y091<#DD1K3Y00Q0'Q'> @CSHUP0.F?1%E .D M6].7G>VL MT%OSS+^CUFFE,1EAPG-#+M_IVIT0&B,E.'3IH3\T.O GOD\$2|S\$D? MN9#0_LZ+>=>[W/9D\>]@>+>KCD13+2\$AH+9VA6-30Z.7;6MZ_ AFI'GG?S<4_M_RZNNZ%ZS] [JFGQA.M:EU&1!1);D\$D&_J'F<1Q9&XUN(O90&|O;V,X^>X^L >R0|>C1>F\$-J|<=> MBW\14\$1!10 (+ U+M\$52631Y@Y4T &3 &9 >+>PO=VJR-W.H965T M0, ^LZ'EJBNJ|H'OQY..B<=>7K2PJIVZ(5>F M\$@U_N_KYI>U353J|U>DIM+&C@P [P-1+HPN\$3872J|U>R&F\^6+Y7L)KLN12BYHT6 MLD&S^R^1%>6'3KX+<?>F|F|T|QM92V92?K*>+6EYUN%4,58SDSP %OS;UY5 MEA&H(7G+TJN+M(3|J|QWV5\$2M.N;7XMKJ'>B,(M+>+ 50P>=>L59D)-.BVWJXY<:(;C)-DQBPT^KDI>=&#DGXIF>_6'G7I7P5&&OZZ.9XCZ M& 5'>S|A1_?FTI8?>RY|&B|>B3<UD;_Th T5YON39'G'~'~(B* MX51|UCWZOW47&J;_S)I|S|G 8CGRAY=|O@Z%K62|;Z;V'-EQQQ222:RPKJY5-3T2'SD'O-FD?>G2|>RZ?>O|O_M]4)Q/LBV_=-.N'-O|XAJ7B;5 7S9O.[Y?M6#AFDMUV' M6=9;4QST\$SKU=9^~7:@.8D';.9G|B|J',LB1WT691|K6+B>,R.8I(YH7'D\$1W1 M7\$JF,^>)M|X3^>XW|<A1',1U!\$TS# M<=>TF.SD3.'N/R>-W,&J|F|P-W7'>R'>M'>#1+T'IBTU&20'K\$G86T=>@>#H MJ|WJZC_+>+IRMXTZ=G1'OB,&(VLNFUO4YHC/C,'N?>+C'H)49'A' (<+6L1+V ME,KNS@<^>VTNKT4|_>2I5&0H'8_ ZCN#>_*=|O|CFFR R^&2;P=> *GR^* M0^ &8&F/F&PP=>_ZXL32\$&SQX+>;OP/RF/>8AE^>H\$YQ8P,YP|684M_|@V' M'!SPV,Y+&C&ADM S)E,78886R BY80A0%\$UQ3 +33>IB17\$>\$P<@>Z\$B M' @_L#4 FBE5WP=V9E0VU!-/L I3.'M M'>T#Q9I5JWVKWS'E&,02NO\,C@&S'G:50B;1>PD)QN49)_A_?1? X=68|@ED#T| (+WHW>T+O7IW=,E0R|L>S M(67|9C&5/>BTRV,1'>O'>6~1C&3;3Q@>|ZXL NS|8R&PO=VJR-W.H965TSG1%+1? D7=>9CS1&*#B'95ANK'#+.5_QIWHB|@RLR1\$#NS:P#PV<(P;C MVF#4@>^3VF#R4@.G-G!>&I);&[OJ3'M#B.O1BJ8_ ME/DMK55&#ZE>"NY^I8J. [FXK22(VIK=TDU.US3N4174<2*7-)@>U8L1\$E M KU#2RRHT\$>7 G2BURIY8_11_JMH8&53>BUIR2FJ7BCQ@J]=#K5V_0*TI5 M|S0""J'&BKDA5#>:O1'505Y70=I@>ARC3R1\$7B41^L'XQ\$SX8MG<~>T U7UYIY<~>#>^ _UJUH|Q9V QR50?>37I37|Z|I2'(DF'BC)U!E19ST\$ _7B?R&V M.'*7HZW6.7@|H6|/UBN^5>7 JB%A#B3,AX0N60'>0'-82S'015S&2'0EAQ\$A0\$2 M'J|F3+>,'IT20:0'>X3->=>92G;7G2>4F>A|JY;#>#%>6 PGS&(>1)'RH8&X) MT|71P;'F/C85|4O Y;HG :43B#HOBLBKZ4|>= [T/4+?#N#B;|GG;GP'WV M79>62>I6GV5\$C7+V1DU<=>SHYR\$%|<=>_AHUN2|S>2|>L'Y_ C46'~>6B27.H M(OCXEY5|Y#E9&81YD#>7\$A;XK1R|Y|Q08K\$>3|HJCGC,DPI.F MPl|/##N'=)\$5\$98JQ^HJ03VE95|.1R&GYG3:N5C;MM2J=C'K'K3;N*GCKNY\$#X M/F1HPY9EHNW M^HLMT >RLK|J0K?J^>=J7ZD'OIZ8\$>N9|PGO(6 ^>X)%>+7&=<^>(Z|Z_9SR\$% M PG\$(&^>)"R A1 L9@>+7/7IC#_WZ|JYJK<6'>HEK'E1Y>U>AG^H'4HD)M M:2\$4K2V/UOZ26-2R/<@>1M.8I(T@>N'N"MC2H3)U5+M1E66,B'>|IVZU<^> M3M62+3+3GQ9J|J|DK&ZQ'JZ|=ROR&=K)D|&D^*T 1850M+92|J)UD|S'>(<2 M=(NP0|B168B92A_KU)D|XN2J|G'G5Q<+>O:0:5XAY9AUW8\$B,D^412?>1:05H M+82B2M>6Q:RM@>TVH/7D03EE?TWGY3O'P;EEIK =>#HT!'7YH+O E!>T'>M' 4V.K(686?>M#M1-2;4K|O1N#H#0/E.#T@>KVRP;15'.6SK8-F=.M(BI?>AXHSO>E!:'T\$K(65L^*N M4,BMLGI9R16>=>5&2;17%Z#|3JO;R/OEQO9Y#>;>Q00,+0&DA^U^M MK+&GWFP()>9>+>PO=VJR-W.H965TNS &5j&@> MW>326/L8#OM^>^QG31J|L8;4N%+XQ_W7NZJN]1.ME(|Z|+1P&/%A9X&I3'U M#2\$Z*|&B>B|K%:GD'J|BQD|5FNA:(I:<52@TDP(4%M-@ M-KR93UR\#_C|<=>OWQN'4K*1<|<->/30'74(+>..<=>K'N'>?>(N2.R'7S)@>_J' ME0XZ|JZQ?>#>K985U3B7 ^>+33D+W@608T\$;N|E|B-V-JX>=7R'Y|K^P16+># M +)&#>UEU8)M|Q43|I<=>#WV N>@\$.(H T7,1<0>=O=V R_KCAJ|D|N|O|H MR^&8&WAN/MFJ8<5<6&F5WF=69=>E6#V012|8&K&_5%609F628;89ABPT|REC'4 M|;_>VZ(K6&&A4L2ZH07M^AH8SK-W;1)1#0;E4G-C|X-B\$QR<\$ M'RGMS|C\$5HVA^X'Y|Z+Y1.P.BE#Q=?>3;24MN1%#@>26CWI+1'118J TSU%3| MAO+&MCP3DQ.0|8(SRW7\FV-.M/033^>^33=I. C#84|V^Q^?BCK(|K/ ?H9 M 7O|9|>?>9 G8EV(|\$#PN<|>_D_1|ZD|J9;M|HJX=SWX2M6;'0T<=>X|>Q|/|^H|&_J.KN @>_P |D I^J|W;WJ&K M&ULM5=M;YLP\$>XK%|F3|H^|F|MET3J|V1-JA8U MV0;9A2-8+3:U39-^*_&S30'IE#AK&GPI&WR/GWONCQ#N9?'@>0%:5PKD9| MKG5Y\$88JR:\$@ZE24V,P3,B'#.5LU'5\$D&CJ C H6QE'4#PM">3>N<F<3.1Z* M2C'82*1HJ|'R'K'G|9|FV#>+1'Q|OSF(<+64ZDF84-2DH+X(H' MCB1DH' 27USAOC5P^WY1F^NU;_#N/QC0?>?TE\$064; (<6@IC;_UP8Q;)'M'A:@>=>GM9P?>Q' _*^<=>X|X'77|>OVFJNU [X]906Q=>+>B'>H^K^>JDL11850Q|WMQC\$2X/8;XW|S RBH.XNYK|J|XTK<3>3<[&#>J' |!>|>=>6E0;E*2*3'(%/3' _XGF+V>=>K|PT'>?P2R&C;LX\$'11^|T=D;^> MK&#>T|H^>1_Y&9Q+T|>79'9I7D5%>=>|JZ+O>=>2YPVOM&_?>P(9'4|H;H0?>C M;|2|Y0%P;A^>V)>|O_ U2|'WU'2>O^>A_#9@>^H'1|>8?>W|I|REA3'_%H=PZT MKOC|>TB; V^O? S.TOH^V^0OW#P1 Q^A3N&U4V-M.W|F<B#|US|<|>?X\$| M(F+4^*0@_U_1ZA50W(F?>S2P+2+C#O.R'U7|F/R&PO=VJR-W.H965T M|Z\$SW9HQ: IDI|DMB|SWN>U>7R4Z|DUTB&GCF3.A14|J\$N00# MG9?>B>I^*#0KIIV'~>Sv.I;AWIC4^R|D&+>@Y<_#79?&?0BSR8:L<8'F<3-7MA\..2&+>+6.O&K3U1 M7>=>1A^T7IUGNW7I9\$XXUDW^C^E-0%>@>_Q|OR|W=ICW.W|ZN63'>#7COVF M>25-14O>@RT|I2>?>D|?|P|S).F1@&@?>C'N;LGGI%#>LHF2_30I M1ULX^EQ1D>2;90|3&F6Q1#P-D^ON%K2@>1&S&KO)<5L|O|8;Y9#2G|F^>7JZ MZUW ^OT.HTO=PIE3 /67.3?K^A.8'>=DPWR>K.G|G1Y| KD07>M\$?2^D^X^+ M&9R??> PNSU@C.C.FD.95XW<X_FVICKX7|I|=INDUSJ@>OXO3 M2|_JEY#WCN9EGOE-T9%|@I(1<K8BU2|OY%?>OMEG<14 _'4QJ|Z|Z\$S^U M+RXP21447-D.F)F;E.Q|C.FD=IDM6XK4RETBYORB@S+>GDG|J|>XV&2JO Q0 M@>9'>B8N8R+>A+|J45|+7U^*W@>UOR:5REJZ3GAE@2@1-GX%+84H;-VL M8(8Y|J4UU(OKA=>I&GKZ>YZC;_Y.G84.T|S&T'8DZPCIH8OBV..3M#>.&8216 MAK2-8>3&.&QG&#<X|&UL MK55M;YLP\$>XK%|JNF5EH+ 9I-&4%>0I9V;16H6;?|>A@>U=C;- DGWIV>PM'. MIM7&+>^I W_5|0D5FE7|19OY;5_ DX0P'8R'>#19AL>=>GPGJL5|9V0RN>+>A MW@B7V=3Q3\$! (56<=>O>?A9 J'2'28?SL.W>10'NGW?7LVSN.L<1+>+>Z'0^2 MJ7+J2|O|CENJ+KAVPOH(CWD?>RGTG|1MK|U|U0V4O&J^>L*(L+>|WIHZK^ MT#S#>+>#>^VUX3.H_K\$40+>#PM1L.X|_ W6USM&X|U|O|@>6'6.MVZL1E'20E'H.N'>#>94GCN.VW\$>CHL'>M&B#>TK<2_0RV3P^AVF<>2I.F74C3B'>F9_>=V9^B5|L@>8R 70R&#>K'>@>Y>U>H^>L'Z\$V#A%>=>H8'P|R M3|G@PE|>_5_>L_>=0QCZ|O-80N 90K>P>#>6X|P'E'>OHL<|O|3 M1V'6(#30S-W6C12|ZJEN2)6|MGPCLD=|"/L^A(28XJN0D3HB;TOY>H1 M@WU#>#>GPF8;30I ME'>@>IE.N'>|>1+>19M+FY>P.J.E'8S2'1G3'MT^NU_2'9 MV9G1N|?31C 3 7VBEU616 J0MYXON&N|.(DHY-J5= 91ST.1.HI64+RVX &#>M'SULI';4'>O>\$=>#W>=>J)Q@>_0J|2P-02P,\$% @O4H-66IX?>=@> M^0<=>1D_IX.'0+>W|K&X+VA=SW8DISOIL'>H|Q+G<=>#1K@>Q M8.MD2TH8<S4\$10'RL<=>+>M9S2^X|V M'NM^H8A21/Q& R.J|K|F|PU|^O4Z7H'P#HM51|A& 17%&3F<=>?>?EG&#>M'>6#8OLUZ@>9.6J|LO+>+>W\$JRB0S^>#>KUV-L&N^>EGC5M.81X7&9V(PGDN<=>N M.Z9U36N'1V @>-J)W\$326|>^OOF55^*+>^8_U|7G|1^_12BB>1.16RG3.E_B M6%>69^VOY_UHY>P&A|U;H_%|Y4|P6I7E\$>.&C<=>6F%W 2JUEL M8Y&X|JWK_7'OY\$MECQA'>H(=>#08Y+>5KZ|>=&UJ4A>@>A3;CUGT+Y+Y M|F M/A'>TPT'H=TXU|02P,\$% @O4H-61Z|>=>4 P%@>_!D_IX.'1W M.W)K&ULM5=M;IHP\$>XK5B9-K;21+RU'2 IW;1.MZX9 VSY^>V#> 5X3FJD=-)^>_&PG)>+0+>D|P|>?7>_SAV>J|@R& DDTR0AXO< 8K|I>MC;3HSI8JG.A_KK<@>J'>K\$9'>K' M94838N')RA@3.NUQ9?WPS'P|C8'5L;3_-5'SN3X F_1L6=<+>#>.(15(&@>NB_M 0PAC@V2Y0\$K1_6'.XWAIO<6'9U|U7CLS)1*>|Y&9VK9L'>X|_Y26.UYUW M@04-^1CZ7119M;L^>A')6|>FQ9I|0EOV3QSP0.P9A?8I|F|N\$EG=VD&5Y M2O31=03? (&G;V:S385VYUUIH<94;5B1)ZEGH|U9MD;B_1O_Z8'1.(4ZD<1 1 M3YFV;(%&S'81'18E>HR%G3&5 EB VH-AD^F^&=>1)4Z.(163%&QO00+>+7\$0'IB M829U? %5JF|V'~>RBVT@>RG165;#V5-17|M;^>|QON?1Z\$3|_?>NA M>O>A^48R'L@<=>+>X9M')#44?>V+7M_#ZZEN8Z|6|X|Z|M3|>Z570;9Z+>+>V'G6'E'93 M7?2 T_4K(3RIV^*3Q\$)'%>LEDH'40|C|KBL;Q>=&M@S1\$2|IG:&AXVPGT|SQ M:A6M^TNE<=>5W2MG5?>Y %>T020B; 7"~>+>06\$>=|T0Y-F1ET<=>XUDXMCFT'RW">G>G_OQ|T#G5 AL9E? <#>N M'>E&AZP|U>UZ;_*#>NH|>Y?Y'14ER4&_T'>D0^6^Y7766P|8>S\$1&@>3*(8YMHT|+7U^>Q99\$Y8->#>9QF?>+>M@>X<IG.I M&U<09H>GW.NM@>S0-S'>X'4\$1#!10 (+U+M\$5D|B; M1P0 (9 9 M>+>PO=VJR-W.H965T\$11W_ \$G\$P\$A<SV411>L.GG M2.(%>ND>XPJG4\$&C|?> <X\$5&40WXN'U6DX>=>C|O>X&K'P\$;2>_Z'0T@>N M5QO2D(\$<+>1'>ZD)=1^PDW ^IKO(P5HOX<6%>V>@>P_196DA6-L&J|RGANW TW AQ M\$>IPS^>A\$Q>1_3.1\$1-0|1:AEX3?TLM0|V|P|N|9N>^Y<C>B&F\$CK; Z|I5 MFCFZHU:~>CE5ZSD|DYD?>Q=>2L3A|0@0%:@>1&5|?> J>B0AF>=>6&1^>M\$YAOL?|11<8|1'9M'8)EK@>ZQV1=;+2|1ZL9|Z|U ^C'5E9R>2OPI=E'Q M'9.P.L3'>K|RFRD85F3|>1&9FHD(M7>1^>DKAD3\$981 '4409\$0P&>^>26'6;R'U^>A&D+1= L_>D&F9V\$D\$0 M;1#Z|V|QX|AD7L;5_#YR@ZX.S^<=>#>H^VZY4S9NX|S|9%>X&S&PL'3P9Q M#0=1=>R^>C21+40 K#1'>L&N7'>O7&A53F|2!% V5_EP_H355F1|~>C^>Q52I@9=>#>A&?>G5V5A);=T(Z9J4US4'J)10|Q3&)<^>VY VY18K1 MZ9;1Z)7HU'>_**@>=T>S0;#>=NMWXK@1SU:UBCG>XO5);>F)F16V00SHVG MD= E96|@>L_-SZ2>?>QTD&20&1^>MG-H= GPR25\$F6P9H.M_9;1.PP&H\$B,|IIT4M'>Z6|IBU'>U\$ 91L\$9 MZ9V9|K1CM|R9|Q\$H.KOJW^XW:N70|>2^AWIA(83_1J0+M M@W? 8)>+>+>N^>L;4E|E4=FYMA&W>OY8_Y_1V#@>WMBZ2@>4;SWV0OH9_0M7O1Q'>7&BBJX&@>L.UW^OAVY)51|OTIR8E^>O#>#>48YHO&=7W|F'PYTTO3M M9V|IOU|> P04 ^>12@U92@OXG\$>#>'>#> @>0_>A|AL+W=OY_>XBJ|W2C8BSL2|S|M(L@>1+> M^B8_2NAHN92U2@>ORU;I|BEJZ^>ASD4I6%NORRA5|IT'E'>59P M^O^>1'>JY>@>5#|91 ^>PM?> >=>M;MQ|FBYH6L;1M710_1|E|Q7|U7DFC8 M+H;^>8&53YR|W_>P|Z|44188ZRJ#L.HH.^R_>=AT'>=<=>3)>\$%R.\$B|U|J|IRGEF8+K29\$NIV MY@>=>56<_>XKAT6E5:CYVVMEL3040M26?M2M5ABNA'LX.634&-Q|H+>LA72EXP M:DK.5.2<=>6&IC^>K>|>1^>_>S0'IRZ'>S|>#>BU&1(|#2GY M1'0M#>7DG<C_1^>1B|YU3R8M3|V04L_K7|D|18D43|7|WY|6K-R.XDRYH M&X|J&O&H6<3?>BBG>5T ME'>M7N^>268K@WFS+H3U;Z'Y(UZ|3|1B-WRYA) K%>E^?T8V /HFS|Z|>1%>TN8=M_1M7R4^>J<@>1%?>12SL)X_FDG_?Z|P>7S04?>=>S&W|R3Y^>A'>ANV3<^>VN M8#H<=>#>F.C|4P^>KEXU_391=MKH(S|O|H88'6&|>Z>H9ZRU|TIC_1^>F VI/2 M^8^>_1P|O| WRI'KB_7&#>(>O:UT+>+>K|?2P>MR29M&R)CDJZGRZ_>^>9|>L MN>+>X|?2P04?>RW/>6F&S=RBZ; <=>@A/L\$BM76FSPV|+9P+|>L>PO>S|U|A^>U MUX'169G\$>#> |D|X|AR.M<=>2Y|V&V(M\$|MYM=AW..2NN'I>=W|>=S|G|N>1.P.M1=HPR_+>+>+>TVX>+>+>M4O9EX@>BZOB_L5|+ P04 M^>_12@U9-Z^>^>|T#_#>0_>A|AL+W=OW:@9.(C:S3=) M<=>_C9AK#04M1(W.O_1J?>Z0#_#>X|P>9H^>H^>6;5LH@>X9R(2U8 M56^>VC=>S|JB;V+>+>@>(CRC|P=BWS\$DILY3-FB1YCAZ?Y:0 MLY _BC57+>MOB=>=..F7EA83P@RB^1VJ.R945DF392T_A>=>UK-D'>F|U>G|T M_VOB51^6L|S RWZLE4P6UM1'.60|FQ3A?=>?CZCK&#>HE| (MEM=B-8|I=65/-8<3@3^IUO@U +>GM0^W%KA|>=X+J6/>9(8&K\$1)|@>CEG M4|U>^>F6;PQ.HU;AUUO0^>|WDZFV|=>#>XEROZNM@>|Z&8#Y^>MXS'1*|>I<X0|_JU_L|>=E|VDP3K M^>=..KV&77ZB2B5\$ 3GB<=>OFWYUR\$>R'>TZ|161&S=>JYOLU<^>VZ\$|IUR MKJ=>1R|Y0H2P<2JEX<=>O@>M/Y..792&L^>L.FL|L|>7|H|+>W00 3 M<=>4E9X8N>PW.15>9C8V9W1|WP6@>RP_Y8)=/^>E.E @>1.8C|LFXUXF^>CDQ6F>S MHHKIHE|AT+7.KESM^>4(G7|>D7L=5|OUY@>YDUB+1R3P?2Z_1_>AS0+>|S|K M\$9PTT'>=IN7B=>ZBVYCYS^>M^>VE'4'F_1I\$A1|>1>ZV.1#FD63IYO |IK8XR; M;..1!>IKOFO.2N|J1OR\$HD|>+?>=>2V|>=>?>@15&|/IN;B|B@Z=P|>+U3 M.1?>0&M&K;V|JRV7K>GLA>U3UDDU6LS-0!>K7|=STFCVC|N^Q'>=>G L M'>M3EQ5LD^>JOASXS3?> D6L1+>|QJNG38%>.>1>=V_WZNO@>E@>|J|11+>9^>BB|G^>MA|>A>=Q501+>U'>_E5Y\$X319\$?>7=0|I>_R6-#>#1|1|@3 _%>+> P04 M'>12@U926U>@C8' ^Z"P&Q_>A|AL+W>O^>1>1LEAK%48|XWJ_7L\$>143|3=>R;EP&X20VH|H34Z7|_|ONZ|>O'>F'K+>Q>UCG|A@>SCR MV5G^>~>X|O6|+>WC1|>25>8P62GWOCSDBR_3LXYG<^>(1#> |1U|S033HH6'>DMXMS81'~>2?>7>1>=>4<1#>DAN020UEH|D|3H5ED MJ.PK|MGD5|T)W=Q|L2|LFM39JPL0.XYV6YM20V.G0G|I_#>M&P^>Z8&B|INA2O MR0I^>TOXIO>E|Z.O2GBIT_OLIU_LH177+(S4.W+1|L|K|/-_0&|9|..D5 M^>A'TOFU>FENEN-O'1%>2)>EJTJYXV=I&=T\$>VD46&8J|D;8'N1:(7'>GUJGO: M87|JVV'..B92MIT%>GGIK L'>=OQSE701|=XCXA&^>B*8H'>H^>OARGYA(AV|& MCI;^>V OU;OU>S(=1>V=5790Y^>LIV|K002U9P|Z|@>H+M>^>_GU\$SSP M^>1^>2UY\$>+>1J|P>=>9|V6FE32?>M1PQC? 2^>HWL^>#>Y\$7?>2GGGKIY|+5M/M<=>#>2&PZEW41+>4%>_H2D|OHL6:(K4_NBOOO^>C>P>^>GX|>+>^>IAN\$>N/ MP|L^>9WOL\$>8\$?>29_ZM-S|8 L_XQ|NXA|>FE(|10\$V%#>1'>IWN'P'>N_>5 MDVXKT^>FTI\$8Z^>N3^>C\$RKB3UP>AH6+>W\$7EYMN+N)>B.OJ<=>#>PZ88C.X(M^>X5|P&V^>1|3>5>9Q|LLA^?>0861^>6^>Z.N

[3XRN!>911J]RM+7XP.86SM! #+1,^PU^G,LIABHS^Q\$.10C=W5Z@PX-7 MZ/6/QO-10TDJ3Z,>3UOQTE62AN1KAIXI=@Z_ *17-&\$G R@TS=2>#8 A#%< MX<|>RE%>+..JLDQI^K15IRM^CTS334^PHBZ+<^AY&+JD7*%FI>LBWJT!<IQ M2SWVQO9/<6B_#190;?F07^""3.>@+73%2SLGN/8/NB:2>TK^BMGMF^MY-YA M^-WU:Q:LWCCCE? VMXQ1*Y%>/OOH\$B\$VZJR1I@<|JP_#WZ_#A+IOBW+1+16D3 M3INS-V0558H1&M_#N1<|C|QX511A5-3F&64TF=>2&4U:WLD.9001N^""<V71 M1>NUN..K.6UYIWIJJ.D>|*?/0-?10&^<= IB#..72JIK(X1K4)<#|/M#681V3#1H M2DN-AZ^2N<..&=>UHXWAPSPN9^RKRZIOW-Y0B1<1T|159Z5Z^R6(KG.J.M.#.WH641S&Z-HISWJIV7QP135H-M2#75/B065/INHWMS>=21IO *W*+3H<@| M051#I^""U%3^<^<67 @ IF2M;8VW9(B0<1O.NI4HAV&/4ZPY7? O&^<IQ.WIJ= M1.&H)IS8M73L1A ES8;*F+IC9Y9J(3H3^T.MK1!\$=Q=X/KY#C:4UO\$<^CG MV/5S1V^16^#N&+IJSY:A@T^3K+X&Z@<=W72D5TJ2V-IFNHF<^VIAUJZ^M MO LV-0556U1^<HIJW+<Q^<Q^Z/8W?KXMI9ZAI1J24IS^Y/HWJ7PUM?>1..-71# MA87^N? +6A_YHOJTMV3BXXSWKS:CKU=C7JW0 1T@6E5442;S2W8Q\$P;8 M+M BL12(KF9^P@>9E<S^S^KO?>7-8M+<+9F83EBOTUV+W&DGGOWY<|<+K M3DJPJT^THFHG?>^FHH=(S^W:DG3BD(7TC-D MJ1RSC;T^FUIUN^P;*P2.P MXTSE?7?1 MZV13B&Z+<|<O+U_5T1PM:RVWSS^Y^H6IJCZ;^T^T6_VF1J>T^>K^<^<45K/L^<|O M2P.\$% @O4H-66>AR0@+ P 10D ID IX;|IW:W&K&UL\$O:YLP\$YU3DR-FIDMS12=0E2DW: I&1IHVV?3B?5^..M1.9U1V2 UL0UC24KIJ^OIL<^< YO<Y&W3^O8W.\$17<?<3F3.R=3IC0571EG61J MRDMD^DW^14&4GHJ^<TN!>+&@<G=|SONYI^..B:9V;2FB^*I43ADN! *U7=R^?3,52D6B^3E#;0F.Z<\\98F+B M; < /BCM.Y..C9.WYC9E|26;.9PIACK\$R#<\$0_MKC /#=#6L9MP^FT6Q0<X7C/M_ M^M^ZU0161^""YSIHHK^9.W\$@P914N.KFN^8 D-7Q\$5;7IAU1Z#1L255+OHP M%6105G1)=<^_X_N_@+<_+T^L\$<9K9;=615SDF@J^ V&B-9L9V-Q8 M#99F2F**R716ZIO^EHI^M^< MO^NS^T2:(WZ=HIO<22JW8^03>.. J2P@R(PEEEZQ_93D22^|37+|<^T^ONN_7U?>= M:Z9A-Y.P^<V>R#>^..%?T7|HMM.M&X5.1K1Z+ |7&B.S|<S1^/IBC:VF<K< ME/KINI|O|<@|5I1U8R&L> NQUCC8&MJIJ9: @<O@/194AO+S00^#MGZIL_F0 M&S&E&LOB4KK(F-B54Z)<@<G3-WY^<LHN^X^|<|IX:7Y1LD=8TS? V\$;>Z22< MNMN.73:(OZ<?<6%)\$*:.#RMJ+H^L.BD4 IE7?W66AGE-&1(X&8^P^7#0 M2JD^Q/MVT<C^<AIW^CYO&Y^UE823K^\$SW6@<8&UU2OXAIX?>.<#<1<^<4F= MM% (GO5)7MOX E;+21ZK2E5+ Y6IYI|Z>:1@<| #|PIT|A=5RW0/E6!8F;..MN-2GM6^J;EKM:GM.^+>MT?T37EPKHCB4^8AQU1#O=.OWEO43;N>?%|:OK?F M2G=1.^|ST/O>%=#O4| 15?F&1.76102P.\$% @ O4H-63G@P^M1.MNAD ID IX;|IW:W&K&UL&K9EMCZ;Y\$<# BD5/ MU9V46S^OR3>= FT=Y5.6NWYV1>X^IH :>?VDVS_?6U@<20 OVFSG2P^FYKQ M2 MOAX8>W9B_SGL^?7HN;|<O@<50&2W2N&+&N&ZS14I| M1GLOVY.M2:#R9 J^|SN1I.1904N11|ONIE7^|IM@B.M4&SGVE=&3N+&A&V1| MOHTS=|T^CEZ1^26G.ZD11T^Z=28KFN2.I? U_ ZTR7AGS2 1= ML2SO+&16N3G04\$HWY>#>+W:Z2AN;LU:LU04O^C4R^H66A^<\$956CK909&71 M3YX;1UPH^Y9P6T4W^Z^X^|X^URAB^<W^LQ3.M 80- I5Z79M><6XFSBRF^W6 M0EQ+Y^|I^Q^?2M_9.6>? ^?2J>9TL+|IG63Y^?RM416K^\$S1I|A@<A^1|A M2I1U>44^BRDEHM^2O&XP^?20X^?T^L^1_NV\$6A.A4S6ZHQZII(=3.>93T> MIY7Q>.@|^*5.H^1.6K0C^?UPQ%16_FF=9#|X|^E.PKXU#>?<_Y1.E.ZQO& MLWJINE7/NW^VF.>.> 6ISG;SJW5((3E|^I MM?CYQOPZOYJ<# F+(6\$)^\$P3^K<: AS1&+<O4(5C?E^..U^36&IB8Q^UO&^?1 MX^?..|O1QTMW^X7?>..|5B&8XNTE.15Y7+UL^1.56;DU>?<4+<..93P^FW/|M^5Y.FKRI12DG.15-B^|<@C.A.1\$>^?<C:UE73L^(6\$Q M^|P1@G4<|IW551^<O&2W^<6%\$1\$0&DQ^?..|VHG@<M_99#R M2>?>7^00^GNDOT/N2|<1DZD3^|/KNCNIMK=Q^<W&4YJ(5^FK-104MI.L M=25>3A4&W+H+0\$BMB- RK&EPW\$5=<8MUT1^26M@<U^W(NV31\$=8@<RL|^|LY MPB^4KJID..B^<V^<AEB^11^?_7-M-1>+<OHG6\$S=N@<+6.I0+<EIKV=5YCDZED(M6K^|TA(H6C<+H=&+S164<^<VONJ16QT^""&?/H93UIF^YAXT^?FVUWOM M2WRVJ.V6I1_5^?9WQIIO=&I&W^I33C^<K^N8G4N/U04|1(IF^V@E_9%R^ MHKK<49)2K@74|PUCAN5&=1>URS^ U!+ P04 "I2@U9^YAQ-FD"> M!@& O^'AL+W=OND254_UF<^<H)58S|^>V_VYTH2A..I6\$OX&O?WGEFYFYDGHF- 913#<C41J4!=<OEP^<W^..|W7B5N2KK2=1/L16XN_Q MO MW\$@3^?<+260@B@|J^?QFWK=P.DIMODOX1.M^5.V-DG2R>+>+1>3C BL1&3^<A.M^SYVL<=&+<S1L;OGM.LMK3 W? \$K^Y75;KPLB8Y8<^TU-7.FWBHA179.^TK MVN_Q_0^TD17R&8|114%>OG>?>E64&1-KO@6NA70|IP00 M&A^UACZCAIL^%CTYOR<^A@T=OX; IO.9C%<UGL^<?E^?FIUSTD^<@<MIJEJ2 \$SSU2+ M KD^<+< X4R#KV.^<A9&Y^1X#(ZQI12PM;=< Y2\$C9Z9AT=7;Y=I&L1 MW^X^..S1.Y1RWNB^|UWQ45V|IIM^6EDT^? *NL.DI@X=XR^3/66^7B2CBM+ M1F7)4637E\$-30B5;\$%<S9^33?%N1P1^..F^<#<N1(VD14-EWOM^Y)BB1|O MPS#94S22-SFB47^<3O>PG2LGD60^6^P.K^<U^<|<X6JEWI(M&M=0ED^;IN2& ME?F1@<+019GTEA^X^<^<DGY^U!+ P04 "I2@U9/52_70_118P M&0^'AL+W=O:ML M@3)=FQ7C:U391>).YI=N4CEHBT:4CT;.^?C0RH_?T#^("HP J=BSS^?<^' MX^?5Z7>@<C43?>2<DCB5-VYV4HK>E?<6&9XM>?<Kof68YB41?%<M M7 C^>D51\$QZM7F 435B4=FZOBI|<Q>UUME1QE|<O>0R29AXO<^<O1GK3L3JK M& |Y&|LIG^<^<C>7B_8C|O1=OBA>4ANW35E&BAE5&6SL&G^YTOUA^?M_""8HG?<M_X|<XZ3^6>6>L^?O^2H5;C|J|^?OF|>>F MY17=>U9>KPSD.P^BII^\$S6_Z5QTR1(716)67I/7@<P^<V M^B^O3IWI1 M8^?<+USP2 M-YWP24N1ZIO?U30F^ M^AOJN1P7|63RY1>N+N;^/OX>?YILO.GQ|9=1OCN3>7 M?UG=>EO; IES0^GVEONFLO_ODOU=>E1T^<N^51>|VLM3M<^<^QW<L+55UUM^I7Y<B_?4J1P^..|P&MGS1&3D&GPA1VZ?%<OV#^<RV/ZLY(R=15W+10G13T1ML MR<4+I1S<12_6J|<W-KF0..<?> W^?Z/D>(B80X2YB)A^A^F(V\$1SD9|L<X%VMQ+XR#|<@-IBY)E0IXSH2NC M=>S9^I1OM&7V-K&E^F&CC8V(|>P5_YJ+<@<?9U47^?/3,1^|<R^8_U!+> M7AH?>2119R/E\$DJG(SD^E7+ (TY^2|IAU!+W+<K11=6_1>P>NM04MMJZNLB M^A^F(V\$1SD9|L(9_5J_>9ILS&OBO1^?B_B=>\$24AM&^O80EF5+1?XD1(9SH M3SXA3U7KYQXS_-@Q1Z/95GJ|<P^..%<72C- @1^)*V TBB^UO1V(VNCP-6K M\$0-11+<1+MY2GYG(F+=1+39C^|UQ..EX)- OG^1YIF:5Z2ZIG+<E^5&31<3 M9RY:PO<4XDW6A-^|Z&T^|<C^%KS16&7?P2.Z=>DYS&D94A- ^|C1LGHW->6Y M1^<5&WM6&ES2KQWRYO>=>L109UH72^<C^A|^<M^<VB>S9Y23+1=US+G&KK^# JZM|RIK?E16:9D^?I3FOVDIE\$91M1^1=9E&9 W&G& MVEZ-DE^TO M^H.NBK8M1&^5VB(I:5Y4H/I050&D71FKI6499FS&+2DAS^C^B^3&S2VJEC:EHYV+<S&4E^|IZ7Y4%H 15&4K6I&G899YCAL>D> M2Q16:78U;|(E^<V? V@N5M\$VIV-AGVSYYI^(RHS8/2^?@M@<-(HBM;4M Z^ M+&A.W=T(<:;>RC- M@=>+Y.S+YO+4=3^*<@QKX.NVOQT/9:C M6>Y..B4ADIMJ=>@MCE NM16.RVXMIL^TKSH^0?2@N@<-(JB M-160LRW;G&U.TI1 L.313XO^<ZD25<ZB8Z3^<MB>?>UMEI1H:E6T13E^CYO M&H^U^<V15TGP+8#2^ (K6M+H.P60\$<+91YIDA8>8RPT.ZM^YH^YLV.G.L0KOGBZ4YD^/1060&D4161^6^T+G M1F^GD151QE.IXMI|ID@89S^?9ZVZOC.RBO;QY .DDP^I3F0VDIE\$91M^:P M=4AF? 2^E5/7U|<V@9>4>D^IE06@<^E412M^O5=OS7 M^<P^IIR?(=<M:L575B82=5ZW<=<9=;R1F6&3UTV&IM^N+13F06D^<E19_11% M:V1:QV14^KJ=IT#<SISH^0720<@<I^"Z TBJ(U?;XSM+I| MR1VR76@6J4Y4H+I7E0F^<E15_1:=&^"Fl-Z^%OZ%\$5^..%Z4&41?91NUUE8? C9N00T&D^("C^<M^ M^V^T@<HC;)H387K^*QOCL^<^V^P_<OHG7?|IMH/4P.VM.^TCPHS872 BB- MHFBEJ=V-KI=<N>@50^T@29@?UUA^3_CZUO70/WPI?O5@ZW;7N0^LEMMIZRRH M?IVAQI<_<O^ Q^O^>8GY5+2J8_U6^<Q10179^9HOAR_>=>J2P1&X^<N^<M^<M^<S3+U^<W^F#1^QJW_P=02P.\$% @ O4H-67^<K^O^C @E@8 ID M IX;|IW:W&K&ULK55=31LP^TK5H8FD^<D23H M:R..5HA-3^<KXV1)=Y+<Q.S.OFEAAUW173H@<A&X^<VEMYYSSSE|D9;1YL M#1L93^3H(<?>7^AC8KH.3V5^1|T96E-B5^V1U5;- <=&.>Y10SC^I&1R8:6G1+106M-1P+<+<HBX^..DHA^K_<6.3PPZ@UW^?>=>^%<120-O^%< ME;H&K&G<8^7FNU.KD#41(9+)=L#<^< M=WPA@1W_+FOIHA. IFI&I|/#@B1T^H=>H20+56I(1^<QOIF3>=<+NG23N1O ME3IE273.XBCN=|<G^<^\$SR C>^..#D3RD^<H&X<^V/E^J1-M4^<CU7Q26 M6E1\$HP^*19%>@ DRX7+=GDE\$N7V9|IWWNW19SN^893^ZW2R8#031OP^18?2Y MR_L(GL11-<D>QC3_W=O19^2GP29@I&BB41^5XJOV^WY^S7-A.5PH9 MW7WYWH Q=>+H4BJM.17+M7.7IZ+N/O3=>W9391^<CMN1^<MM7YKK; 7VK0BD21Y|DOHU:6N)ACL^<M^<U^<O^U^K1U525QKU=H^4WV^ON^? / MV.1+<VSLUR2MS;JCA^|L- 7XL=>1>=>SFI<G=N5D)9)F^N.AT1&2FGH+UO7: M^#Y^%1AI+ZEGOAP.^*Z#K2ZWQ>=>F4_1I2O^4SL^110 (<+U^5ET+AT&K MTPC_QO 9>=>KPO=VIR-W; H965T230RTI>=>B0P19M=>B.1>1=0^2^+<44D#<SD124@<DRY9 MNWVW1Y^EGN201FOZ^>=>E1FVS2=>5..9X<367GN02YQ>=>^<3&.<@<N1%FE+<Q MHS& /EVR U>3WR^UQNI3PP7- UNZ9I-9<I<-(C2C84)X11E- MN@M^QUM0MAOS|S|G6.B7HCYV_IYV6T.QC1K^<F&47ZOB>VQ->DUB@O M-730Y-21N|<O=>1^|<K^<^<R^P&J/V(H6B;5SG-60Z^?YBUN MDI= R7>=C0@RR^?^V#50 2.^O^<TV_U&I\$38\$V..1-AU@+T2.^#X2^*X#OOL MTR.|DSI@1TP/S7#91UP>6J&JSI@U>P^<OS^#1^A MDBYN^|VOK=6-U0^JB.5I1YG&FQ? Y9^/1NK+GXQ)Y85C 29I@EDOR^<2 M&KDVQ- (6X=<)&B?Y.W7WOQ^<O^WSCKPA<4^..?BITRS^X9214^SALLZHU&E MM|IDN.@IS^<O^FVX6G@<GWC^CQ17YCC9X;XH7KWF?> GT+I&A&X+IH=>D&L M1^<#_MF3GOIIF^H1UM00<=>DILG+M^?WAON2>R(S9 M_#=>QWVY?IE#WAX-T^<X^<K^<YYD_2A<I02M^YD2N>M2Y2L=J1^<I^G MGMA@812K- GHGW2^O^<O^<P^<CPDSS^?> BOLL\$<Z.IX.TI.ZI41^<S3&O142H_ MYU(4IJB1+Y250.22L?F_?>^<4+1^F+<S&N\$N8A83Y2&BIA(OC6D^<?>D^?>M1.M.IHWSH^|IB8&5.5>4^E&BXCDZK_>|>7- K9P9J24D;DQTKL^1^<=<#TM|J|S1?I5I5B|^|^|^|^#<+E^?>1^<+<I-UTZ@CGUDGCYELI|W7\$BB MY^<U&|<U6|<J=I31=^CY1F|<F>J&S4@/G7U.FB15TM(F;XN4B8-5O4TJ&B MDI#^<C8U9@Q1&3ORG&?2RGIOE^5\$).O(PXJ^?2^<2%>)>T11O.O:R#E7<S8B M@X2Y2JB^A^E(6^<^\$A2181^?7C8 OH57F)5+<2&B)M^A+E(F>S^<4A8@<2%<C^A^ MOE>- C^<X_#1BKY/M1&50A15%+ 33^W5Q61D2U^<TO/|E+G<8Y5^<17 M1^8IGR^<P/F(=Z2)B^A^E(6^<^\$A2181|G6G^WY?U #4^<N)NMU6^92N16^/EF+<+C+<E1^Z-21O MCK<^<10HPI^Z T^TH+H+001=>M^MK6K+<+215 M^%22C4BOY9D.666E_9%<0&45^|H76FV1QE=>N^?7I&WDM2&O7/R^V3FU+21 GNO M00C9/N51>?>9%<0&4%JH72FU- IEM#<6/HW5/GV|ISEK(C:BCIO|OZUO- MS)>|LK3615I|ZMOCIU^ T^TISV30.2O.AM^*F=7^X&W7816?<7X>(>Z06)=|@WRMMI|<7TURS10>|TX72^<C^ MA| (<""UST;126TWYVR1I5^\$T^<F^IYV1P^HIF@<L1&4\$S^X?7@%>^..I^W MB&S.XA01H^<^?5%<?PE)D2^<U^<8M93E^<SD M_GM1P^> I1^XAAA^<F@<^AC1X)<X^K^<K^<P^HIF@<L1&4\$S^X?7@%>^..I^W MB&S.XA01H^<^?5%<?PE)D2^<U^<8M93E^<SD M_GM1P^> |T/GWDZIKY;2\$<@AU^*5DIP^%4.E7RG(CFZ51 M&UBU#2RD)Y>DG_<OOFB44+&=>YD)N1G1;8X9GL6KW^Q9N^|J@<V10+<+<E1MZ/P^G5^H^<Y>B.W? =>+I2<390VQ0+&8A^<255R8NR^MILMPU1^<27J1\$..<41 M^<E^<V^P^J^D&Z+5;7Z|>S01QN^<1DN@<C^7W165J3_ UK41-C^<^RI-S^11 MNY-K5YQ^<I.A\$<10%P\$9C^..-HPF^E^O M-<835T1^2&GLI?D)7G5L.Y@N4UHIK&B-S\$<B@/OL@LB6G(KBMDUO^<F^C6D^<9G MX50MP^FWYWE^<C^W961+3V^ANG3.IYKF+<|I16E1Y<2^K.WXS^|E1@2TU^ MV+ =>GOTS^K=2T^<F6F1+3>=>96P7|I6V^ZM^O1\$<L^?G 63JUT6GRBS=<6X15^V+3<=>..P%O M.L^<M9G@KZV1L4=I>ZU8? N=0QALZ^|Q5KF<F7Y9J&Z^?1\$<SORH+8&M_3 MR5D>9>R^<R^M1_4<3=3IKH&+H(GVHZNM1>=>8&CH^Y0 M^<QIBU^P60>=>C4^<O^<5^<1^<JRVCK06^4Y5M4^6VHZHPIKEP %<#K3I3HJMFUE9;54ML^6F7^<E1&Q^?>1^<#ZM;U;5 EMJ.L^<F&A9V^OK619 MDL#<FRO3&IT09L6Q58H_C%GQ+IHN69M+|W^JE5Q&M@<JBI&OR^VC5..^Y(M>7<I&EY^_3_<O^X(EA62)3Y2(6A2^XPBCI3<C^_R@51Q/U16/U^>S17U1+ M P04 "I2@U9|A+KK@<^..?<0_<A^<W=O-U-B>1:|PTFIC=V513Q\$E0 M 6=M1^<E^<A^<17S 100YR2GH6N^Y_1GO@P10@8B/DHUIRKM^\$SEN;JLK?>4>G7N M>6JY^%FL^<F+<=<I-G+<F06; L^?YYI^21|U9J L18C01UX6)WEO?%<NFCQA5CK M..GY1^""USK)8 KSJF=A<IG^09<MLEIC2H.WOE^C^<P18 11^H1UKZ.DHSG M^\$ASYDGQ^<V^O^YRP@14^9X^M^<J3>B1JF&B^\$8B1^R?>9XL1191=>8&(<S^G M1^3M^""93.94AOQO&Y^>S.IO.R>=>FC&Y_SZ=C M MQO>A^O060^E(52P7?|V?>I^<U+<I^<K HV(B22?L^? JZ\$V G @P.I H@;PT (MIJH=>=41X|<10I0S>@A16 >74O>W2<^<H^K/QA10|<O6AEBLEJ7T4O^?.. MEH1MS=|S\$Q GC=<@RDZ1|^?..Y&Z^Z6_L2U011^M65D/XH^<?0B\$? DI1^<2=5150>=>F-JR-ZT2IIN^R<^<@_0-Y^K14I.G_<9 M2SQSQT>=>..I4H0M^<2>YD1D@W^<N^C^W^<T^R<2^<X18=2I=741P&1ZTR?&& MW@/_B_LY^|<C^<^H^2-W ?^<H@C:5D>=>SR&LIGABIVYU>?>L^<F M1^<10XS5F1 M6V1^<0^TU.WE00T1GQ:DP#?>Y1810S=LBH1ZFUEUX=>?<BV>.>1 W-!\$H M5J9>?ZP&PO=VIR-W; H965T^<#L1IA^<^?A^39K03(GOO_F\$=< MX0301^2^K<KDS^<BYU&K^H01)H620|GCI>=8\$*4D M^?<3^JIRE2I5>3^<N^<B^<Z>7^?>^..UY1R.BNQNDM1B^<^Y03194>?I2E TV5 M7D@+> Z^OWFO.PIAS@<5-RF19@R1.C| H1PFBS3^19P|&@0; 7?ZL O_O+ M R9EP^O0@/417N1X+> 18M93S6-SDD M_GM1P^> I1^XAAA^<F@<^AC1X)<X^K^<K^<P^HIF@<L1&4\$S^X?7@%>^..I^W MB&S.XA01H^<^?5%<?PE)D2^<U^<8M93E^<SD M_GM1P^> |T/GWDZIKY;2\$<@AU^*5DIP^%4.E7RG(CFZ51 M&UBU#2RD)Y>DG_<OOFB44+&=>YD)N1G1;8X9GL6KW^Q9N^|J@<V10+<+<E1MZ/P^G5^H^<Y>B.W? =>+I2<390VQ0+&8A^<255R8NR^MILMPU1^<27J1\$..<41 M^<E^<V^P^J^D&Z+5;7Z|>S01QN^<1DN@<C^7W165J3_ UK41-C^<^RI-S^11 MNY-K5YQ^<I.A\$<10%P\$9C^..-HPF^E^O M-<835T1^2&GLI?D)7G5L.Y@N4UHIK&B-S\$<B@/OL@LB6G(KBMDUO^<F^C6D^<9G MX50MP^FWYWE^<C^W961+3V^ANG3.IYKF+<|I16E1Y<2^K.WXS^|E1@2TU^ MV+ =>GOTS^K=2T^<F6F1+3>=>96P7|I6V^ZM^O1\$<L^?G 63JUT6GRBS=<6X15^V+3<=>..P%O M.L^<M9G@KZV1L4=I>ZU8? N=0QALZ^|Q5KF<F7Y9J&Z^?1\$<SORH+8&M_3 MR5D>9>R^<R^M1_4<3=3IKH&+H(GVHZNM1>=>8&CH^Y0 M^<QIBU^P60>=>C4^<O^<5^<1^<JRVCK06^4Y5M4^6VHZHPIKEP %<#K3I3HJMFUE9;54ML^6F7^<E1&Q^?>1^<#ZM;U;5 EMJ.L^<F&A9V^OK619 MDL#<FRO3&IT09L6Q58H_C%GQ+IHN69M+|W^JE5Q&M@<JBI&OR^VC5..^Y(M>7<I&EY^_3_<O^X(EA62)3Y2(6A2^XPBCI3<C^_R@51Q/U16/U^>S17U1+ M P04 "I2@U9|A+KK@<^..?<0_<A^<W=O-U-B>1:|PTFIC=V513Q\$E0 M 6=M1^<E^<A^<17S 100YR2GH6N^Y_1GO@P10@8B/DHUIRKM^\$SEN;JLK?>4>G7N M>6JY^%FL^<F+<=<I-G+<F06; L^?YYI^21|U9J L18C01UX6)WEO?%<NFCQA5CK M..GY1^""USK)8 KSJF=A<IG^09<MLEIC2H.WOE^C^<P18 11^H1UKZ.DHSG M^\$ASYDGQ^<V^O^YRP@14^9X^M^<J3>B1JF&B^\$8B1^R?>9XL1191=>8&(<S^G M1^3M^""93.94AOQO&Y^>S.IO.R>=>FC&Y_SZ=C M MQO>A^O060^E(52P7?|V?>I^<U+<I^<K HV(B22?L^? JZ\$V G @P.I H@;PT (MIJH=>=41X|<10I0S>@A16 >74O>W2<^<H^K/QA10|<O6AEBLEJ7T4O^?.. MEH1MS=|S\$Q GC=<@RDZ1|^?..Y&Z^Z6_L2U011^M65D/XH^<?0B\$? DI1^<2=5150>=>F-JR-ZT2IIN^R<^<@_0-Y^K14I.G_<9 M2SQSQT>=>..I4H0M^<2>YD1D@W^<N^C^W^<T^R<2^<X18=2I=741P&1ZTR?&& MW@/_B_LY^|<C^<^H^2-W ?^<H@C:5D>=>SR&LIGABIVYU>?>L^<F M1^<10XS5F1 M6V1^<0^TU.WE00T1GQ:DP#?>Y1810S=LBH1ZFUEUX=>?<BV>.>1 W-!\$H M5J9>?ZP&PO=VIR-W; H965T^<#L1IA^<^?A^39K03(GOO_F\$=< MX0301^2^K<KDS^<BYU&K^H01)H620|GCI>=8\$*4D M^?<3^JIRE2I5>3^<N^<B^<Z>7^?>^..UY1R.BNQNDM1B^<^Y03194>?I2E TV5 M7D@+> Z^OWFO.PIAS@<5-RF19@R1.C| H1PFBS3^19P|&@0; 7?ZL O_O+ M R9EP^O0@/417N1X+> 18M93S6-SDD M_GM1P^> I1^XAAA^<F@<^AC1X)<X^K^<K^<P^HIF@<L1&4\$S^X?7@%>^..I^W MB&S.XA01H^<^?5%<?PE)D2^<U^<8M93E^<SD M_GM1P^> |T/GWDZIKY;2\$<@AU^*5DIP^%4.E7RG(CFZ51 M&UBU#2RD)Y>DG_<OOFB44+&=>YD)N1G1;8X9GL6KW^Q9N^|J@<V10+<+<E1MZ/P^G5^H^<Y>B.W? =>+I2<390VQ0+&8A^<255R8NR^MILMPU1^<27J1\$..<41 M^<E^<V^P^J^D&Z+5;7Z|>S01QN^<1DN@<C^7W165J3_ UK41-C^<^RI-S^11 MNY-K5YQ^<I.A\$<10%P\$9C^..-HPF^E^O M-<835T1^2&GLI?D)7G5L.Y@N4UHIK&B-S\$<B@/OL@LB6G(KBMDUO^<F^C6D^<9G MX50MP^FWYWE^<C^W961+3V^ANG3.IYKF+<|I16E1Y<2^K.WXS^|E1@2TU^ MV+ =>GOTS^K=2T^<F6F1+3>=>96P7|I6V^ZM^O1\$<L^?G 63JUT6GRBS=<6X15^V+3<=>..P%O M.L^<M9G@KZV1L4=I>ZU8? N=0QALZ^|Q5KF<F7Y9J&Z^?1\$<SORH+8&M_3 MR5D>9>R^<R^M1_4<3=3IKH&+H(GVHZNM1>=>8&CH^Y0 M^<QIBU^P60>=>C4^<O^<5^<1^<JRVCK06^4Y5M4^6VHZHPIKEP %<#K3I3HJMFUE9;54ML^6F7^<

[illegible]

#2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */ .pl a .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } word-wrap: break-word; */ } .report td.pl a a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .rou .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num .report .num { text-align: right; white-space: nowrap; } .report .num { padding-left: 2em; } .report .num { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1.html 216 338 1 false 62 0 false 11 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://www.aziyo.com/role/DocumentDocumentAndEntityInformationDocument and Entity Information Cover 1 false false R2.htm 995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParentheticals CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals) Statements 6 false false R7.htm 995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 995200405 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Sheet http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) Statements 8 false false R9.htm 995210101 - Disclosure - Organization and Description of Business Sheet http://www.aziyo.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 9 false false R10.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 995210301 - Disclosure - Recently Issued Accounting Standards Sheet http://www.aziyo.com/role/DisclosureRecentlyIssuedAccountingStandards Recently Issued Accounting Standards Notes 11 false false R12.htm 995210401 - Disclosure - Sale of Orthobiologics Business Sheet http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusiness Sale of Orthobiologics Business Notes 12 false false R13.htm 995210501 - Disclosure - Stock-Based Compensation Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 995210601 - Disclosure - Inventory Sheet http://www.aziyo.com/role/DisclosureInventory Inventory Notes 14 false false R15.htm 995210701 - Disclosure - Long-Term Debt Sheet http://www.aziyo.com/role/DisclosureLongTermDebt Long-Term Debt Notes 15 false false R16.htm 995210801 - Disclosure - Revenue Interest Obligation Sheet http://www.aziyo.com/role/DisclosureRevenueInterestObligation Revenue Interest Obligation Notes 16 false false R17.htm 995210901 - Disclosure - Common Stock and Warrants Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrants Common Stock and Warrants Notes 17 false false R18.htm 995211001 - Disclosure - Commitment and Contingencies Sheet http://www.aziyo.com/role/DisclosureCommitmentAndContingencies Commitment and Contingencies Notes 18 false false R19.htm 995211101 - Disclosure - Net Loss Per Share Sheet http://www.aziyo.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 19 false false R20.htm 995211201 - Disclosure - Segment Information Sheet http://www.aziyo.com/role/DisclosureSegmentInformation Segment Information Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 23 false false R24.htm 99920302 - Disclosure - Recently Issued Accounting Standards (Policies) Sheet http://www.aziyo.com/role/DisclosureRecentlyIssuedAccountingStandardsPolicies Recently Issued Accounting Standards (Policies) Policies http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 99930403 - Disclosure - Sale of Orthobiologics Business (Tables) Sheet http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessTables Sale of Orthobiologics Business (Tables) Tables http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusiness 26 false false R27.htm 99930503 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.aziyo.com/role/DisclosureStockBasedCompensation 27 false false R28.htm 99930603 - Disclosure - Inventory (Tables) Sheet http://www.aziyo.com/role/DisclosureInventoryTables Inventory (Tables) Tables http://www.aziyo.com/role/DisclosureInventory 28 false false R29.htm 99930703 - Disclosure - Long-Term Debt (Tables) Sheet http://www.aziyo.com/role/DisclosureLongTermDebtTables Long-Term Debt (Tables) Tables http://www.aziyo.com/role/DisclosureLongTermDebt 29 false false R30.htm 99930903 - Disclosure - Common Stock and Warrants (Tables) Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables Common Stock and Warrants (Tables) Tables http://www.aziyo.com/role/DisclosureCommonStockAndWarrants 30 false false R31.htm 99931103 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.aziyo.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.aziyo.com/role/DisclosureNetLossPerShare 31 false false R32.htm 99931203 - Disclosure - Segment Information (Tables) Sheet http://www.aziyo.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.aziyo.com/role/DisclosureSegmentInformation 32 false false R33.htm 99940201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation and Liquidity (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails Summary of Significant Accounting Policies - Basis of Presentation and Liquidity (Details) Details 33 false false R34.htm 99940202 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Share (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails Summary of Significant Accounting Policies - Net Loss per Share (Details) Details 34 false false R35.htm 99940203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 35 false false R36.htm 99940204 - Disclosure - Summary of Significant Accounting Policies - Leases (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails Summary of Significant Accounting Policies - Leases (Details) Details http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 99940205 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails Summary of Significant Accounting Policies - Long-Lived Assets (Details) Details 37 false false R38.htm 99940206 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 38 false false R39.htm 99940207 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit risk (Details) Sheet http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails Summary of Significant Accounting Policies - Concentration of Credit risk (Details) Details 39 false false R40.htm 99940402 - Disclosure - Sale of Orthobiologics Business - Financial results (Details) Sheet http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails Sale of Orthobiologics Business - Financial results (Details) Details 40 false false R41.htm 99940403 - Disclosure - Sale of Orthobiologics Business - Non-cash reconciliation (Details) Sheet http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails Sale of Orthobiologics Business - Non-cash reconciliation (Details) Details 41 false false R42.htm 99940501 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.aziyo.com/role/DisclosureStockBasedCompensationTables 42 false false R43.htm 99940502 - Disclosure - Stock-Based Compensation - Stock Options Activity (Details) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails Stock-Based Compensation - Stock Options Activity (Details) Details 43 false false R44.htm 99940503 - Disclosure - Stock-Based Compensation - Option Valuation Assumption (Details) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails Stock-Based Compensation - Option Valuation Assumption (Details) Details 44 false false R45.htm 99940504 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-Based Compensation - Restricted Stock Units (Details) Details 45 false false R46.htm 99940505 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails Stock-Based Compensation - Employee Stock Purchase Plan (Details) Details 46 false false R47.htm 99940506 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 47 false false R48.htm 99940601 - Disclosure - Inventory (Details) Sheet http://www.aziyo.com/role/DisclosureInventoryDetails Inventory (Details) Details http://www.aziyo.com/role/DisclosureInventoryTables 48 false false R49.htm 99940701 - Disclosure - Long-Term Debt - SWK Loan Facility (Details) Sheet http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails Long-Term Debt - SWK Loan Facility (Details) Details 49 false false R50.htm 99940702 - Disclosure - Long-Term Debt - Long-Term Debt - Table (Details) Sheet http://www.aziyo.com/role/DisclosureLongTermDebtLongTermDebtTableDetails Long-Term Debt - Long-Term Debt - Table (Details) Details 50 false false R51.htm 99940801 - Disclosure - Revenue Interest Obligation - (Details) Sheet http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails Revenue Interest Obligation - (Details) Details http://www.aziyo.com/role/DisclosureRevenueInterestObligation 51 false false R52.htm 99940901 - Disclosure - Common Stock and Warrants - Registered Direct Offering of Common Stock and Warrants (Details) Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails Common Stock and Warrants - Registered Direct Offering of Common Stock and Warrants (Details) Details 52 false false R53.htm 99940902 - Disclosure - Common Stock and Warrants - Private Placement of Common Stock (Details) Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails Common Stock and Warrants - Private Placement of Common Stock (Details) Details 53 false false R54.htm 99940903 - Disclosure - Common Stock and Warrants - Warrant Activity (Details) Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails Common Stock and Warrants - Warrant Activity (Details) Details 54 false false R55.htm 99940904 - Disclosure - Common Stock and Warrants - Warrants fair value rollforward (Details) Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails Common Stock and Warrants - Warrants fair value rollforward (Details) Details 55 false false R56.htm 99940905 - Disclosure - Common Stock and Warrants - Warrant pricing inputs (Details) Sheet http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails Common Stock and Warrants - Warrant pricing inputs (Details) Details 56 false false R57.htm 99941001 - Disclosure - Commitment and Contingencies - License and Supply (Details) Sheet http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails Commitment and Contingencies - License and Supply (Details) Details 57 false false R58.htm 99941002 - Disclosure - Commitment and Contingencies - Legal Proceedings (Details) Sheet http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails Commitment and Contingencies - Legal Proceedings (Details) Details 58 false false R59.htm 99941101 - Disclosure - Net Loss Per Share (Details) Sheet http://www.aziyo.com/role/DisclosureNetLossPerShareDetails Net Loss Per Share (Details) Details http://www.aziyo.com/role/DisclosureNetLossPerShareTables 59 false false R60.htm 99941102 - Disclosure - Net Loss Per Share - Anti-dilutive securities (Details) Sheet http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails Net Loss Per Share - Anti-dilutive securities (Details) Details 60 false false R61.htm 99941201 - Disclosure - Segment Information - Disaggregation (Details) Sheet http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails Segment

Information - Disclosure (Details) Details 61 false false R62.htm 99941202 - Disclosure - Segment Information - Reconciliation of segment gross profit (Details) Sheet
http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails Segment Information - Reconciliation of segment gross profit (Details) Sheet
Details 62 false false All Reports Book All Reports elut-20240630.xsd elut-20240630_cal.xml elut-20240630_def.xml elut-20240630_lab.xml elut-20240630_pre.xml elut-20240630x10q.htm
http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT {
"version": "2.2", "instance": { "elut-20240630x10q.htm": { "nsPrefix": "elut", "nsuri": "http://www.aziyo.com/20240630", "dts": { "schema": { "local": { "elut-20240630.xsd" },
"remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/typer/2020-01-21/typer.xsd",
"https://www.xbrl.org/dtr/typer/2022-03-31/typer.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
"https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/srt/2024/srt-2024.xsd" }, "calculationLink": { "local": {
"elut-20240630_cal.xml" }, "definitionLink": { "local": { "elut-20240630_def.xml" }, "labelLink": { "local": { "elut-20240630_lab.xml" }, "presentationLink": { "local": {
"elut-20240630_pre.xml" }, "inline": { "local": { "elut-20240630x10q.htm" }, "keyStandard": 260, "axisCustom": 78, "axisStandard": 23, "axisCustom": 0,
"memberStandard": 25, "memberCustom": 32, "hidden": { "total": 22, "http://xbrl.sec.gov/dei/2024": 5, "http://www.aziyo.com/20240630": 3, "http://fasb.org/us-gaap/2024": 14
}, "contextCount": 216, "entityCount": 1, "segmentCount": 62, "elementCount": 628, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 677,
"http://xbrl.sec.gov/dei/2024": 32, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation",
"longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document",
"subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name":
"dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "div", "div": "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name":
"dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "div", "div": "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R2": { "role": "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 -
Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType":
"statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As Of 6 30 2024 UaRyKATJZk6 UHkfUWP6mw", "name": "us-
gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": {
"p": "td", "tr": "table", "div": "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"As Of 6 30 2024 UaRyKATJZk6 UHkfUWP6mw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO",
"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr": "table", "div": "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first":
true, "unique": true }, "R3": { "role": "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParenteticals", "longName": "995200105 - Statement -
CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false",
"groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As Of 6 30 2024 us-
gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_5W57YxCotE2z4ZhfoOPKeg", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef":
"Unit_Divide_USD_shares_ZFSHPfA7k6FvFZHXndXlNW", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table", "div": "div", "body", "html" },
"reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As Of 6 30 2024 us-gaap_StatementClassOfStockAxis_us-
gaap_CommonClassAMember_5W57YxCotE2z4ZhfoOPKeg", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Unit_Standard_shares_2XATN2TYGrTlfvea0LUQ",
"xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "p", "td": "tr", "table", "div": "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm",
"unique": true }, "R4": { "role": "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations", "longName": "995200200 -
Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault":
"false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-
VW2k6qR_b561lmoq", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr": "table", "div": "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true },
"uniqueAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR_b561lmoq", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef":
"Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "p": "td", "tr": "table", "div": "div", "body", "html" },
"reportCount": 1, "baseRef": "elut-20240630x10q.htm", "unique": true }, "R5": { "role":
"http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "longName": "995200300 - Statement - CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
STOCKHOLDERS' EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": {
"contextRef": "As Of 12 31 2022 us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-gaap_StatementEquityComponentsAxis_us-
gaap_CommonStockMember_bAKObBR3kWO0DzsTo0eg", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil":
"false", "lang": null, "decimals": "-3", "ancestors": { "b": "p", "td": "tr", "table", "div": "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 12 31 2022 us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_us-
gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAKObBR3kWO0DzsTo0eg", "name": "us-gaap:StockholdersEquity", "unitRef":
"Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "b": "p", "td": "tr", "table", "div": "div", "body", "html" },
"reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R6": { "role":
"http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenteticals", "longName": "995200305 - Statement -
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)", "shortName": "CONDENSED CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical",
"menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration 4 1 20

uniqueAnchor": {"contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R15": { "role": "http://www.aziyo.com/role/DisclosureLongTermDebt", "longName": "995210701 - Disclosure - Long-Term Debt", "shortName": "Long-Term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R16": { "role": "http://www.aziyo.com/role/DisclosureRevenueInterestObligation", "longName": "995210801 - Disclosure - Revenue Interest Obligation", "shortName": "Revenue Interest Obligation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "elut:RevenueInterestObligationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R17": { "role": "http://www.aziyo.com/role/DisclosureCommonStockAndWarrants", "longName": "995210901 - Disclosure - Common Stock and Warrants", "shortName": "Common Stock and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R18": { "role": "http://www.aziyo.com/role/DisclosureCommitmentAndContingencies", "longName": "995211001 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "elut:RevenueInterestObligationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R19": { "role": "http://www.aziyo.com/role/DisclosureNetLossPerShare", "longName": "995211101 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R20": { "role": "http://www.aziyo.com/role/DisclosureSegmentInformation", "longName": "995211201 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR_b56J1mog", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqm0ohMIQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR_b56J1mog", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R23": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R24": { "role": "http://www.aziyo.com/role/DisclosureRecentlyIssuedAccountingStandardsPolicies", "longName": "99920302 - Disclosure - Recently Issued Accounting Standards (Policies)", "shortName": "Recently Issued Accounting Standards (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R25": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "elut:ScheduleOfEstimatedUsefulLivesOfAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R26": { "role": "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessTables", "longName": "99930403 - Disclosure - Sale of Orthobiologics Business (Tables)", "shortName": "Sale of Orthobiologics Business (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R27": { "role": "http://www.aziyo.com/role/DisclosureStockBasedCompensationTables", "longName": "99930503 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R28": { "role": "http://www.aziyo.com/role/DisclosureInventoryTables", "longName": "99930603 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R29": { "role": "http://www.aziyo.com/role/DisclosureLongTermDebtTables", "longName": "99930703 - Disclosure - Long-Term Debt (Tables)", "shortName": "Long-Term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"] }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R30": { "role": "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables", "longName": "99930903 - Disclosure - Common Stock and Warrants (Tables)", "shortName": "Common Stock and Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "

gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm20", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } } , "R33": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation and Liquidity (Details)", "shortName": "Summary of Significant Accounting Policies - Basis of Presentation and Liquidity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm20", "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "unique": true } } , "R34": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies - Net Loss per Share (Details)", "shortName": "Summary of Significant Accounting Policies - Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As Of 6 30 2024 us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_5W57YxCotE2z4ZhfoOPKeg", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_ZF5HPpA7k6FvZHzndXlNw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true } , "uniqueAnchor": null } , "R35": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "longName": "99940203 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As Of 6 30 2024 us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zle2Q1YLZ0eoD5LKKqeyw", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true } , "uniqueAnchor": null } , "R36": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "longName": "99940204 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)", "shortName": "Summary of Significant Accounting Policies - Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As Of 6 30 2024 UaRykATJZk6_UHkFUWP6mw", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm20", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeLeasesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } } , "R37": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails", "longName": "99940205 - Disclosure - Summary of Significant Accounting Policies - Long-Lived Assets (Details)", "shortName": "Summary of Significant Accounting Policies - Long-Lived Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR_b56j1mog", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "us-gaap:ImpairmentOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR_b56j1mog", "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf", "us-gaap:ImpairmentOfLongLivedAssetsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } } , "R38": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "longName": "99940206 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 srt_RangeAxis_srt_MaximumMember_PnTbA1xObkmRPuAXffivBQ", "name": "elut:RevenueFromContractWithCustomerTermOfPayment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 srt_RangeAxis_srt_MaximumMember_PnTbA1xObkmRPuAXffivBQ", "name": "elut:RevenueFromContractWithCustomerTermOfPayment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } } , "R39": { "role": "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails", "longName": "99940207 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit risk (Details)", "shortName": "Summary of Significant Accounting Policies - Concentration of Credit risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jwI9ShhklCUMcF17RcCWQ", "name": "elut:NumberOfMajorCustomers", "unitRef": "Unit_Standard_customer_Wltn8NulJkagFxmZv1C4_g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } , "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_jwI9ShhklCUMcF17RcCWQ", "name": "elut:NumberOfMajorCustomers", "unitRef": "Unit_Standard_customer_Wltn8NulJkagFxmZv1C4_g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } } , "R40": { "role": "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails", "longName": "99940402 - Disclosure - Sale of Orthobiologics Business - Financial results (Details)", "shortName": "Sale of Orthobiologics Business - Financial results (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm20", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true } , "uniqueAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_elut_OrthobiologicsBusinessMember_TjrCATFDmkm43g", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "unique": true } } , "R41": { "role": "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails", "longName": "99940403 - Disclosure - Sale of Orthobiologics Business - Non-cash reconciliation (Details)", "shortName": "Sale of Orthobiologics Business - Non-cash reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration 1 1 2023 To 6 30 2023 UyhRdxvWjEKZZXwFf5ivg", "name": "us-gaap:DepreciationAndAmortizationDiscontinuedOperations", "unitRef": "Unit_Standard_USD_bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true } } , "R42": { "role": "http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails", "longName": "99940501 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm20", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_-2XATN2TY0GrTifvea0LUO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true } , "uniqueAnchor": { "contextRef": "As Of 6 8 2023 us-gaap_PlanNameAxis_elut_StockOptionPlan2020Member_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_uorKJBER1EG_DXEv13kPxg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_-2XATN2TY0GrTifvea0LUO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true } , "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm20", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "Unit_Standard_shares_-2XATN2TY0GrTifvea0LUO", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html"] , "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true } , "uniqueAnchor": { "contextRef": "http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails", "longName": "99940503 - Disclosure - Stock-Based Compensation - Option Valuation Assumption (Details)", "shortName": "Stock-Based Compensation - Option Valuation Assumption (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4BRmuTtkRp0S22LLwAdwHHg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef":

Unit Standard pure BNYvialJl0eeuTj YZytDg, "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap AwardTypeAxis us-gaap_EmployeeStockOptionMember GFfmX xm3UuBtGDP7i7V0q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "unique": true }, "R45": { "role": "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "longName": "99940504 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)", "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap AwardTypeAxis us-gaap_RestrictedStockUnitsRSUMember 7rAHletbdU27pxY6dpznrq", "name": "elut:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap AwardTypeAxis us-gaap_RestrictedStockUnitsRSUMember 7rAHletbdU27pxY6dpznrq", "name": "elut:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R46": { "role": "http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "longName": "99940505 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)", "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap AwardTypeAxis us-gaap_EmployeeStockMember 2FvAMghVCOWPHJLABfpjp", "name": "elut:EmployeeStockPurchasePlanOfferingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap AwardTypeAxis us-gaap_EmployeeStockMember 2FvAMghVCOWPHJLABfpjp", "name": "elut:EmployeeStockPurchasePlanOfferingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R47": { "role": "http://www.aziyo.com/role/DisclosureStockBasedCompensationExpenseDetails", "longName": "99940506 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 opvc1-VW2k6qR b56j1mog", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR b56j1mog", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R48": { "role": "http://www.aziyo.com/role/DisclosureInventoryDetails", "longName": "99940601 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As Of 6 30 2024 UaRykATJZk6 UHkfUWP6mw", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 6 30 2024 UaRykATJZk6 UHkfUWP6mw", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R49": { "role": "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "longName": "99940701 - Disclosure - Long-Term Debt - SWK Loan Facility (Details)", "shortName": "Long-Term Debt - SWK Loan Facility (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As Of 6 30 2024 us-gaap StatementClassOfStockAxis us-gaap_CommonClassAMember 5W57YxCoIE24ZhfOoPKeg", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit Divide USD shares ZFShPfpA7k6FvFZhdXINw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "uniqueAnchor": { "contextRef": "As Of 8 10 2022 us-gaap DebtInstrumentAxis elut_SWKLoanFacilityMember wTnUgvsr1UIG9sWoFqoeg", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "unique": true }, "R50": { "role": "http://www.aziyo.com/role/DisclosureLongTermDebtLongTermDebtTableDetails", "longName": "99940702 - Disclosure - Long-Term Debt - Long-Term Debt - Table (Details)", "shortName": "Long-Term Debt - Long-Term Debt - Table (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As Of 6 30 2024 UaRykATJZk6 UHkfUWP6mw", "name": "us-gaap:LongTermDebt", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As Of 6 30 2024 UaRykATJZk6 UHkfUWP6mw", "name": "us-gaap:LongTermDebt", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R51": { "role": "http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails", "longName": "99940801 - Disclosure - Revenue Interest Obligation - (Details)", "shortName": "Revenue Interest Obligation - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 us-gaap FairValueByLiabilityClassAxis elut_RevenueInterestObligationMember 6JhyDAAEsmzjbpE7dgra", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 us-gaap FairValueByLiabilityClassAxis elut_RevenueInterestObligationMember 6JhyDAAEsmzjbpE7dgra", "name": "us-gaap:InterestExpenseDebt", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Oeqn0ohMIO", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R52": { "role": "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "longName": "99940901 - Disclosure - Common Stock and Warrants - Registered Direct Offering of Common Stock and Warrants (Details)", "shortName": "Common Stock and Warrants - Registered Direct Offering of Common Stock and Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As Of 6 30 2024 us-gaap ClassOfWarrantOrRightAxis elut_PrefundedWarrants2024Member fdOgHbJzkmXcJRI7EF1O", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "Unit Divide USD shares ZFShPfpA7k6FvFZhdXINw", "xsiNil": "false", "lang

"details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap TypeOfArrangementAxis elut LicenseAgreementWithCookBiotechMember 60QPO2qqU0inCz9Yv58Fug", "name": "elut:PercentageOfRoyaltyOnSales", "unitRef": "Unit Standard pure BNYvjalj00eujiT YZyTdG", "xsiNil": "false", "lang": "null", "decimals": "1NF", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 us-gaap TypeOfArrangementAxis elut LicenseAgreementWithCookBiotechMember 60QPO2qqU0inCz9Yv58Fug", "name": "elut:PercentageOfRoyaltyOnSales", "unitRef": "Unit Standard pure BNYvjalj00eujiT YZyTdG", "xsiNil": "false", "lang": "null", "decimals": "1NF", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R58": { "role": "http://www.aziy.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails", "longName": "99941002 - Disclosure - Commitment and Contingencies - Legal Proceedings (Details)", "shortName": "Commitment and Contingencies - Legal Proceedings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As Of 6 30 2024 UaRykATJZK6 UHkfUWP6mw", "name": "us-gaap:LossContingencyPendingClaimsNumber", "unitRef": "Unit Standard lawsuit PFDM1boPq0ecsNnefgyfHA", "xsiNil": "false", "lang": "null", "decimals": "1NF", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 9 1 2021 To 6 30 2024 srt LitigationCaseAxis elut FibercellLitigationProductLiabilityMember ZZIOPE-rEuMTDhgHwVKtG", "name": "us-gaap:LossContingencyNewClaimsFiledNumber", "unitRef": "Unit Standard lawsuit PFDM1boPq0ecsNnefgyfHA", "xsiNil": "false", "lang": "null", "decimals": "1NF", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "unique": true }, "R59": { "role": "http://www.aziy.com/role/DisclosureNetLossPerShareDetails", "longName": "99941101 - Disclosure - Net Loss Per Share (Details)", "shortName": "Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR b56j1mog", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Qeqn0ohMIQ", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR b56j1mog", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Qeqn0ohMIQ", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R60": { "role": "http://www.aziy.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails", "longName": "99941102 - Disclosure - Net Loss Per Share - Anti-dilutive securities (Details)", "shortName": "Net Loss Per Share - Anti-dilutive securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit Standard shares -2XATN2TY0GrTfiva0LUQ", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "p": "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit Standard shares -2XATN2TY0GrTfiva0LUQ", "xsiNil": "false", "lang": "null", "decimals": "0", "ancestors": { "p": "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R61": { "role": "http://www.aziy.com/role/DisclosureSegmentInformationDisaggregationDetails", "longName": "99941201 - Disclosure - Segment Information - Disaggregation (Details)", "shortName": "Segment Information - Disaggregation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration 1 1 2024 To 6 30 2024 4ajcd-oL9Ei1kuZOM9gm2Q", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "R62": { "role": "http://www.aziy.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "longName": "99941202 - Disclosure - Segment Information - Reconciliation of segment gross profit (Details)", "shortName": "Segment Information - Reconciliation of segment gross profit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration 4 1 2024 To 6 30 2024 opvc1-VW2k6qR b56j1mog", "name": "elut:GrossProfitBeforeIntangibleAssetAmortization", "unitRef": "Unit Standard USD bDXpm9Fv4Ea8Qeqn0ohMIQ", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": { "p": "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" }, "reportCount": 1, "baseRef": "elut-20240630x10q.htm", "first": true, "unique": true }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": { "elut_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aziy.com/20240630", "localname": "AccountingPoliciesTable", "presentation": { "http://www.aziy.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" }, "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." }, "label": "Accounting Policies [Line Items]" } } }, "auth_ref": { "elut_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aziy.com/20240630", "localname": "AccountingPoliciesTable", "presentation": { "http://www.aziy.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails" }, "lang": { "en-us": { "role": { "documentation": "Schedule reflecting accounting policies." }, "label": "Accounting Policies [Table]" } } }, "auth_ref": { "us-gaap:AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": { "http://www.aziy.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r77": "r690" }, "us-gaap:AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.aziy.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" }, "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": { "r631": "r631", "us-gaap:AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": { "http://www.aziy.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r824" }, "us-gaap:AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.aziy.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r80" }, "ecd:Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": { "r745" }, "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": { "http://www.aziy.com/role/StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r90", "r690", "r930" }, "us-gaap:AdditionalPaidInCapitalMember

Adjustments Service Cost" } } }, "auth_ref": ["r792"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } } }, "auth_ref": ["r758"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } } }, "auth_ref": ["r765"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } } }, "auth_ref": ["r721", "r731", "r741", "r765", "r773", "r777", "r785"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } } }, "auth_ref": ["r783"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"] }, "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } }, "auth_ref": ["r409", "r418"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] }, "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } }, "auth_ref": [] }, "us-gaap_AmortizationOffFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffFinancingCosts", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing costs and debt discount", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } } }, "auth_ref": ["r108", "r337", "r807", "r883"] }, "us-gaap_AmortizationOffIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffIntangibleAssets", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails"] }, "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "negatedLabel": "Intangible asset amortization expense", "verboseLabel": "Intangible asset amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth_ref": ["r9", "r285", "r286", "r659"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth_ref": ["r240"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"] }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } }, "auth_ref": ["r29"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"] }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } } }, "auth_ref": ["r443"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } } }, "auth_ref": ["r139", "r150", "r177", "r205", "r245", "r253", "r263", "r266", "r275", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r445", "r450", "r475", "r509", "r588", "r653", "r654", "r690", "r708", "r843", "r844", "r886"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } }, "auth_ref": ["r172", "r185", "r205", "r275", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r445", "r450", "r475", "r690", "r843", "r844", "r886"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } } }, "auth_ref": ["r780"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } } }, "auth_ref": ["r781"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } } }, "auth_ref": ["r776"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } } }, "auth_ref": ["r776"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } } }, "auth_ref": ["r776"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } } }, "auth_ref": ["r776"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosures [Text Block]", "terseLabel": "Award Timing MNPI Disclosures" } } } }, "auth_ref": ["r776"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } } }, "auth_ref": ["r776"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } } }, "auth_ref": ["r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r404", "r405", "r406", "r407", "r408"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } } }, "auth_ref": ["r779"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } } }, "auth_ref": ["r778"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } } }, "auth_ref": ["r777"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] }, "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } } }, "auth_ref": ["r777"] }, "us-gaap_BasisOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"] }, "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation and Liquidity", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } }, "auth_ref": [] }, "us-gaap_CapitalExpenditureDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpenditureDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"] }, "lang": { "en-us": { "role": { "label": "Capital Expenditure, Discontinued Operations", "negatedLabel": "Expenditures for property, plant and equipment", "documentation": "Amount of capital expenditure attributable to discontinued operations." } } } }, "auth_ref": ["r72"] }, "elut_CardiovascularMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CardiovascularMember", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails"] }, "lang": { "en-us": { "role": { "label": "Cardiovascular", "documentation": "Represents the information pertaining to Cardiovascular." } } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } } }, "auth_ref": ["r27", "r175", "r638"] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"] }, "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts

entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": ["r28", "r138"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r27", "r112", "r201"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net decrease in cash and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r112"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r756"] }, "elut_ChangesInOperatingAssetsAndLiabilitiesDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ChangesInOperatingAssetsAndLiabilitiesDiscontinuedOperationsAbstract", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Changes in Operating Assets and Liabilities, Discontinued Operations [Abstract]", "terseLabel": "Changes in operating assets and liabilities." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r753"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r751"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "elut_ClassCommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ClassCommonStockWarrantsMember", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for class A common stock warrant.", "label": "Class A Common Stock Warrants [Member]", "verboseLabel": "Class A Warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentHeticals", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r166", "r180", "r181", "r182", "r205", "r233", "r234", "r237", "r239", "r247", "r248", "r275", "r306", "r308", "r309", "r310", "r313", "r314", "r345", "r346", "r349", "r352", "r359", "r475", "r548", "r549", "r550", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r576", "r597", "r615", "r625", "r626", "r627", "r628", "r629", "r796", "r808", "r816"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r180", "r181", "r182", "r247", "r345", "r346", "r347", "r349", "r352", "r357", "r359", "r548", "r549", "r550", "r551", "r666", "r796", "r808"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r47"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollar per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r360"] }, "elut_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised during the period.", "label": "Class of Warrant or Right, Exercised", "negatedLabel": "Exercised" } } }, "auth_ref": [] }, "elut_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ClassOfWarrantOrRightIssued", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights issued during the period.", "label": "Class of Warrant or Right, Issued", "terseLabel": "Issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of common stock per warrant (in shares)", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding", "periodStartLabel": "Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r47"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r757"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r757"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r86", "r142", "r510", "r575"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitment and Contingencies." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock" }

"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitment and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r124", "r296", "r297", "r632", "r831", "r836"] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSvkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Class A Common stock", "terseLabel": "Class A Common stock", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": ["r931"] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Class B Common stock", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": ["r931"] }, "elut_CommonStockIssuedUponConversionWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CommonStockIssuedUponConversionWarrants", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The value of the common stock that warrants are being converted into in a noncash (or part noncash) transaction. \\Part noncash\\ refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Common Stock Issued Upon Conversion Warrants", "terseLabel": "Conversion of Common Warrants and Prefunded Warrants to common stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r698", "r699", "r700", "r702", "r703", "r704", "r705", "r811", "r812", "r815", "r874", "r929", "r931"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSvkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollar per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r89"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r89", "r376"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r89"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r14", "r89", "r576", "r594", "r931", "r932"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r89", "r511", "r690"] }, "us-gaap_CommonStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CommonStockWarrantMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails", "http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for common stock warrant.", "label": "Common stock warrants", "terseLabel": "Common stock warrants" } } }, "auth_ref": [] }, "elut_CommonUnitsSold": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CommonUnitsSold", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "The number of common units sold during the reported period.", "label": "Common Units Sold", "terseLabel": "Aggregate common units sold" } } }, "auth_ref": [] }, "elut_CommonUnitsSoldNumberOfStockEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CommonUnitsSoldNumberOfStockEachUnit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "The number of common stocks for each common units old during the reported period.", "label": "Common Units Sold Number Of Stock Each Unit", "terseLabel": "Number of common stock per unit" } } }, "auth_ref": [] }, "elut_CommonUnitsSoldPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CommonUnitsSoldPricePerShare", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Amount paid per common units sold.", "label": "Common Units Sold Price Per Share", "terseLabel": "Common unit purchase price (in dollar per unit)" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r762"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income", "auth_ref": ["r761"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r763"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r760"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Computer hardware and software", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r32", "r33", "r52", "r53", "r272", "r631"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r32", "r33", "r52", "r53", "r272", "r543", "r631"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employee, supplier, lender." } } }, "auth_ref": ["r32", "r33", "r52", "r53", "r272", "r631", "r800"] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r55", "r158"] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r631"] }, "us-gaap_ConcentrationRiskPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Percentage", "verboseLabel": "Concentration risk (as a percent)", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \\benchmark\\ (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r32", "r33", "r52", "r53", "r272"] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": ["r31", "r32", "r33", "r34", "r52", "r137", "r631"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employee, supplier, lender) of the concentration." } } }, "auth_ref": ["r32", "r33", "r52", "r53", "r272", "r631"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr":

"debit", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations" }, "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": { "r102", "r103", "r500" } }, { "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "Cost of goods sold", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": { }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": { "http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails" }, "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "documentation": "The name of the counterparty to the debt instrument." } } }, "auth_ref": { "r206", "r207", "r319", "r347", "r494", "r497", "r508", "r643", "r645" } }, { "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": { }, { "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": { }, { "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" }, "lang": { "en-us": { "role": { "label": "Customer concentration risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": { "r116", "r272" } }, { "elut_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CustomerOneMember", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents one major customer of the entity.", "label": "Customer One [Member]", "terseLabel": "One Customer" } } }, "auth_ref": { }, { "elut_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "CustomerTwoMember", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents another major customer of the entity.", "label": "Customer Two [Member]", "terseLabel": "Another customer" } } }, "auth_ref": { }, { "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Debt" } } }, "auth_ref": { }, { "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebt" }, "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": { "r125", "r203", "r289", "r290", "r291", "r292", "r293", "r304", "r305", "r315", "r321", "r322", "r323", "r324", "r325", "r326", "r331", "r338", "r339", "r341", "r482" } }, { "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": { "r19", "r79", "r80", "r140", "r141", "r208", "r316", "r317", "r318", "r319", "r320", "r322", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r661", "r662", "r663", "r664", "r665", "r689", "r809", "r832", "r833", "r834", "r882", "r884" } }, { "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": { }, { "elut_DebtInstrumentBasisSpreadOnVariableRateInKind": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtInstrumentBasisSpreadOnVariableRateInKind", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the in-kind variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate, In Kind", "terseLabel": "Interest in-kind spread basis" } } }, "auth_ref": { }, { "elut_DebtInstrumentExitFeePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtInstrumentExitFeePercent", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the debt instrument, for exit.", "label": "Debt Instrument, Exit Fee, Percent", "terseLabel": "Exit fee (as a percent)" } } }, "auth_ref": { }, { "elut_DebtInstrumentExitFeePercentagePlusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtInstrumentExitFeePercentagePlusAmount", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "The termination fee amount added to the exit fee percent of the aggregate principal amount funded prior to termination transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Instrument, Exit Fee, Percentage Plus Amount", "terseLabel": "Exit fee termination plus" } } }, "auth_ref": { }, { "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "presentation": { "http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Present value of future minimum payments of obligation", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": { "r329", "r474", "r662", "r663", "r876", "r877", "r878", "r879", "r880" } }, { "elut_DebtInstrumentInterestInKind": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtInstrumentInterestInKind", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "Interest rate in kind on debt instrument as an option for interest payment.", "label": "Debt Instrument, Interest In Kind" } } }, "auth_ref": { }, { "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Weighted average interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": { "r82", "r334", "r882" } }, { "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Long-Term Debt", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r208", "r316", "r317", "r318", "r319", "r320", "r322", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r661", "r662", "r663", "r664", "r665", "r689", "r809", "r832", "r833", "r834", "r882", "r884" } }, { "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r19", "r208", "r316", "r317", "r318", "r319", "r320", "r322", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r661", "r662", "r663", "r664", "r665", "r689", "r809", "r832", "r833", "r834", "r882", "r884" } }, { "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": { "r19", "r43", "r46", "r54", "r128", "r129", "r208", "r316", "r317", "r318", "r319", "r320", "r322", "r327", "r328", "r329", "r330", "r332", "r333", "r334", "r335", "r336", "r337", "r340", "r661", "r662", "r663", "r664", "r665", "r689", "r809", "r882", "r884" } }, { "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]", "documentation": "Indicates type of variable interest rate on debt instrument." } } }, "auth_ref": { "r507" } }, { "elut_DebtPrepaymentPenaltiesAfterFirstAnniversary": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtPrepaymentPenaltiesAfterFirstAnniversary", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "The pre-payment penalty after first anniversary, expressed as a percentage of the outstanding principal amount of debt.", "label": "Debt Prepayment Penalties, After First Anniversary", "terseLabel": "Prepayment penalty after first anniversary (as a percent)" } } }, "auth_ref": { }, { "elut_DebtPrepaymentPenaltiesPriorToFirstAnniversary": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtPrepaymentPenaltiesPriorToFirstAnniversary", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "The percentage of pre-payment penalties prior to first anniversary of the debt, as a percentage of the aggregate principal amount funded prior to the termination plus remaining unpaid interest payments scheduled to be paid during the first year of the debt.", "label": "Debt Prepayment Penalties, Prior to First Anniversary", "terseLabel": "Prepayment penalty prior to first anniversary (as a percent)" } } }, "auth_ref": { }, { "elut_DebtQuarterlyPrincipalAmortizationAsPercentToFundedAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DebtQuarterlyPrincipalAmortizationAsPercentToFundedAmount", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "Quarterly principal amortization as a percentage of the funded amount at the time of the closing of the loan facility agreement.", "label": "Debt Quarterly Principal Amortization, As Percent To Funded Amount", "terseLabel": "Quarterly principal amortization (percent)" } } }, "auth_ref": { }, { "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortizationDiscontinuedOperations", "presentation": { "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails" }, "lang": { "en-us": { "role": { "label": "Depreciation and Amortization, Discontinued Operations", "terseLabel": "Depreciation", "documentation": "Amount of depreciation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations." } } }, "auth_ref": { "r169", "r807" } }, { "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": { "r9", "r245", "r257", "r266", "r653", "r654" } }, { "elut_DeviceProtectionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DeviceProtectionMember", "presentation": { "http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to device protection.", "label": "Device Protection [Member]", "terseLabel": "Device Protection" } } }, "auth_ref": { }, { "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" }, "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r371", "r667", "r668", "r669", "r670", "r671", "r672", "r673" } }, { "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" }, "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": { "r371", "r667", "r668", "r669", "r670", "r671", "r672", "r673" } }, { "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensation" }, "lang": { "en-

us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "verboseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r375", "r379", "r410", "r411", "r413", "r677"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationAlternativeCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationAlternativeCashFlowInformationAbstract", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Alternative Cash Flow Information [Abstract]", "terseLabel": "Significant investing items." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "terseLabel": "Recognized a gain", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": ["r59", "r61", "r63", "r74"] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "terseLabel": "Earn-out period", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r67"] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Sale of Orthobiologics Business" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails",
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r5"] }, "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails",
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Held-for-sale or Disposed of by Sale", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": ["r4", "r5", "r6"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails",
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r170"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails",
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "elut_DisposalGroupIncludingDiscontinuedOperationConsiderationPayableAfterClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationPayableAfterClosing", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of consideration receivable after closing in the form of earn-out payments to be received for the disposal of assets and liabilities, including discontinued operation." }, "label": "Disposal Group, Including Discontinued Operation, Consideration, Payable After Closing", "verboseLabel": "Purchase price due after closing in the form of earn-out payments" } } }, "auth_ref": [] }, "elut_DisposalGroupIncludingDiscontinuedOperationConsiderationPayableAfterClosingEarnOutOnRevenuePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationPayableAfterClosingEarnOutOnRevenuePercent", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "The percent on actual revenue payable to the selling entity by the buying entity in the applicable year that is derived from sales of the Products defined as ('Earn-Out Products') under the Purchase Agreement.", "label": "Disposal Group, Including Discontinued Operation, Consideration, Payable After Closing, Earn-Out On Revenue, Percent", "terseLabel": "Earn-out payments, as a percent actual revenue" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of goods sold", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r71", "r171"] }, "elut_DisposalGroupIncludingDiscontinuedOperationEarnOutAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationEarnOutAmount", "crdr": "credit", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of earn-out payments received during the reported period under the sale of entity's assets and business.", "label": "Disposal Group Including Discontinued Operation, Earn Out Amount", "terseLabel": "Earn-out payments received" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r71"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "totalLabel": "Gross profit", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r71", "r171"] }, "elut_DisposalGroupIncludingDiscontinuedOperationIndemnityHoldbackAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationIndemnityHoldbackAmount", "crdr": "credit", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the indemnity holdback amount to be held by buyer under the purchase agreement.", "label": "Disposal Group Including Discontinued Operation, Indemnity Holdback Amount", "terseLabel": "Indemnity holdback amount" } } }, "auth_ref": [] }, "elut_DisposalGroupIncludingDiscontinuedOperationIndemnityHoldbackAmountRetainmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationIndemnityHoldbackAmountRetainmentPeriod", "presentation": []
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the indemnity hold back retainment period by buyer under the purchase agreement.", "label": "Disposal Group Including Discontinued Operation, Indemnity Holdback Amount, Retainment Period", "terseLabel": "Retainment Period" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "terseLabel": "Interest Expense", "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r20", "r21", "r23", "r71"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r71"] }, "elut_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Net sales", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": ["r71", "r171"] }, "elut_DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "DisposalGroupIncludingDiscontinuedOperationSalesAndMarketingExpense", "crdr": "debit", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of sales and marketing expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Sales and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]", "terseLabel": "Financial results" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusiness"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Sale of Orthobiologics Business", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r57", "r119"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": []
"http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails",
"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r674", "r675"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": []

"http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. } } }, "auth_ref": [] }, "dei.DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei.DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei.DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei.DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei.DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": [] }, "dei.DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r744"] }, "dei.DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [] }, "ecd.DvddsOrOthrErngsPdOnEqtyAwrdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/MemberDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r755"] }, "us-gaap.EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap.EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share - basic (in dollar per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r192", "r218", "r219", "r220", "r221", "r222", "r223", "r230", "r233", "r237", "r238", "r239", "r244", "r439", "r442", "r462", "r463", "r504", "r521", "r647"] }, "elut.EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic and Diluted, Other Disclosure 1 [Abstract]", "terseLabel": "Denominator" } } }, "auth_ref": [] }, "us-gaap.EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share - diluted (in dollar per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r192", "r218", "r219", "r220", "r221", "r222", "r223", "r233", "r237", "r238", "r239", "r244", "r439", "r442", "r462", "r463", "r504", "r521", "r647"] }, "us-gaap.EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r29", "r30", "r241"] }, "us-gaap.EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r229", "r240", "r242", "r243"] }, "us-gaap.EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Other Disclosures" } } }, "auth_ref": [] }, "us-gaap.EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap.EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "verboseLabel": "Unrecognized compensation costs", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r412"] }, "us-gaap.EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted-average recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r412"] }, "us-gaap.EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Total unrecognized compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r873"] }, "us-gaap.EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap.EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Options to purchase common stock", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "elut.EmployeeStockPurchasePlanOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "EmployeeStockPurchasePlanOfferingPeriod", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "documentation": "The offering period of employee stock purchase plan, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Stock Purchase Plan, Offering Period", "terseLabel": "Offering period" } } }, "auth_ref": [] }, "dei.EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei.EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei.EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei.EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei.EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei.EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r710"] }, "dei.EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei.EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate

'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": [] } , "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } } , "auth_ref": ["r710"] } , "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } } , "auth_ref": ["r795"] } , "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } , "auth_ref": [] } , "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": ["r710"] } , "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } , "auth_ref": [] } , "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } , "auth_ref": ["r794"] } , "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } , "auth_ref": ["r710"] } , "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } } , "auth_ref": ["r710"] } , "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } , "auth_ref": ["r710"] } , "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"] , "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } , "auth_ref": ["r710"] } , "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } } , "auth_ref": ["r749"] } , "ecd_EqtyAwrdsAdjExclgValRprtIdnSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtIdnSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } } , "auth_ref": ["r790"] } , "ecd_EqtyAwrdsAdjJsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjJsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } } , "auth_ref": ["r790"] } , "ecd_EqtyAwrdsInSummryCompstnTblForAplblyrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblyrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } } , "auth_ref": ["r790"] } , "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } , "auth_ref": ["r14", "r167", "r189", "r190", "r191", "r209", "r210", "r211", "r215", "r222", "r224", "r226", "r246", "r276", "r279", "r287", "r361", "r430", "r431", "r434", "r435", "r436", "r440", "r441", "r442", "r445", "r452", "r453", "r454", "r455", "r456", "r458", "r461", "r476", "r477", "r478", "r479", "r480", "r481", "r483", "r484", "r491", "r520", "r534", "r535", "r536", "r554", "r615"] } , "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } } , "auth_ref": ["r759"] } , "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } } , "auth_ref": ["r717", "r727", "r737", "r769"] } , "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } } , "auth_ref": ["r714", "r724", "r734", "r766"] } , "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category" } } } , "auth_ref": ["r765"] } , "elut_ExercisePriceAsPercentageOfMarketValueOfShareOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ExercisePriceAsPercentageOfMarketValueOfShareOfCommonStock", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents the exercise price as a percentage of market value of share of common stock at closing on the date of the grant.", "label": "Exercise Price As A Percentage Of Market Value Of Share Of Common Stock", "verboseLabel": "Exercise price as a percentage of market value of share of common stock at closing on the date of the grant" } } } , "auth_ref": [] } , "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails", "http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Fair value adjustment", "terseLabel": "Change in fair value", "verboseLabel": "Loss on revaluation of warrant liability", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } } , "auth_ref": ["r1", "r9"] } , "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails"] , "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Warrant Liabilities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r464", "r465", "r466", "r685"] } , "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails"] , "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } } , "auth_ref": ["r464", "r465", "r685"] } , "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByLiabilityClassAxis", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables"] , "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r467", "r468", "r469", "r470", "r471", "r472", "r473"] } , "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables", "http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "label": "Fair Value By Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } } , "auth_ref": ["r467", "r468", "r469", "r470", "r471", "r472", "r473"] } , "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables"] , "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": ["r467", "r468", "r469", "r470", "r471", "r472"] } , "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables"] , "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } } , "auth_ref": ["r467", "r468", "r469", "r470", "r471", "r472", "r473"] } , "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables"] , "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of rollforward of the aggregate fair value of the warranty liability", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and

transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r467", "r472", "r473"] } }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": ["r11"] }, "elut_FairValueOfWarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "FairValueOfWarrantsIssued", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of fair value of warrants issued.", "label": "Fair Value of Warrants Issued", "terseLabel": "Fair value of warrants issued" } } }, "auth_ref": [] }, "elut_FiberCellLitigationProductLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "FiberCellLitigationProductLiabilityMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents lawsuits alleging that the plaintiffs were exposed to and/or contracted tuberculosis and/or suffered substantial symptoms and complications following the implantation of FiberCell during spinal fusion operations.", "label": "FiberCell Litigation Product Liability [Member]", "terseLabel": "FiberCell Litigation Product Liability" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r721", "r731", "r741", "r773"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r721", "r731", "r741", "r773"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r721", "r731", "r741", "r773"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r721", "r731", "r741", "r773"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r721", "r731", "r741", "r773"] }, "ecd_FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r754"] }, "elut_GainLossOnRevaluationOfRevenueInterestObligationAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "GainLossOnRevaluationOfRevenueInterestObligationAndOther", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of gain (loss) on revaluation of revenue interest obligation and other.", "label": "Gain (Loss) On Revaluation Of Revenue Interest Obligation And Other", "negatedLabel": "Gain on revaluation of revenue interest obligation" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Business", "negatedLabel": "Gain on sale of Orthobiologics Business", "terseLabel": "Gain on sale of Orthobiologics Business", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": ["r449", "r807"] }, "us-gaap_GainsLossesOnRestructuringOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnRestructuringOfDebt", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"], "lang": { "en-us": { "role": { "label": "Gains (Losses) on Restructuring of Debt", "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete." } } }, "auth_ref": ["r13"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "negatedLabel": "General and administrative", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r107", "r599"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r107"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r98", "r104", "r149", "r205", "r275", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r475", "r649", "r653", "r818", "r820", "r821", "r822", "r823", "r843"] }, "elut_GrossProfitBeforeIntangibleAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "GrossProfitBeforeIntangibleAssetAmortization", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails", "http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails"], "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses, excluding intangible asset amortization, directly attributable to the revenue generation activity." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to Be Disposed of", "terseLabel": "Impairment losses", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": ["r9", "r120", "r683"] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": ["r0", "r123"] }, "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r99", "r144", "r149", "r505", "r516", "r649", "r653", "r818", "r820", "r821", "r822", "r823"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss from continuing operations", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r135", "r149", "r205", "r214", "r222", "r275", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r439", "r442", "r463", "r475", "r516", "r649", "r818", "r820", "r821", "r822", "r823", "r843"] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Net loss from continuing operations per share - basic (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r100", "r145", "r192", "r214", "r218", "r219", "r220", "r221", "r222", "r233", "r237", "r238", "r439", "r442", "r463", "r504", "r898"] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Income (loss) from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r59", "r60", "r61", "r62", "r63", "r74", "r171", "r433", "r517"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "totalLabel": "Net income (loss)", "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": ["r59", "r60", "r61", "r62", "r63", "r70",

"r73", "r135"], "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Net income (loss) from discontinued operations per share - basic (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r101", "r192", "r234", "r237", "r238", "r895", "r898"] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Net income (loss) from discontinued operations per share - diluted (in dollars per share)", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": ["r136", "r234", "r237", "r238"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": ["r674", "r675"] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Sale of Orthobiologics Business", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails"], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r12", "r18", "r22", "r58", "r64", "r65", "r66", "r68", "r69", "r73", "r75", "r76", "r122"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r288", "r294", "r295", "r468", "r472", "r473", "r531", "r533", "r600", "r635", "r684", "r900"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r294", "r295", "r468", "r472", "r473", "r531", "r533", "r600", "r635", "r684", "r900"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r154", "r163", "r225", "r226", "r245", "r258", "r266", "r424", "r425", "r432", "r522", "r680"] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": ["r188", "r422", "r423", "r426", "r427", "r428", "r429", "r547"] }, "elut_IncreaseDecreaseContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseContingentLiability", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contingent Liability", "documentation": "Amount of increase (decrease) in contingent liability." } } }, "auth_ref": [] }, "elut_IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherDiscontinuedOperations", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"], "lang": { "en-us": { "role": { "label": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received, the amount of obligations and expenses incurred but not paid, and other current liabilities, attributable to discontinued operations." } } }, "auth_ref": [] }, "elut_IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndPayablesToTissueSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedExpensesAndPayablesToTissueSuppliers", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Expenses and Payables to Tissue Suppliers", "documentation": "Amount of increase (decrease) in accounts payable and accrued expenses and payables to tissue suppliers." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r8"] }, "elut_IncreaseDecreaseInAccountsReceivableDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInAccountsReceivableDiscontinuedOperations", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"], "lang": { "en-us": { "role": { "label": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services, attributable to discontinued operations." } } }, "auth_ref": [] }, "elut_IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability and Other Liabilities", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services, attributable to discontinued operations." } } }, "auth_ref": [] }, "elut_IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInContractWithCustomerLiabilityAndOtherLiabilities", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability and Other Liabilities", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services, attributable to discontinued operations." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInsuranceSettlementsReceivable", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Insurance Settlements Receivable", "documentation": "The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities, attributable to discontinued operations." } } }, "auth_ref": ["r8"] }, "elut_IncreaseDecreaseInInventoryDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInInventoryDiscontinuedOperations", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"], "lang": { "en-us": { "role": { "label": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities, attributable to discontinued operations." } } }, "auth_ref": [] }, "elut_IncreaseDecreaseInObligationsToTissueSuppliersDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "IncreaseDecreaseInObligationsToTissueSuppliersDiscontinuedOperations", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails"], "lang": { "en-us": { "role": { "label": "The increase (decrease) during the reporting period in the amounts payable to tissue suppliers, attributable to discontinued operations." } } }, "auth_ref": [

"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r713", "r789"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r713", "r789"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r713", "r789"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r284", "r829", "r830"] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails", "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense related to revenue interest obligation", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": ["r108", "r335", "r343", "r664", "r665"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Interest Expense", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r256", "r804"] }, "elut_InterestExpenseRecordedAsAdditionalRevenueInterestObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "InterestExpenseRecordedAsAdditionalRevenueInterestObligation", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "documentation": "The amount of interest expense recorded as additional revenue interest obligation.", "label": "Interest Expense Recorded As Additional Revenue Interest Obligation", "terseLabel": "Interest expense recorded as additional revenue interest obligation or long-term debt" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r196", "r199", "r200"] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureInventory", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": ["r281"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureInventoryDetails", "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves", "verboseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r118", "r640"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureInventoryDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r184", "r639", "r690"] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": ["r155", "r174", "r183", "r281", "r282", "r283", "r499", "r646"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureInventoryDetails", "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r118", "r642"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureInventoryDetails", "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Net of Reserves", "verboseLabel": "Work in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r118", "r641"] }, "elut_LawsuitAgainstMedtronicSofamorDanekUsaInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LawsuitAgainstMedtronicSofamorDanekUsaInc.Member", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails", "lang": { "en-us": { "role": { "documentation": "Represents lawsuits filed by the entity against Medtronic Sofamor Danek USA, Inc. (Medtronic) alleging breach of the 2019 Tissue Product Supply Agreement (the \"Supply Agreement\") between the entity and Medtronic. In particular, the complaint alleges that Medtronic did not honor its contractual obligations to obtain insurance coverage and to defend and indemnify the entity for over 100 lawsuits against the entity alleging claims arising from the use of FiberCel products distributed by Medtronic." "label": "Lawsuit Against Medtronic Sofamor Danek USA, Inc. [Member]", "terseLabel": "Medtronic Litigation" } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "label": "Legal Fees", "negatedTerseLabel": "FiberCel litigation costs, net", "terseLabel": "FiberCel litigation costs, net", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": ["r801"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r487"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year ended December 31, 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year ended December 31, 2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year ended December 31, 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r488"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails", "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "For the six months ended December 31, 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r885"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r19", "r79", "r80", "r81", "r84", "r85", "r86", "r87", "r205", "r275", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r446", "r450", "r451", "r475", "r574", "r648", "r708", "r843", "r886", "r887"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r94", "r143", "r513", "r690", "r810", "r828", "r881"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r81", "r173", "r205", "r275", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r446", "r450", "r451", "r475", "r690", "r843", "r886", "r887"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "elut_LicenseAgreementWithCookBiotechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LicenseAgreementWithCookBiotechMember", "presentation": ["http://www.aziyo.com/20240630", "localname": "LicenseAgreementWithCookBiotechMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails", "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to license agreement with Cook Biotech.", "label": "License agreement with Cook Biotech" } } }, "auth_ref": [] }, "elut_LigandPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LigandPharmaceuticalsMember", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails", "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Ligand Pharmaceuticals.", "label": "Ligand Pharmaceuticals" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [] }

"http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" |, "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r78", "r83"] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": |

"http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": | | }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": |

"http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": | | }, "elut_LitigationNumberOfLawsuitLackOfInsuranceCoverage": { "xbrltype": "integerItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LitigationNumberOfLawsuitLackOfInsuranceCoverage", "presentation": | "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "documentation": "The number of lawsuits the entity alleges a counter party did not obtain insurance coverage from product usage per supply agreement with counter party.", "label": "Litigation, Number of Lawsuit Lack of Insurance Coverage", "terseLabel": "Number of lawsuits without insurance coverage" } } }, "auth_ref": | | }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserveCurrent", "crdr": "credit", "presentation": | "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "label": "Estimated Litigation Liability, Current", "terseLabel": "Contingent liability for legal proceedings", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": ["r86", "r837"] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": |

"http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Total amount of settlements", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": | | }, "elut_LoanAgreementCovenantThresholdAmountOfAssetSaleMandatoryPrepayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LoanAgreementCovenantThresholdAmountOfAssetSaleMandatoryPrepayment", "crdr": "credit", "presentation": |

"http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" |, "lang": { "en-us": { "role": { "documentation": "The threshold amount of non-ordinary course asset sales in excess of which is exempted from mandatory prepayment.", "label": "Loan Agreement Covenant, Threshold Amount of Asset Sale, Mandatory Prepayment", "terseLabel": "Threshold amount in excess of which exempted from mandatory prepayment" } } }, "auth_ref": | | }, "elut_LoanFacilityMandatoryPrepaymentCasualtyProceedsOfSecurityExcess": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LoanFacilityMandatoryPrepaymentCasualtyProceedsOfSecurityExcess", "crdr": "credit", "presentation": |

"http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" |, "lang": { "en-us": { "role": { "documentation": "The amount of threshold of casualty proceeds of assets upon which the lender or agent maintains a lien in excess of which is to redeem the loan balance", "label": "Loan Facility Mandatory Prepayment Casualty Proceeds of Security Excess", "terseLabel": "Casualty proceeds threshold amount in excess of which is used to redeem loan balance" } } }, "auth_ref": | | }, "elut_LoanFacilityMandatoryPrepaymentPercentageCasualtyProceedsOfSecurity": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LoanFacilityMandatoryPrepaymentPercentageCasualtyProceedsOfSecurity", "presentation": | "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" |, "lang": { "en-us": { "role": { "documentation": "The percentage of mandatory redemption of term loan facility amount of any casualty proceeds in excess of \$250,000 with respect to assets upon which the lender or agent maintains a lien.", "label": "Loan Facility Mandatory Prepayment Percentage Casualty Proceeds of Security", "terseLabel": "Percentage of casualty proceeds in excess of \$250,000 to redeem loan balance" } } }, "auth_ref": | | }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": | "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation" |, "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": | | }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": |

"http://www.aziyo.com/role/DisclosureLongTermDebtLongTermDebtTableDetails" |, "lang": { "en-us": { "role": { "label": "Long-term Debts", "totalLabel": "Term Loan Facility, net of unamortized discount and deferred financing costs", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r19", "r141", "r328", "r342", "r662", "r663", "r689", "r897"] }, "us-gaap_LongTermDebtByMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtByMaturityAbstract", "presentation": |

"http://www.aziyo.com/role/DisclosureLongTermDebtLongTermDebtTableDetails" |, "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Contractual maturities of the long-term debt" } } }, "auth_ref": | | }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": |

"http://www.aziyo.com/role/DisclosureLongTermDebtLongTermDebtTableDetails" |, "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities", "negatedLabel": "Current Portion", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r178"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": | "http://www.aziyo.com/role/DisclosureLongTermDebtLongTermDebtTableDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Legal Proceedings", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r298", "r299", "r300", "r303", "r419", "r660", "r838", "r839"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": | "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r298", "r299", "r300", "r303", "r419", "r660", "r838", "r839"] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": |

"http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual", "terseLabel": "Total estimated liability", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": ["r298", "r797"] }, "us-gaap_LossContingencyClaimsSettledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyClaimsSettledNumber", "presentation": | "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Number of cases settled", "documentation": "Number of claims settled." } } }, "auth_ref": ["r838", "r839"] }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNewClaimsFiledNumber", "presentation": | "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of lawsuits filed or asserted", "documentation": "The total number of new claims filed pertaining to a loss contingency during the period." } } }, "auth_ref": ["r838", "r839"] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": |

"http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of active lawsuits or claims filed or asserted", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": ["r838", "r839"] }, "us-gaap_LossContingencyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyReceivable", "crdr": "debit", "presentation": | "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails" |, "lang": { "en-us": { "role": { "label": "Loss Contingency, Receivable", "terseLabel": "Receivable from litigation costs", "documentation": "Amount of receivable related to a loss contingency accrual. For example, an insurance recovery receivable." } } }, "auth_ref": ["r842"] }, "us-gaap_LossContingencyReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyReceivableCurrent", "crdr": "debit", "presentation": |

"http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets" |, "lang": { "en-us": { "role": { "label": "Loss Contingency, Receivable, Current", "terseLabel": "Receivables of litigation costs", "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable." } } }, "auth_ref": ["r842"] }, "elut_LossesOnProductRecallAndMarketWithdrawal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "LossesOnProductRecallAndMarketWithdrawal", "crdr": "debit", "presentation": |

"http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" |, "lang": { "en-us": { "role": { "documentation": "Amount of losses on product recall and market withdrawal.", "label": "Losses on Product Recall and Market Withdrawal", "terseLabel": "Losses associated with viable bone matrix recall and market withdrawal" } } }, "auth_ref": | | }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": |

"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" |, "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": ["r272", "r669", "r692", "r695", "r846", "r899", "r901", "r902", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928"] }, "elut_MaximumIssuableSharesForWarrantsAtClosingOfFinancing": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "MaximumIssuableSharesForWarrantsAtClosingOfFinancing", "presentation": |

"http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" |, "lang": { "en-us": { "role": { "documentation": "The maximum number shares issuable in the exercise of warrants at the closing date of a financing.", "label": "Maximum Issuable Shares For Warrants At Closing Of Financing", "terseLabel": "Maximum shares issuable at closing" } } }, "auth_ref": | | }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": |

"http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",

"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails",

"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",

"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" |, "lang": { "en-us": { "role": { "label": "Maximum" } } }, "auth_ref": ["r299", "r300", "r301", "r302", "r373", "r419", "r466", "r498", "r530", "r532", "r542", "r566", "r567", "r620", "r621", "r622", "r623", "r624", "r633", "r634", "r658", "r666", "r676", "r685", "r686", "r687", "r688", "r693", "r845", "r888", "r889", "r890", "r891", "r892", "r893"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": | "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure", "documentation": "Measure Name", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": | "http://xbrl.sec.gov/ecd/role/PvpDisclosure" |, "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r757"] }, "elut_MeasurementInputCommonStockPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "MeasurementInputCommonStockPriceMember", "presentation": | "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails" |, "lang": { "en-us": { "role": { "documentation": "Measurement input using common stock price", "label": "Measurement Input, Common Stock Price [Member]", "terseLabel": "Common stock price" } } }, "auth_ref": | | }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": | "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails" |, "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected term (years)", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": ["r877", "r878", "r879"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": |

"http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails" |, "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility factor", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r685", "r877", "r878", "r879"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": |

"http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails" |, "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r877", "r878", "r879"] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"MeasurementInputTypeAxis", "presentation": { "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails" }, "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": { "r464", "r465", "r466", "r685" } }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": { "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails" }, "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": { "r464", "r465", "r466", "r685" } }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": { "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" }, "lang": { "en-us": { "role": { "label": "Minimum" } } }, "auth_ref": { "r299", "r300", "r301", "r302", "r373", "r419", "r466", "r498", "r530", "r532", "r542", "r566", "r567", "r620", "r621", "r622", "r623", "r624", "r633", "r634", "r658", "r666", "r676", "r685", "r686", "r687", "r693", "r845", "r888", "r889", "r890", "r891", "r892", "r893" } }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r776" } }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": { "r784" } }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": { "r272", "r669", "r692", "r695", "r846", "r899", "r901", "r902", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928" } }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": { "r758" } }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "presentation": { "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]", "terseLabel": "Significant operating non-cash reconciliation items" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r198" } }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r198" } }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "auth_ref": { "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Cash used in operating activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r112", "r113", "r114" } }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "auth_ref": { "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r105", "r114", "r146", "r171", "r186", "r187", "r191", "r205", "r214", "r218", "r219", "r220", "r221", "r222", "r225", "r226", "r235", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r439", "r442", "r463", "r475", "r519", "r596", "r613", "r614", "r706", "r843" } }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": { "http://www.aziyo.com/role/DisclosureNetLossPerShareDetails" }, "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": { "r194", "r218", "r219", "r220", "r221", "r230", "r231", "r236", "r239", "r442" } }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": { "http://www.aziyo.com/role/DisclosureNetLossPerShareDetails" }, "lang": { "en-us": { "role": { "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "terseLabel": "Net loss from continuing operations", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": { "r231", "r239" } }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": { "http://www.aziyo.com/role/DisclosureNetLossPerShareDetails" }, "lang": { "en-us": { "role": { "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic", "terseLabel": "Net income from discontinued operations", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders." } } }, "auth_ref": { "r231", "r239" } }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards" } } }, "auth_ref": { "r213", "r216", "r217", "r227", "r228", "r273", "r277", "r278", "r437", "r438", "r440", "r442", "r457", "r460", "r490", "r492", "r493", "r501", "r502", "r503", "r537", "r538", "r539", "r540", "r541" } }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureRecentlyIssuedAccountingStandards" }, "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recently Issued Accounting Standards", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": { "r164", "r168", "r212", "r213", "r216", "r217", "r227", "r228", "r273", "r277", "r278", "r437", "r438", "r440", "r442", "r457", "r460", "r490", "r492", "r493", "r501", "r502", "r503", "r537", "r538", "r539", "r540", "r541" } }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureRecentlyIssuedAccountingStandardsPolicies" }, "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": { "r231", "r239" } }, "elut_NewAssetBasedRevolvingLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "NewAssetBasedRevolvingLoanFacilityMember", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" }, "lang": { "en-us": { "role": { "documentation": "Represents new asset-based revolving loan facility.", "label": "New Asset-Based Revolving Loan Facility" } } }, "auth_ref": { "ecd_NonPeeNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": { "r748" } }, "ecd_NonPeeNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": { "r747" } }, "ecd_NonPeeNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": { "r765" } }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r784" } }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r784" } }, "elut_NumberOfMajorCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "NumberOfMajorCustomers", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" }, "lang": { "en-us": { "role": { "documentation": "Number of major customers.", "label": "Number of Major Customers", "terseLabel": "Number of major customer" } } }, "auth_ref": { "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": { "http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails" }, "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business

activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r654", "r819"] },

"elut_NumberOfPatientsAffectedFromPostSurgicalMycobacteriumTuberculosisMtbInfectionsTreatedWithVbmProduct": { "xbrltype": "integerItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "NumberOfPatientsAffectedFromPostSurgicalMycobacteriumTuberculosisMtbInfectionsTreatedWithVbmProduct",

"presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails"] }, "lang": { "en-us": { "role": { "documentation": "Number of patients affected from post-surgical mycobacterium tuberculosis (mtb) infections treated with vbm product.", "label": "Number of Patients Affected from Post-Surgical Mycobacterium Tuberculosis (MTB) Infections Treated with VBM Product", "terseLabel": "Number of patients affected from post-surgical mycobacterium tuberculosis (mtb) infections treated with vbm product" } } }, "auth_ref": [] }, "elut_NumberOfPatientsReceivedTissueFromRecalledVbmProduct": { "xbrltype": "integerItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "NumberOfPatientsReceivedTissueFromRecalledVbmProduct", "presentation": [

"http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails"] }, "lang": { "en-us": { "role": { "documentation": "Number of patients that received tissue from bone matrix (VBM) product lot that was recalled.", "label": "Number of Patients Received Tissue From Recalled VBM Product", "terseLabel": "Number of individuals received tissue from the recalled VBM lot" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": [

"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"] }, "lang": { "en-us": { "role": { "label": "Office equipment and furniture", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r149", "r649", "r818", "r820", "r821", "r822", "r823"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails"] }, "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Future minimum lease commitments under non-cancelable operating leases" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails"] }, "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r486"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [

"http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesDetails"] }, "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets and other", "terseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r485"] }, "elut_OperatingLeaseRightOfUseAssetExtensions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "OperatingLeaseRightOfUseAssetExtensions", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, "lang": { "en-us": { "role": { "documentation": "The value of the operating lease right-of-use asset extensions executed not resulting in cash receipts or cash payments in the period.", "label": "Operating Lease Right-of-Use Asset Extensions", "terseLabel": "Operating lease right-of-use asset extensions executed" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "presentation": [

"http://www.aziyo.com/role/DisclosureOrganizationAndDescriptionOfBusiness"] }, "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r56", "r134", "r544", "r545"] }, "elut_OrthobiologicsBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "OrthobiologicsBusinessMember", "presentation": ["http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessFinancialResultsDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails"] }, "lang": { "en-us": { "role": { "documentation": "This member stands for Orthobiologics Business.", "label": "Orthobiologics Business [Member]", "terseLabel": "Divestiture of Orthobiologics" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Operating lease right-of-use assets and other", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r176"] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"] }, "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "terseLabel": "Cook Biotech License and Supply Agreements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"] }, "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Current operating lease liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r80", "r690"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r85"] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"] }, "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expense (income), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r109"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r757"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r719", "r729", "r739", "r771"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r722", "r732", "r742", "r774"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] }, "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r722", "r732", "r742", "r774"] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r746"] }, "elut_PayablesToTissueSuppliersCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PayablesToTissueSuppliersCurrent", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "documentation": "Represents the amount payables to tissue suppliers, classified as current.", "label": "Payables to Tissue Suppliers, Current", "terseLabel": "Payables to tissue suppliers" } } }, "auth_ref": [] }, "us-gaap_PaymentOffinancingAndStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentOffinancingAndStockIssuanceCosts", "crdr": "credit", "presentation": [

"http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails"] }, "lang": { "en-us": { "role": { "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Private placement fees", "verboseLabel": "Transaction fees", "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities." } } }, "auth_ref": ["r26"] }, "elut_PaymentOffLicenseFeePerYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PaymentOffLicenseFeePerYear", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"] }, "lang": { "en-us": { "role": { "documentation": "License fee payable annually per agreement.", "label": "Payment of License Fee per Year", "terseLabel": "License fee payments per year" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails"] }, "lang": { "en-us": { "role": { "label": "Payments for Legal Settlements", "terseLabel": "Settlement amount", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": ["r7"] }, "us-gaap_PaymentsOffinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOffinancingCosts", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, "lang": { "en-us": { "role": { "label": "Payments of Financing Costs", "negatedLabel": "Deferred financing costs", "terseLabel": "Deferred financing costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": ["r26"] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParentetical", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenteticals"] }, "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance and offering costs", "verboseLabel": "Amount allocated to issuance of the common stock", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r26"] }, "elut_PaymentsOnRevenueInterestObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PaymentsOnRevenueInterestObligation", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, "lang": { "en-us": { "role": { "documentation": "The cash outflow on payments on revenue interest obligation.", "label": "Payments On Revenue Interest Obligation", "negatedLabel": "Payments on revenue interest obligation" } } }, "auth_ref": [] }, "us-

gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payments for taxes upon vesting of restricted stock units", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": ["r195"] }, "us-gaap PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Expenditures for property, plant and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r110"] }, "ecd PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r756"] }, "ecd PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r756"] }, "ecd PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r748"] }, "ecd PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r765"] }, "ecd PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r758"] }, "ecd PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r747"] }, "elut_PercentageOfRoyaltyOnSales": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PercentageOfRoyaltyOnSales", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to percentage of royalty o sales.", "label": "Percentage of Royalty on Sales", "terseLabel": "Percentage of royalty on sales" } } }, "auth_ref": [] }, "elut_PerformanceBasedOptionsMarketConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PerformanceBasedOptionsMarketConditionsMember", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time for meeting certain market conditions.", "label": "Performance Based Options, Market Conditions [Member]", "terseLabel": "Options that vest on achievements of price thresholds" } } }, "auth_ref": [] }, "elut_PerformanceBasedOptionsProductApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PerformanceBasedOptionsProductApprovalMember", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time subject to specified product approval.", "label": "Performance Based Options, Product Approval [Member]", "terseLabel": "Options that vest 10th day after FDA's approval of CanGarooRM product" } } }, "auth_ref": [] }, "us-gaap PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872"] }, "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872"] }, "ecd PnsnAdjsPrtrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrtrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r749"] }, "ecd PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r793"] }, "ecd PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r748"] }, "elut_PrefundedUnitsSold": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PrefundedUnitsSold", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "The number of prefunded units sold during the reported period.", "label": "Prefunded Units Sold", "terseLabel": "Number of Prefunded Units to sell" } } }, "auth_ref": [] }, "elut_PrefundedUnitsSoldPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PrefundedUnitsSoldPricePerShare", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "documentation": "Amount paid per prefunded units sold.", "label": "Prefunded Units Sold Price Per Share", "terseLabel": "Prefunded unit purchase price (in dollar per unit)" } } }, "auth_ref": [] }, "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for prefunded stock warrant issued in 2023.", "label": "Prefunded Warrants, 2023 [Member]", "terseLabel": "2023 Prefund Warrants" } } }, "auth_ref": [] }, "elut_PrefundedWarrants2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PrefundedWarrants2024Member", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for prefunded stock warrant issued in 2024.", "label": "Prefunded Warrants, 2024 [Member]", "terseLabel": "2024 Prefunded Warrants" } } }, "auth_ref": [] }, "elut_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"], "lang": { "en-us": { "role": { "documentation": "This member stands for prefunded stock warrant.", "label": "Prefunded Warrants [Member]", "terseLabel": "Prefunded Warrants" } } }, "auth_ref": [] }, "us-gaap PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r802"] }, "us-gaap PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails"], "lang": { "en-us": { "role": { "label": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of Orthobiologics Business", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": ["r25"] }, "us-gaap ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds allocated to common shares", "verboseLabel": "Proceeds from direct registered offering and warrants, net of offering costs", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureLongTermDebtSvkLoanFacilityDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r806"] }, "us-gaap ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Proceeds from private placement and warrants", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": ["r3"] }, "us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from sales of common stock through Employee Stock Purchase Plan", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r3", "r17"] }, "us-gaap ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from exercise of warrants", "documentation": "The cash inflow from issuance of rights to purchase common

shares at predetermined price (usually issued together with corporate debt)."} } }, {"auth_ref": ["r3"] } }, {"us-gaap_ProceedsFromWarrantExercises": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [" "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, {"lang": {"en-us": {"role": {"label": "Proceeds from Warrant Exercises", "verboseLabel": "Proceeds from exercises of Common Warrants and Prefunded Warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, {"auth_ref": ["r805"] } }, {"elut_ProcessingAndResearchEquipmentMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ProcessingAndResearchEquipmentMember", "presentation": [" "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"] }, {"lang": {"en-us": {"role": {"documentation": "Represents the information pertaining to processing and research equipment." }, {"label": "Processing and research equipment." } } }, {"auth_ref": [" "], {"srt_ProductOrServiceAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [" "http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails"] }, {"lang": {"en-us": {"role": {"label": "Product and Service [Axis]" } } }, {"auth_ref": ["r269", "r500", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r637", "r667", "r691", "r693", "r694", "r696", "r697", "r840", "r841", "r846", "r899", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928"] } }, {"srt_ProductsAndServicesDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [" "http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails"] }, {"lang": {"en-us": {"role": {"label": "Product and Service [Domain]" } } }, {"auth_ref": ["r269", "r500", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r637", "r667", "r691", "r693", "r694", "r696", "r697", "r840", "r841", "r846", "r899", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928"] } }, {"us-gaap_ProfitLoss": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [" "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, {"lang": {"en-us": {"role": {"label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, {"auth_ref": ["r171", "r186", "r187", "r197", "r205", "r214", "r222", "r225", "r226", "r227", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r439", "r442", "r444", "r447", "r448", "r463", "r475", "r505", "r518", "r553", "r596", "r613", "r614", "r681", "r682", "r707", "r803", "r843"] } }, {"us-gaap_PropertyPlantAndEquipmentByTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [" "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"] }, {"lang": {"en-us": {"role": {"label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, {"auth_ref": ["r10", "r489"] } }, {"us-gaap_PropertyPlantAndEquipmentNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [" "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] }, {"lang": {"en-us": {"role": {"label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, {"auth_ref": ["r10", "r489", "r506", "r515", "r690"] } }, {"us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [" "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"] }, {"lang": {"en-us": {"role": {"label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, {"auth_ref": ["r10", "r159", "r162", "r514"] } }, {"us-gaap_PropertyPlantAndEquipmentTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [" "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"] }, {"lang": {"en-us": {"role": {"label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, {"auth_ref": ["r121", "r489"] } }, {"us-gaap_PropertyPlantAndEquipmentUsefulLife": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [" "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"] }, {"lang": {"en-us": {"role": {"label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, {"auth_ref": [" "] } }, {"us-gaap_ProvisionForDoubtfulAccounts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [" "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, {"lang": {"en-us": {"role": {"label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, {"auth_ref": ["r193", "r280"] } }, {"ecd_PvpTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [" "http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, {"lang": {"en-us": {"role": {"label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, {"auth_ref": ["r746"] } }, {"ecd_PvpTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [" "http://xbrl.sec.gov/ecd/role/PvpDisclosure"] }, {"lang": {"en-us": {"role": {"label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, {"auth_ref": ["r746"] } }, {"srt_RangeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [" "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"] }, {"lang": {"en-us": {"role": {"label": "Statistical Measurement [Axis]" } } }, {"auth_ref": ["r299", "r300", "r301", "r302", "r372", "r373", "r405", "r406", "r407", "r419", "r466", "r495", "r496", "r498", "r530", "r532", "r542", "r566", "r567", "r620", "r621", "r622", "r623", "r624", "r633", "r634", "r658", "r666", "r676", "r685", "r686", "r687", "r688", "r693", "r700", "r835", "r845", "r878", "r889", "r890", "r891", "r892", "r893"] } }, {"srt_RangeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [" "http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"] }, {"lang": {"en-us": {"role": {"label": "Statistical Measurement [Domain]" } } }, {"auth_ref": ["r299", "r300", "r301", "r302", "r372", "r373", "r405", "r406", "r407", "r419", "r466", "r495", "r496", "r498", "r530", "r532", "r542", "r566", "r567", "r620", "r621", "r622", "r623", "r624", "r633", "r634", "r658", "r666", "r676", "r685", "r686", "r687", "r688", "r693", "r700", "r835", "r845", "r878", "r889", "r890", "r891", "r892", "r893"] } }, {"us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "presentation": [" "http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails"] }, {"lang": {"en-us": {"role": {"label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "terseLabel": "Reconciliation of segment gross profit to the consolidated loss from operations" } } }, {"auth_ref": [" "] } }, {"ecd_RecoveryOfErrCompDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": {"en-us": {"role": {"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, {"auth_ref": ["r714", "r724", "r734", "r766"] } }, {"elut_RegisteredDirectOfferingOfCommonStockAndWarrantsAndPrivatePlacementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RegisteredDirectOfferingOfCommonStockAndWarrantsAndPrivatePlacementMember", "presentation": [" "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails"] }, {"lang": {"en-us": {"role": {"documentation": "Information on Registered Direct Offering of Common Stock and Warrants and Private Placements.", "label": "Registered Direct Offering of Common Stock and Warrants and Private Placement [Member]", "terseLabel": "Registered Direct Offering of Common Stock and Warrants and Private Placement" } } }, {"auth_ref": [" "] } }, {"elut_RegisteredDirectOfferingOfCommonStockAndWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RegisteredDirectOfferingOfCommonStockAndWarrantsMember", "presentation": [" "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParentetical", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParenteticals"] }, {"lang": {"en-us": {"role": {"documentation": "Information on Registered Direct Offering of Common Stock and Warrants.", "label": "Registered Direct Offering of Common Stock and Warrants [Member]", "terseLabel": "Registered Direct Offering of Common Stock and Warrants" } } }, {"auth_ref": [" "] } }, {"elut_RepaymentsOfInsurancePremiumFinancings": {"xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RepaymentsOfInsurancePremiumFinancings", "crdr": "credit", "presentation": [" "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, {"lang": {"en-us": {"role": {"documentation": "Amount of cash outflow to repay insurance premium financings.", "label": "Repayments of Insurance Premium Financings", "negatedLabel": "Repayments of insurance premium financings" } } }, {"auth_ref": [" "] } }, {"us-gaap_RepaymentsOfLongTermDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [" "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"] }, {"lang": {"en-us": {"role": {"label": "Repayments of Long-term Debt", "negatedLabel": "Repayments of long-term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, {"auth_ref": ["r111", "r551"] } }, {"srt_RepurchaseAgreementCounterpartyNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [" "http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] }, {"lang": {"en-us": {"role": {"label": "Counterparty Name [Domain]" } } }, {"auth_ref": ["r206", "r207", "r319", "r494", "r497", "r508", "r644", "r645"] } }, {"us-gaap_ResearchAndDevelopmentExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [" "http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"] }, {"lang": {"en-us": {"role": {"label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, {"auth_ref": ["r421", "r635", "r653", "r894"] } }, {"us-gaap_ResearchAndDevelopmentExpenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [" "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"] }, {"lang": {"en-us": {"role": {"label": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, {"auth_ref": [" "] } }, {"us-gaap_ResearchAndDevelopmentExpensePolicy": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [" "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"] }, {"lang": {"en-us": {"role": {"label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs", "documentation": "Disclosure of

accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } } , "auth_ref": ["r420"] } , "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date" } } } , "auth_ref": ["r715", "r725", "r735", "r767"] } , "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } } , "auth_ref": ["r716", "r726", "r736", "r768"] } , "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } } , "auth_ref": ["r723", "r733", "r743", "r775"] } , "elut_RestrictedStockUnitsMarketConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RestrictedStockUnitsMarketConditionsMember", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"] , "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified market conditions are met.", "label": "Restricted Stock Units, Market Conditions[Member]", "terseLabel": "RSUs that vest on achievements of price thresholds" } } } , "auth_ref": [] } , "elut_RestrictedStockUnitsProductApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RestrictedStockUnitsProductApprovalMember", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"] , "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified product approval.", "label": "Restricted Stock Units, Product Approval [Member]", "terseLabel": "RSUs that vest 10th day after FDA's approval of CanGarooRM product" } } } , "auth_ref": [] } , "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"] , "lang": { "en-us": { "role": { "label": "Restricted stock units", "terseLabel": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } } , "auth_ref": [] } , "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationAndLiquidityDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } } , "auth_ref": ["r91", "r130", "r512", "r537", "r541", "r552", "r577", "r690"] } , "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } } , "auth_ref": ["r167", "r209", "r210", "r211", "r215", "r222", "r224", "r226", "r276", "r279", "r287", "r430", "r431", "r434", "r435", "r436", "r440", "r441", "r442", "r452", "r454", "r455", "r458", "r461", "r483", "r484", "r534", "r536", "r554", "r931"] } , "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"] , "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Total sales", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } } , "auth_ref": ["r147", "r148", "r245", "r254", "r255", "r262", "r266", "r269", "r271", "r272", "r370", "r371", "r500"] } , "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"] , "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } } , "auth_ref": ["r272", "r799"] } , "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"] , "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } } , "auth_ref": ["r165", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r636"] } , "elut_RevenueFromContractWithCustomerTermOfPayment": { "xbrltype": "durationItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueFromContractWithCustomerTermOfPayment", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents the term for payment for contracts with customers.", "label": "Revenue From Contract With Customer, Term of Payment", "terseLabel": "Term of payment" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenue Interest Obligation" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationAgreementTerm", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents the term of agreement.", "label": "Revenue Interest Obligation, Agreement Term", "verboseLabel": "Term of agreement" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationAnnualMinimumSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationAnnualMinimumSale", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "The amount of minimum sales in revenue interest obligation agreement.", "label": "Revenue Interest Obligation, Annual Minimum Sale", "verboseLabel": "Annual minimum sale" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationCumulativeSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationCumulativeSales", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "The amount of cumulative sales as basis of the amount due in revenue interest obligation agreement.", "label": "Revenue Interest Obligation, Cumulative Sales", "verboseLabel": "Cumulative sales" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationCurrent", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "documentation": "Amount of revenue interest obligation, classified as current.", "label": "Revenue Interest Obligation, Current", "terseLabel": "Current portion of revenue interest obligation" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationCurrentFromCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationCurrentFromCurrentYear", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "The current amount of revenue of interest obligation arising from the current period annual minimum payment obligation.", "label": "Revenue Interest Obligation, Current from Current Year", "terseLabel": "Short term revenue interest obligation from current period amendment" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationMember", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to revenue interest obligation.", "label": "Revenue Interest Obligation", "auth_ref": [] } , "elut_RevenueInterestObligationMilestonePaymentWaiverAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationMilestonePaymentWaiverAmount", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Waiving of milestone payment under revenue interest obligation.", "label": "Revenue Interest Obligation, Milestone Payment Waiver Amount", "terseLabel": "Milestone payment waived amount" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationNoncurrent", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "documentation": "Amount of revenue interest obligation, classified as noncurrent.", "label": "Revenue Interest Obligation, Noncurrent", "label": "Long-term revenue interest obligation" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPaymentAgreedUponSatisfactionOfRoyaltyObligationsForFirstThreeQuartersOf2023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPaymentAgreedUponSatisfactionOfRoyaltyObligationsForFirstThreeQuartersOf2023", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Amount of payment agreed to pay upon satisfaction of all royalty obligations for the first three fiscal quarters of 2023.", "label": "Revenue Interest Obligation, Payment Agreed upon Satisfaction of Royalty Obligations for First Three Quarters of 2023", "terseLabel": "Payment agreed upon satisfaction of royalty obligations for first three quarters" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPaymentAgreedUponSatisfactionOfRoyaltyObligationsForFourthQuarterOf2023": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPaymentAgreedUponSatisfactionOfRoyaltyObligationsForFourthQuarterOf2023", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Amount of payment agreed to pay upon satisfaction of all royalty obligations for the fourth quarter of 2023.", "label": "Revenue Interest Obligation, Payment Agreed upon Satisfaction of Royalty Obligations for Fourth Quarter of 2023", "terseLabel": "Payment agreed upon satisfaction of royalty obligations for the fourth quarter" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPaymentForCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPaymentForCurrentPeriod", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Amount of payment related to current fiscal period obligations under revenue interest obligation during the reported period.", "label": "Revenue Interest Obligation, Payment For Current Period", "terseLabel": "2024 quarterly minimum payment" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPaymentInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPaymentInPeriod", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Amount of payment under revenue interest obligation during the reported period.", "label": "Revenue Interest Obligation, Payment In Period", "terseLabel": "Total payments" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPaymentsDueBasedOnCumulativeSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPaymentsDueBasedOnCumulativeSales", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents the amount of payments due based on cumulative sales.", "label": "Revenue Interest Obligation, Payments Due Based on Cumulative Sales", "verboseLabel": "Payments due based on cumulative sales" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPercentageOfFutureSales": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPercentageOfFutureSales", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents the percentage of future sales for revenue interest obligation.", "label": "Revenue Interest Obligation, Percentage of Future Sales", "verboseLabel": "Percentage of future sales" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationPercentageOfPaymentsMade": { "xbrltype": "percentItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationPercentageOfPaymentsMade", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents the percentage of payment made of the total amount paid for revenue interest obligation.", "label": "Revenue Interest Obligation, Percentage of Payments Made", "terseLabel": "Percentage of payment made" } } } , "auth_ref": [] } , "elut_RevenueInterestObligationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "RevenueInterestObligationTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligation"] , "lang": { "en-us": { "role": { "documentation": "The entire disclosure on revenue interest obligation.", "label": "Revenue Interest Obligation [Text Block]", "verboseLabel": "Revenue Interest Obligation" } } } , "auth_ref": [] } , "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"] , "lang": { "en-us": { "role": { "label": "Royalty Expense", "terseLabel": "Royalty expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of

technology or intellectual property." } } }, "auth_ref": "r106" } } }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } } }, "auth_ref": { "r784" } } }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } }, "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } } }, "auth_ref": { "r784" } } }, "elut_SWKLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "SWKLoanFacilityMember", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails" } }, "lang": { "en-us": { "role": { "documentation": "Represents term loan facility agreement with SWK Funding LLC.", "label": "SWK Loan Facility" } } } }, "auth_ref": { } } }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": { "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails" } }, "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Proceeds from issuance of shares", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } } }, "auth_ref": { } } }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParentheticals" } }, "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } } }, "auth_ref": { } } }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": { "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails" } }, "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares issued", "verboseLabel": "Shares sold (in shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } } }, "auth_ref": { } } }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": { "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails" } }, "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in USD per share)", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } } }, "auth_ref": { } } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.aziyo.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" } }, "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } } }, "auth_ref": { "r29" } } }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureNetLossPerShareTables" } }, "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential common shares excluded from calculation, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } } }, "auth_ref": { "r29" } } }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureLongTermDebtTables" } }, "lang": { "en-us": { "role": { "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Summary of PPP loan recorded within long-term debt", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and information necessary to a fair presentation." } } } }, "auth_ref": { } } }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessTables" } }, "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedules of assets and liabilities, financial results and cash flow reconciliation of the discontinued operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } } }, "auth_ref": { "r12", "r18", "r22", "r58", "r64", "r65", "r66", "r68", "r69", "r73", "r75", "r76", "r122" } } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureNetLossPerShareTables" } }, "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss per share attributable to common stockholders", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } } }, "auth_ref": { "r817" } } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" } }, "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } } }, "auth_ref": { "r49" } } }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensationTables" } }, "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense recognized", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } } }, "auth_ref": { "r49" } } }, "elut_ScheduleOfEstimatedUsefulLivesOfAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ScheduleOfEstimatedUsefulLivesOfAssetsTableTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" } }, "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of estimated useful lives of the assets.", "label": "Schedule Of Estimated Useful Lives Of Assets [Table Text Block]", "terseLabel": "Summary of estimated useful lives of the assets" } } } }, "auth_ref": { } } }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureInventoryTables" } }, "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Summary of inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } } }, "auth_ref": { "r24", "r95", "r96", "r97" } } }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" } }, "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } } }, "auth_ref": { "r10", "r489" } } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": { "http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails" } }, "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } } }, "auth_ref": { "r38", "r39", "r40" } } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureSegmentInformationTables" } }, "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of sales information", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } } }, "auth_ref": { "r38", "r39", "r40" } } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" } }, "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } } }, "auth_ref": { "r376", "r378", "r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r404", "r405", "r406", "r407", "r408" } } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensationTables" } }, "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Summary of stock options outstanding, exercisable and vested or expected to vest", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } } }, "auth_ref": { "r15", "r16", "r131" } } }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.aziyo.com/role/DisclosureStockBasedCompensationTables" } }, "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Summary of weighted-average assumptions were used to determine the fair value of options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share

options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } },
"auth_ref": ["r133"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfStockByClassTable", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails"], "lang": { "en-us":
{ "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible,
and preferred stocks." } } }, "auth_ref": ["r41", "r42", "r43", "r44", "r45", "r46", "r126", "r128", "r129", "r130", "r180", "r181", "r182", "r247", "r345", "r346", "r347", "r349",
"r352", "r357", "r359", "r348", "r349", "r549", "r550", "r551", "r666", "r796", "r808"] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": [
"http://www.aziyo.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Unvested Restricted Stock Units Roll Forward
[Table Text Block]", "terseLabel": "Schedule of RSU activity", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [] },
"dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b)
registered security." } } }, "auth_ref": ["r709"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "SecurityExchangeName", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label":
"Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r711"] }, "us-gaap_SegmentReportingAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information" } } }
}, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingDisclosureTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformation"], "lang": { "en-us": { "role": { "label": "Segment
Reporting Disclosure [Text Block]", "terseLabel": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables.
Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment
sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10
percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of
all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r150", "r245", "r249",
"r250", "r251", "r252", "r253", "r259", "r260", "r261", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r272", "r650", "r651", "r652", "r653", "r655", "r656", "r657"] },
"us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "localname":
"SegmentReportingInformationLineItems", "presentation": ["http://www.aziyo.com/role/DisclosureSegmentInformationDisaggregationDetails"], "lang": { "en-us": { "role": {
"label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract", "presentation": []
}, "http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails"], "lang": { "en-us": { "role": { "label": "Segment Reporting, Other
Significant Reconciling Item, Consolidated [Abstract]", "terseLabel": "Adjustments." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": []
}, "http://www.aziyo.com/role/DisclosureSegmentInformationReconciliationOfSegmentGrossProfitDetails",
"http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense",
"negatedLabel": "Sales and marketing", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or
selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Sales and marketing",
"documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r107"] }, "us-gaap_ShareBasedCompensation": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": []
}, "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash
Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r8"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement
by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-
based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnHnMnS' format, for example, 'P1Y3M13D' represents
reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r677"]
}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement
by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "documentation": "The number of equity-based
payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r397"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement
by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)",
"documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect
as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r397"] },
"elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.aziyo.com/20240630", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue", "crdr": "debit", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Fair value of share-based
awards granted.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value",
"terseLabel": "Total fair value of the restricted stock units granted" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based
Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "documentation": "The
number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan,
performance target plan)." } } }, "auth_ref": ["r395"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based
Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel":
"Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than
stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r395"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based
Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at the end",
"periodStartLabel": "Unvested at the beginning", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that
validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r392", "r393"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement
by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares Underlying RSUs",
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": []
}, "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement
by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at the ending (in
dollars per share)", "periodStartLabel": "Unvested at the beginning (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award
under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r392", "r393"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
"presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based
Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
"terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based
Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "documentation": "The
number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r396"] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",

"presentation": "I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value\", \"terseLabel\": \"Vested (in dollars per share)\", \"documentation\": \"The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.\" } } }, \"auth_ref\": [\"r396\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]\", \"verboseLabel\": \"Weighted-average assumptions were used to determine the fair value of options\" } } }, \"auth_ref\": [] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate\": { \"xbrltype\": \"percentItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate\", \"terseLabel\": \"Dividend yield assumption to estimate fair value\", \"verboseLabel\": \"Dividend yield\", \"documentation\": \"The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.\" } } }, \"auth_ref\": [\"r406\"] I, \"elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExpenseRecognitionTerm\": { \"xbrltype\": \"durationItemType\", \"nsuri\": \"http://www.aziyo.com/20240630\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExpenseRecognitionTerm\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails\". \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"Expected expense recognition period of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.\" \"label\": \"Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Expense Recognition Term\", \"terseLabel\": \"Period to recognize costs\" } } }, \"auth_ref\": [] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate\": { \"xbrltype\": \"percentItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate\", \"verboseLabel\": \"Volatility factor\", \"documentation\": \"The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.\" } } }, \"auth_ref\": [\"r405\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate\": { \"xbrltype\": \"percentItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate\", \"verboseLabel\": \"Risk-free interest rate\", \"documentation\": \"The risk-free interest rate assumption that is used in valuing an option on its own shares.\" } } }, \"auth_ref\": [\"r407\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails\". \"http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails\". \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award [Line Items]\", \"terseLabel\": \"Stock-Based Compensation\", \"documentation\": \"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.\" } } }, \"auth_ref\": [\"r376\", \"r378\", \"r380\", \"r381\", \"r382\", \"r384\", \"r385\", \"r386\", \"r387\", \"r388\", \"r389\", \"r390\", \"r391\", \"r392\", \"r393\", \"r394\", \"r395\", \"r396\", \"r397\", \"r398\", \"r399\", \"r400\", \"r401\", \"r404\", \"r405\", \"r406\", \"r407\", \"r408\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized\": { \"xbrltype\": \"sharesItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails\". \"http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized\", \"terseLabel\": \"Grant of equity awards authorized\", \"verboseLabel\": \"Common stock reserved for future issuance\", \"documentation\": \"Number of shares authorized for issuance under share-based payment arrangement.\" } } }, \"auth_ref\": [\"r679\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant\": { \"xbrltype\": \"sharesItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails\". \"http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant\", \"terseLabel\": \"Number of shares available for grant\", \"verboseLabel\": \"Awards available for grant\", \"documentation\": \"The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.\" } } }, \"auth_ref\": [\"r48\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]\", \"verboseLabel\": \"Weighted-Average Remaining Contractual Term (years)\" } } }, \"auth_ref\": [] I, \"elut_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://www.aziyo.com/20240630\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"documentation\": \"No definition available.\" \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]\", \"terseLabel\": \"Aggregate Intrinsic Value\" } } }, \"auth_ref\": [] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod\": { \"xbrltype\": \"sharesItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod\". \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period\", \"negatedLabel\": \"Forfeited\", \"documentation\": \"The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.\" } } }, \"auth_ref\": [\"r390\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross\": { \"xbrltype\": \"sharesItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails\". \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross\", \"terseLabel\": \"Options granted\", \"verboseLabel\": \"Granted\", \"documentation\": \"Gross number of share options (or share units) granted during the period.\" } } }, \"auth_ref\": [\"r388\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue\": { \"xbrltype\": \"perShareItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value\", \"verboseLabel\": \"Weighted average grant date fair value of options granted\", \"documentation\": \"The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.\" } } }, \"auth_ref\": [\"r398\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue\", \"crdr\": \"debit\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value\", \"verboseLabel\": \"Aggregate Intrinsic Value (in dollars)\", \"documentation\": \"Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.\" } } }, \"auth_ref\": [\"r48\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber\": { \"xbrltype\": \"sharesItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number\", \"periodEndLabel\": \"Outstanding at the end\", \"periodStartLabel\": \"Outstanding at the beginning\", \"documentation\": \"Number of options outstanding, including both vested and non-vested options.\" } } }, \"auth_ref\": [\"r384\", \"r385\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]\", \"verboseLabel\": \"Number of Shares\", \"documentation\": \"A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.\" } } }, \"auth_ref\": [] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice\": { \"xbrltype\": \"perShareItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price\", \"periodEndLabel\": \"Outstanding at the end (in dollars per share)\", \"periodStartLabel\": \"Outstanding at the beginning (in dollars per share)\", \"documentation\": \"Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.\" } } }, \"auth_ref\": [\"r384\", \"r385\"] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward\": { \"xbrltype\": \"stringItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]\", \"verboseLabel\": \"Weighted-Average Exercise Price\" } } }, \"auth_ref\": [] I, \"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue\": { \"xbrltype\": \"monetaryItemType\", \"nsuri\": \"http://fasb.org/us-gaap/2024\", \"localname\": \"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue\", \"crdr\": \"debit\", \"presentation\": \"I \"http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails\" I, \"lang\": { \"en-us\": { \"role\": { \"label\": \"Share-based Compensation Arrangement

by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "verboseLabel": "Vested and exercisable at the end (in dollars)", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "verboseLabel": "Vested and exercisable at the end", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Vested and exercisable at the end (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r401"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)", "terseLabel": "Increase in number of shares reserve for issuance", "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan." } } }, "auth_ref": ["r48"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r380", "r381", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r404", "r405", "r406", "r407", "r408"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r390"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r388"] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation Plans", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r375", "r383", "r402", "r403", "r404", "r405", "r408", "r414", "r415", "r416", "r417"] }, "elut_ShareBasedCompensationPerformanceBasedSharePricePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ShareBasedCompensationPerformanceBasedSharePricePeriod", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "documentation": "The period over which share price threshold is calculated for performance awards to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation, Performance Based, Share Price, Period", "terseLabel": "Share price threshold period" } } }, "auth_ref": [] }, "elut_ShareBasedPaymentArrangementSharePricePeriodForVesting": { "xbrltype": "durationItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ShareBasedPaymentArrangementSharePricePeriodForVesting", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Period over which share price must exceed pre-determined price by certain date as a vesting condition, in a share-based agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Share Price Period for Vesting", "terseLabel": "Period over which price must exceed \$10 for awards to vest" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "verboseLabel": "Contractual term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r678"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationOptionValuationAssumptionDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r404"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r132"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Vested and exercisable (in years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r401"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Price of the common stock purchased as percentage of fair market value of common stock", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance at the ending (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-term Debt", "terseLabel": "Current portion of long-term debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r77", "r140", "r690", "r896"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r115", "r202"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails", "http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNetLossPerShareDetails", "http://www.aziyo.com/role/DocumentDocumentAndEntityInformation", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r166", "r180", "r181", "r182", "r205", "r233", "r234", "r237", "r239", "r247", "r248", "r275", "r306", "r308", "r309", "r310", "r313", "r314", "r345", "r346", "r349", "r352", "r359", "r475", "r548", "r549", "r550", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r576", "r597", "r615", "r625", "r626", "r627", "r628", "r629", "r796", "r808", "r816"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r14", "r89", "r92", "r93", "r167", "r189", "r190", "r191", "r209", "r210", "r211", "r215", "r222", "r224", "r226", "r246", "r276", "r279", "r287", "r361", "r430", "r431", "r434", "r435", "r436", "r440", "r441", "r442", "r452", "r453", "r454",

"r455", "r456", "r458", "r461", "r476", "r477", "r478", "r479", "r480", "r481", "r483", "r484", "r491", "r520", "r534", "r535", "r536", "r554", "r615"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParentheticals"] , "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r209", "r210", "r211", "r246", "r484", "r500", "r546", "r565", "r568", "r569", "r570", "r571", "r572", "r573", "r576", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r595", "r598", "r599", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r615", "r701"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] , "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "auth_ref": [] , "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.aziyo.com/role/DisclosureRevenueInterestObligationDetails"] , "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r227", "r374", "r797", "r798", "r814"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticals", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficitParentheticals"] , "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r209", "r210", "r211", "r246", "r274", "r484", "r500", "r546", "r565", "r568", "r569", "r570", "r571", "r572", "r573", "r576", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r589", "r590", "r591", "r592", "r593", "r595", "r598", "r599", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r615", "r701"] }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"] , "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r718", "r728", "r738", "r770"] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [] , "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"] , "lang": { "en-us": { "role": { "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "terseLabel": "Fair value upon issuance", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] , "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"] , "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] , "elut_StockBasedCompensationDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "StockBasedCompensationDiscontinuedOperations", "crdr": "debit", "presentation": [] , "http://www.aziyo.com/role/DisclosureSaleOfOrthobiologicsBusinessNonCashReconciliationDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"] , "lang": { "en-us": { "role": { "documentation": "Amount of stock-based compensation attributable discontinued operations.", "label": "Stock-based Compensation, Discontinued Operations", "terseLabel": "Stock-based compensation" } } }, "auth_ref": [] , "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "verboseLabel": "Exercises of Common Warrants and Prefunded Warrants (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r14", "r43", "r89", "r92", "r130", "r332"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [] , "http://www.aziyo.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)", "verboseLabel": "Shares issued under ESPP", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r14", "r88", "r89", "r130"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock in connection with registered direct offering, net of issuance costs of \$1.1 million (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r14", "r88", "r89", "r130", "r15", "r626"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock units, net of shares withheld and taxes paid (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r14", "r130"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "verboseLabel": "Exercises of Common Warrants and Prefunded Warrants", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r14", "r88", "r89", "r92", "r93", "r130"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r14", "r88", "r89", "r130"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock in connection with registered direct offering, net of issuance costs of \$1.1 million", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r14", "r88", "r89", "r130", "r554", "r615", "r626", "r707"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock units, net of shares withheld and taxes paid", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r14", "r88", "r89", "r130"] }, "elut_StockOptionPlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "StockOptionPlan2020Member", "presentation": [] , "http://www.aziyo.com/role/DisclosureStockBasedCompensationDetails", "http://www.aziyo.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"] , "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2020 plan.", "label": "2020 Plan" } } }, "auth_ref": [] , "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit"] , "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the ending", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r89", "r92", "r93", "r117", "r578", "r594", "r616", "r617", "r690", "r708", "r810", "r828", "r881", "r931"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [] , "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"] , "lang": { "en-us": { "role": { "label": "Common Stock and Warrants", "terseLabel": "Stockholders' equity (deficit)" } } }, "auth_ref": [] , "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrants"] , "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Common Stock and Warrants", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r127", "r204", "r344", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r361", "r459", "r618", "r619", "r630"] }, "us-gaap_SubsiidiaryOrEquityMethodInvesteeSaleOfStockBySubsiidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsiidiaryOrEquityMethodInvesteeSaleOfStockBySubsiidiaryOrEquityInvesteeTable", "presentation": [] , "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails"] , "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] , "us-gaap_SubsiidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsiidiarySaleOfStockAxis", "presentation": [] , "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails"] , "lang": { "en-us": { "role": { "label": "Subsidiary Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] , "us-gaap_SubsiidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsiidiarySaleOfStockLineItems", "presentation": [] , "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails"] , "lang": { "en-us": { "role": { "label":

"Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Private Placement of Common Stock", "verboseLabel": "Common Stock and Warrants", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [1], "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow and Non-Cash Financing Activities Disclosures" } } }, "auth_ref": [1], "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r764"] }, "us-gaap_TangibleAssetImpairmentChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TangibleAssetImpairmentChargesAbstract", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLongLivedAssetsDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Assets" } } }, "auth_ref": [1], "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r756"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r763"] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowances", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": ["r151", "r152", "r153", "r825", "r826", "r827"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement" } } }, "auth_ref": ["r783"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r785"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.aziyo.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [1], "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r786"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r787"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r787"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r785"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r785"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r788"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r786"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLicenseAndSupplyDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r443"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r782"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.aziyo.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r35", "r36", "r37", "r156", "r157", "r160", "r161"] }, "elut_ViableBoneMatrixVbmProductLitigationFraudMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ViableBoneMatrixVbmProductLitigationFraudMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Represents lawsuits related to viable bone matrix (VBM) product alleging fraudulent inducement.", "label": "Viable Bone Matrix (VBM) Product Litigation, Fraud [Member]", "terseLabel": "Viable Bone Matrix Litigation, Fraudulent Inducement" } } }, "auth_ref": [1], "elut_ViableBoneMatrixVbmProductLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "ViableBoneMatrixVbmProductLitigationMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommitmentAndContingenciesLegalProceedingsDetails"], "lang": { "en-us": { "role": { "label": "Represents lawsuits related to viable bone matrix (VBM) product.", "label": "Viable Bone Matrix (VBM) Product Litigation [Member]", "terseLabel": "Viable Bone Matrix Litigation" } } }, "auth_ref": [1], "ecd_VstngDtFrValOfEqtyAwrdGrntdAndVstldnCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdGrntdAndVstldnCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r752"] }, "elut_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "WarrantLiabilityMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Liability related to security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant Liability [Member]" } } }, "auth_ref": [1], "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantActivityDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants Outstanding", "verboseLabel": "Offering Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r698", "r699", "r702", "r703", "r704", "r705"] }, "elut_WarrantNumberOfTradingDaysToExerciseAfterApprovalOfProduct": { "xbrltype": "integerItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "WarrantNumberOfTradingDaysToExerciseAfterApprovalOfProduct", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "The number of trading days after the approval of a product to exercise warrants.", "label": "Warrant Number Of Trading Days To Exercise After Approval Of Product", "terseLabel": "Number of trading days after clearance by the U.S. Food & Drug Administration of the Company's CanGaroORM antibiotic-eluting biologic envelope to exercise warrant" } } }, "auth_ref": [1], "elut_WarrantPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "WarrantPricePerShare", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Per share amount received for each share of warrant sold in the stock transaction.", "label": "Warrant Price Per Share", "terseLabel": "Price per warrant (in USD per share)" } } }, "auth_ref": [1], "elut_WarrantsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "WarrantsActivityTableTextBlock", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Summary of the Offering Warrants activity" } } }, "auth_ref": [1], "elut_WarrantsAndRightsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "WarrantsAndRightsExercised", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails"], "lang": { "en-us": { "role": { "label": "Value of exercised derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price", "label": "Warrants and Rights Exercised", "negatedLabel": "Exercised" } } }, "auth_ref": [1], "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails", "http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantsFairValueRollforwardDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "periodEndLabel": "Warrant liability", "periodStartLabel": "Warrant liability", "terseLabel": "Warrant liability value", "verboseLabel": "Warrant liability", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": ["r877", "r878", "r879"] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsWarrantPricingInputsDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Fair value calculation input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r877", "r878", "r879"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsPrivatePlacementOfCommonStockDetails"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in PnYnMnDnHnMns format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r877", "r878", "r879"] }, "elut_WarrantsIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.aziyo.com/20240630", "localname": "WarrantsIssuedDuringPeriod", "presentation": ["http://www.aziyo.com/role/DisclosureCommonStockAndWarrantsRegisteredDirectOfferingOfCommonStockAndWarrantsDetails", "http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails"], "lang": { "en-us": { "role": { "label": "Number of new warrants issued during the period.", "label": "Warrants Issued During Period", "terseLabel": "Warrants issued", "verboseLabel": "Warrants sold" } } }, "auth_ref": [1], "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.aziyo.com/role/DisclosureLongTermDebtSwkLoanFacilityDetails"], "lang": { "en-us": { "role": { "label": "Warrants Not Settleable in Cash, Fair Value Disclosure", "terseLabel": "Warrant value", "documentation": "Fair value portion of warrants not settleable in cash classified as equity." } } }, "auth_ref": ["r875", "r876", "r880"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.aziyo.com/role/DisclosureNetLossPerShareDetails", "http://www.aziyo.com/role/StatementCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding - diluted (in shares)", "verboseLabel": "Weighted average number of common shares, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r232", "r239"] },

```

us-gaap: WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItem type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.aziy.com/role/DisclosureNetLossPerShareDetails", "http://www.aziy.com/role/StatementCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding - basic (in shares)", "verboseLabel": "Weighted average number of common shares, basic (in shares)", "documentation": "Number of basic shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": "r230", "r239" ], "elut: WhenCumulativeSalesOfProductsExceed100.0Member": { "xbrltype": "domainItem type", "nsuri": "http://www.aziy.com/20240630", "localname": "WhenCumulativeSalesOfProductsExceed100.0Member", "presentation": [ "http://www.aziy.com/role/DisclosureRevenueInterestObligationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the scenario when cumulative sales of products exceed $100.0.", "label": "Cumulative sales of products exceed $100M" } } }, "auth_ref": [ ], "elut: WhenCumulativeSalesOfProductsExceed300.0Member": { "xbrltype": "domainItem type", "nsuri": "http://www.aziy.com/20240630", "localname": "WhenCumulativeSalesOfProductsExceed300.0Member", "presentation": [ "http://www.aziy.com/role/DisclosureRevenueInterestObligationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the scenario when cumulative sales of products exceed $300.0.", "label": "Cumulative sales of products exceed $300M" } } }, "auth_ref": [ ], "elut: WomenSHealthMember": { "xbrltype": "domainItem type", "nsuri": "http://www.aziy.com/20240630", "localname": "WomenSHealthMember", "presentation": [ "http://www.aziy.com/role/DisclosureSegmentInformationDisaggregationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Women's Health.", "label": "Women's Health [Member]", "terseLabel": "Women's Health" } } }, "auth_ref": [ ], "ecd_YrEndFrValOffEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItem type", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOffEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r750" ] } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "230", "Topic": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "SubTopic": "230", "Topic": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1D", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748299/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-6" }, {"r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-6" }, {"r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-6" }, {"r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7A" }, {"r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7A" }, {"r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-6" }, {"r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7A" }, {"r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7B" }, {"r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7B" }, {"r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7B" }, {"r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-7B" }, {"r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-2" }, {"r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147480081/944-40-50-2" }, {"r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/214748009/946-205-45-4" }, {"r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147479170/946-210-S99-1" }, {"r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147479134/946-220-S99-3" }, {"r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fash.org/1943274/2147479134/946-220-S99-3" } } ZIP 82 0001558370-24-011988-xbrl.zip IDEA: XBRL DOCUMENT begin 644001558370-24-011988-xbrl.zip M4S1!!10 { +M+53E5}5XMD+@+3WV 1 96QU=TR, #T #8S, YJ XMS-V0:25#YM20DX4*1 M6H"TK? WUUP2T?E^@i16AMiC2R(3C0;Z PUTHP^M=7M6T14Z28ZWPAZ^? A+G4,5V+4MIDBBNBjJk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~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

[illegible]

M> 305+ISIE# LLE&#(FX)HJZ9&A#1 IZY>OI&FQV4(G.ZJ:5\$H)U&8DN"B/S MRNIDZW5@-+I3D)S4I@>B-IAQIOSS^>N;CF"XH-H0588 SD\$>N/N M<2343CCNA=5TU7.7L%#6@NVU-10GDL16#A1>E5F24=M/W6U\$U37#1#JD HL-&Z2?>1 OBN>E+C/M>878BV2_0(CX=51#2 DZ#Q"D">8'0P<F4R3_JH_5-4KHU<?Z"Zi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a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

W400/Q=,HCS2;P3NEW01/%X MP> R0IV5I@FI7Z;KOP2XEE\$0YV1/<ZXICF#CG1P D5ORV1/G0A@OP1 MA%XJH7D6(7;>IYX3EMY%6!&:"D'V0@KB@1CP2\$!\$*8<4I
(L&\$@E"9Y4) M7+Y\$!\$82&LRL1;WJH7K32KMUHPH.NWUC9;LWLDIY<24.IKNOY?>WDVJ M2QI" M7OP6.RH7 R*9*
DIXA8X\$WGC>?/7OXWE;YUKGBOQCOIMK4#1<*&IXTPVU7%=>J4T%>WKH=-.9G1B4&MGYCXA.N&G!>G@M'X&EA0+<CP3Z.8%>E!>D.S1C9>XF 1WPF=

3LOI4 W&L6A>W@B@BKW&L(15F L789@U7%>E+>+G=>E9%>GPG'A.KI@M'N%>@/O5T'F6!>."IDFN.D@/F789>#9BH=<G.E7XAVI'>MBC6 5\$!H<
M@H'L<@C.L1A>+LWC%WEE;>Z9QKIC<D J"VYQ<=>+>KGN- MUXA4JRPETHULZVR9U7?>.(A)D>B".R":QC0.XXC65Z9W.LU'ZXKSO JMGCA4HX.H9IQ89IS8<4*Y%L>>>
(X)U@EKLIE6/GXJ:E\$QW10Q?>E= M'YHJRG=>L'CCVY'RMR'>SVVN'L'ZGA!>LDBD'>JHHH.MR'>YKIV:28UK6C.M@>#>Z2ZA'YD'AT=RA@>P">@>D17\$G.UDK<9L&
#F0S3C L'P'R'W3O M'Y6'7Q>T&=<A1&L1.B!>+>2\$NF+<C2\$70T775B@PN7B3".3.S.=>1\$!>M-9<#>1\$>6292+4MV25+VJ3L(P1+!>\$.GV)B.HJ<JW95!>0"39S.MV?>

0FQ0:92EM00XJHGHJ>T8D.Y+P\$Z>X\$52.&J\$>NGBDITJ\$T23G6MI&L3.0F.M"J".BAD"VSPGS:9=-H<8>."N>L#W><<"L2/8JOYLA4UMQ.N0IM55AFOPAI+YN.ML7LM:QH:CON[-Y
VLI">DYC:U+I&KEV0?O>=<G\$B^O^>IKR..NB)+G=3<3%<L/>L^J2DMB/\$70"+VVM.Y+URG(MFEV#*S.M#L3QHJ\$%<DC/F%UKN^+>@C^/\$DHO"RFN7">
G.R%JDPY:U%UXXI\$>=<M#B.9251YJH3C#>NGBRNPRI3DZC#JH3L6/LJA/>M#30QYH7B%<DWC:IR7.MXZSR\$%14.R.U.OQFJX\$>09C#:651+451M8\$&F+&.7/1786:<KF#3
M#H"OGL8?>P.C#1#3.70FC.KP.GZ#RGXKRY=>TKV13XLFIJL1#29%>MCEP-FEWY15(8)C2Y.<@YQZ2<>+>>4I#JH+8>X&C6.BM#J?>9A#
M.O(88P1+0HOG5XWOG&S<@2H#J1=-1%>H&X3H0.%>C.GCNXMS395C6X0:M.MWL7+4AULZ2D:JU+IN2N9\$6M9:IE#N#HIEJ&E<+<M13Y.<@PKDTRKXZU7WD:RQ
*WRV2X?>*M#NP@/8Z8.IQJCB4L&C.\$\$IBHIV>AOXA.Z#>*E)W1WYFA.&5%<M&PF."\$T=\$13KFB&D.M.A3ABV+95(<@JFLE1276KM\$JHJW1:
<JY9D76L>J<KMQOW(UJ\$)>=\$B\$>FA77BJ:FA76E.VY+Y450G61M9HT.\$\$.MHAZ51(MO7L+J.%0\$OUHOKDW"JOY35TF.MES.MIR2^N)M\$W6TP89ECC<Y<Y
C"BOH90\$SFL>X"=N5WMX.MUYC&F1H\$XZ%13XHC0?YQ20IBRF+22X.M<HJM.P1=\$>TDB9#>7THIR&H4.M3A0M\$KX8>CX2)8.M.7%>27>=1
IFULU+086.D6>3<=UFL.KAS04M<M6%W78NIKH165F+ZS%W1WSVMJQI=W=UOXW62/IL@IB/G+I23LS.W3W"TM<+>7.0W(T)T3C2PT&T+>
(P<8KK=<+>1.RR&S&N2T.#31+NNL:XS6&Z5LIRZ.MHBWZ8.MX7SEZHLQ1C\$9YZA."RH<=<7\$2\$AN.10>9OEG&ZB0081B896>V9SJ\$J5C<@0B05N19K2?>
IA+U2Z27WH>>KLA"J\$MXXM.H1D#>4070.ME<6N2R>2<=>796\$GS/92/IBR<4>RM7R=OH2.#K&U56D+G6.&PQ&K\$W01P.M.MO1#E3D@.<70NR#H/Q
DB2W1J6H+H&#ZVJ14FOO%572.A.8/Z.7DG.M2FFN.W.O&7H(N73>YH(OH2=<Q.6C7F<4C7+>+<VCDVA%AR<A.#4HCE
M&K.RJ\$VY6&L3EOGLK29H<E=KUNKIPAGI60HA#M.M63C\$F89ZV2(\$X3Z5%ZF@+>1PR7.&MA&D501ZX8FK*QXBFEYU62Y/E5XG
MT\$D1<6>3>XB72?<G\$G&D90>Y89@AD7.5114L\$=F.W%W%T"OC.LH1FJFA#A&S#N<A%\$%>MCG%IL%ZNP2C)B***+L\$B#59HMB31Y*E2AH(WUE=-M"U(T35PKO)>I
M@ZWGUEW<=>7FTIU>@HTP.M#6R>N.IPRJ6E=IEJSY=IHXN1+>2EH.H43D)OGIM#<=<YBP0.RR5.YU1#M.X1Z>X53J1@U@H<=<F.H.8597)D3UD=-SR)A9RCD+L
NG\$>8VR9#5FEM.K@VHJ/K1<=<6.93%E2EFH0?>Z.R.MQ\$AL1.0VY>2G\$>GD.0HIE4C7ZHN#YVG.D54D)HGF84.AF=92(A&9YF6.1<MRP\$)C.<JUK&1.5VFI.M#H+51
<1X&S4B&S:QR.WT.LX9H"PV7V6@R.R.O.MI.73/LA1+X)1&)>1UEFJ370"3XS\$.B\$0JDOOBBM.0\$1<Q\$>Y1M)M(K/L.EI.W=WX+Z6G0IB@<#AR#M#&EP>017
MAUNHXE0<6+>L.M19QIT85?YA<RHH(8H\$#0C>@FEXEYMF.LM2/LGJLJ.Y7X16N1.K843.M2MD<@W+YF6+IV8C\$M5Q51.01FB+Z5"KK<ILT@614EQR"Z>#T&#>2/>7>
M#NHCO4W&M.LTFVC0:QD747@B\$12XN.LT@V96UM.F7J3DA=<2.M12?+>3L.R.Y#8>DPY+Y0\$A>F%>H2XNB)HHH+P.3V)>#24>U.0U.8%
MN79U3\$W5IADG.M3.EG1">@912JKA54>2DL.N.MOMCD1.P15W&6"613=<1MZ015P1R3Y.9BITV=8N1J6=>JLZ">@AOW12.XY&4(S)>I&Q7H<#>2\$>SL1.MUJ2IA4P01\$9YRN
D1J.T.B3"J\$>2/@QO3JH.S2.&I(2)<5R8.A=PS.M.B#8FRNCNAR.MZ@3(DZ>8%P0R0\$16(E.L1REG&A1AGW2350>HE.0<Y#KMF05D)G.LUO1L.O+S(78N1M#A1">43T3R<)>XX<
003JLSB.ME/D?>0<X.XRWS"8U>+>1CO=>L\$>G@IE^<B0Y1+H.NRZ>#<K6U0Y=<+X+M8>5NN4W.V0>01SB8IL.O.<@WHTC4IV1>#<#B1B#1="34Q>90GH"J1=L1M
MOMVRJAH.W.290/QH.85WB/VQ.AOUB#VE">VN64#MIGC7.617(I3)UJOS.M4+ZJ>3LQ30>Y=<A15L.R0.BW.N.EG&H1X5F3G.VZPAUH.K&B.E4(C.NJH.M
ZL.WR1@BNSW&AWV@>T.E1J1)>>2.02:5VC=I#H.R.<=>10X720>H67<MUQTS(CV#>+I1V+K+S)O&S>9EIMCS&A(UN\$3\$KEF12.269V&FV1.Y#<G.#M12>4FE.Z.M&E<
<@D1IEZ13O3P<+>1.5L0N1#<#W6&REFE.G.W.L1H&1+Y><=>(9D3J&SBRXIU9.MJK.3YV(SBJI.V=O9WHCR46<4>06F&AC.M3.R
1Q1ZCY6A4C8GTNHVR1.PY9ZX6V1.E\$Z\$BESDE.<G)S4WM^50&A1.M1=IHW=BNFTLY.XP(6%>)>RWEV+Z785R.*1%T2AP74#C#1P+X<@<T.MWAJO.9P)M#
J3)MI02T@S2LE.4\$4Q0=<S1GQ12D1Z7X\$T\$OIRKL\$<CR2D.M5%6B0.IY7.OA>JW-IK<D.8T3.P9>9R0V.
(4N.T.<@ITU#3.U<1%RD4NEO.02AT<=>RG<=>DG/CGL.W>96>A^<F#Y#>M1#VA51TF.T\$WN.AB(AO4WU.7.1C<<85K.2I2\$N70.EN2CU/7.T99G.I=<@9R.M#JXIU#1-?>62CGX"?
J2R.UW8>8%KXZLY\$SW4&4%>1QOZ?>1<GKZM1Q?M5T.Y+B=H9I(C1=>FONNN)W\$T+I5J0>RX1RT.BLPN(WY60Y3J)E2T3XC.M<=>ILD#BQ?E\$K16WUG7GDO3?+>QHLE9
ZRNMBG.HP(FHJ1Z9183Q)H@<LMS.321>1OZM<8MIY6V>L.O.6M5Z6ZV&B3.Z.U.<S)J5&6KJ5031FMC&L.H6TK381JH2Z\$<ZFF&
H19WC.GAA.94(LU1H.0\$>=<5KW.CNDEGWZ+Z&A0IA.M680T?LNOIB14IW."#07#9.XOLXH.77D@W<+>1JCL.8J=5D9KW.EQ04AWZ4O.M#<S&Y>2BNZ#<1JNMKG
5BMAW51&@<I4UCV4D?PZBD.JS+1#<#(BKC.K.Z.MMG(OU61=>7.3FU\$M8G9VM00)>3S<F1<@90T(D3E>Q>@<VZB0?U.14.7IRC.M#NYPZK1L.V6X7I10
3M5(WC9#<#X#6.J8X">3.M6MKY.M.(T4VH9+V.RQIN8RKIR9G<+>13MC.6A/GP708R7YU0+>31.N.D.MF#H.2<UEUZ.O.U34UEXHTDJK#1Z134+>#0(Q7B88(I
1R5FRJ1B\$<K.M2K\$03P?ZSFOT7J2>.YD>2N51Q01+L<=>B+LAAITKIDEH05KJF.VWX<#M4L\$>2=>8JG0C2TPK#K<#K#>#Z.NC1^FQ2>2.WOFF#Z6L7HOK.(R1K1W.M<P+
+I1D.O)>#<#Q(O)<#&Y92DM?>2<+1#2>3.BAWP7JPM49<5>XBJA6O.M1<@2719.YOJG6M04LEK)YMB74JG&31W#IBAE.R1OPI.M
1S451X.76>3>1.L#>N.EQO1PT1V14NUM91719A.LT.H%96.MZW7<54#1.1QQHVMX2IVK<P.D62J\$8MUQC91&B2M.M34.07S4UJ1.LV8IVTKO1(437
AIVPU4IHU6#<#R1=JRSJ.MICM4(10B6(I3Y1W#J/(=1C)70%<@P1YXOB"Y.PS15A5JE20PGTHYG.*M&M.WFA82>.0WW#<48IM.BA(4T.T2+Y1.S...%U.S#<YR\$E.RH:DR

[illegible]

[illegible]

0P.F9#T00Z8V3^G7(ZU.^0.. M50PFG,GICJ12,=45=4P. 119L@T.(2ZC8+Y.P.#*FB IN1/0IVH(Y%=(M^H(#\$OTN\$Z>+%WID0QDPL#MD;D%10<=%LCP%4Y4\$!A
J^=Y8=HH&CHL,NY.M^XF@Z+1&2R.UB-(ZDH+U\$K42SE^%KB=D-T.B3\$P\$0CPM^2.M0L^0H1^@H6G^M^WSZ&A^%0ZB&P.T15K^#99EJE^@Y8IY1^M^W^X\$1.3KQMUJ>D4
M^F5.S.TEWN&XZ+1X^>+<1&K>W.^L.N6\$5&G&WZ^M^K3UY0A1Y^#S.^U01B\$1(23GTA.E^<^DY.MB/FO&G^#M.XOIG^TB20KG.^X+HHI.^1&+AS.3E8W^EFOICLH^\$=1^#
5H@P02.M^#L\$K^>2IQ.XD+Y2NZ6W.9.M5YOM85K3^K^A191^+L^H^H5E(ENGL4LHWK21OBOSL&J)/AFD^2^E^R^M^0.M26A@<15NVN^>OV5+J2V.YBDNN>3/IZ\$.8GP5?
01)0>HC|BA!&0)@0^CJ/.MOQ@1G(F\$Q(^90^HPPF^D+1)J^=N=Y&GY28TSD@42V)SHL1X@VBC^#CIE.#.#04RC.MZ0.713)OV#74(POI@U-4W.DHO..W1\$T:1^1^Q-
+1^NCG0P+1^NG/L^1^CH.M^1^B0^>1^1^E^L^#200.^?1^0.Q.T.G.4T\$3Q^#M&VBSY1P^17^KXBW;1\$F18GG<^(VY1)0K=1X5K9P+V-W1R\$R.#59#8^1^M^MUFT^?<
1BU4^/G.JG19U\$7^#..^1^G1C\$=^@JDE07X^@2XH60QE61(8Y^MRHHU7^\$A.GN\$MGD^G^Y^7Y2N1&0M4W^X3J1^1^C^H^KDVB^FP@D6<=&P^V)C6K261^>0.M101^M12
HLS^U^M^KGLX^1R^=61AT3ZBDWJ7AWUHB^0.DZP^+Y1^OXTLN^FRW^X0\$VGVH6ZLKG31\$9K1=M^A.PG+6KB=M^PWS#E.(E.MV2KF391^L^B^JOI^?6C^&2+NT31DFT7B.72H
<IZ@1<=9I2J.M3+T.YZ^BN8N85DQ^?ZB6T.15\$X<28.GZMVY2Z.V\$GFO5M21JW6DS;RH^0^BC1^>4Z^G^MVY9.L7RML<=>5F>#8.1/1^1^U.SUIA^28T2.2L
M5IU4XPTJ.ZW1C3\$X0^>60^0\$IL^VHJKE=6.N%U08<#CJ+9.F00Q9J\$.-MI^G8R6J;CL<&CLVHHWJ>+H^NX^UW45\$+U-ATK^LP^518008/9Y%[@9Z^-T(SXX^YLP@+>PY^)=
=HNKE.M019\$&3.M7PJ;M.K9@8L^C^?3C91^X1^1^>6Z\$.54C.M5N(OR1+8.^145CO1^L^CW1\$&PD^67FJA23U71^1^EHL)DR^4^&247^+>1\$Z4.MXE6+Q1X\$K^CZ9)0)SG6<
1^QAVB/BFH@Y9\$&-(P@&#B@1@|PR@=>@13H2@C.MC@+7Z^V4T9.151MT0@R178T5P14^1^2W8N8P@G.DW^8&.WKK5+1.PMC.MV-
>8UVA1^#&HEU1@|VXYD1\$S.46N87ML9KFU(Y1^4TGOLE.IX1\$S.M>33161^FAZ&GL1L^WK9E^@336F0#^@Q.TOOPLWT^YH.BR0V^J2765M5..M7VBG1W.#7>=?
13X>1&7\$WJ;1V5TF2001^A78^Z^G81^>S6.=>3/R.Q.M51=123.Y1K3RFX4^?J.^+1U.MW^YAA1^#32\$S.DU6>82+B2B.ZY2D^Q^P4^C09\$W.SF9K\$4ZRF627^15^M-
8=0.ZNPU78+L18^8^Z.21X5\$.#.R13&FG#:#1601WH^%WL1V1|GV;1M=WM#.#.\$K.W10(2358@.V4A#^AT1L^0%|+;H&2DLW2>0.;|PLH93|)^?0.M1@HINC^YQ^0R6FSV)^+
P1X6Z4P@OH\$1=J2N.R1^E.CA.X9^#AF1D=1@M-JFCB=@#T0#M^PYD1VSS7Y57KAN86=M1XB.G.\$#.#9(AN^P8.M.YT7RJB1^A9.8^<1^M021GAL1^=S36\$M^M0M10+^P1C
1D1F&C|H1^..H0>M7VY.IWC^H2U+1^J6W)UQ.Y02.U2&N^H1MYJPD.^<ZKX&S^3#..^0Q7GAAG.M^#&#>\$K\$55)TO+Y9&61^B\$<9.M1042^D^X2U^#7F(HCND@<
(C1.9.^P%|K^ZV72050^9PJBK1Y+8^E^1^X%1M^WAPC%.@VW&L1^+N@&=J42H.(S33B9W^#&0H8&L\$1E1Y+U7.31.MBL^219E&@CSHY?
JC)^G71EPK7>E1.2/QTP@6#0^#K+1^%KXT1L.G80HG&7^?P21.M^80.^#>B\$4.^@7V.Y1^&N7B&?U1RF^YU1EXM(156TG21087Z|CUPH>M1&@Z&M0.ZN115.++>75_153
5-00?_AHNT_15^51H&G^KP.8JX.ZY#^MU^?0N&|K;W1+QL1S8C6\$<T4X1\$^B-G_UE%\$SUYGZ.#P1>)(B1^Z1M0B.^%TP1T^R^"A4F0.UH1^>\$1\$R\$>EQ^#0A^F@U0Z
5U<^#0>Z0QH<1H.MK<4J.SF1.LDFA1^@QZ1>V.VZABD19<=&1NH\$T.^#&=1&8^&2\$#>@HOV\$5.MN4^1^L^SR0FGT1^1P300V^CPEU0>=UPDN^K1Q1QZ2M1+>02|SW492TS|7#>1@-
QK<=&531FT9.VH2N>1^Q0<04+1JWQ0W76D(M..51FR<T^6Y0.#E^1M6R.F0A.UXW2N1^1^#>G1K^Y1.YD.Q#D1^80Q/2(F6<30\$G^XK1F7&TBV1)^5+SYGT1>=&F^1H^MGIK?
=QP^41C.M@=BSZ1X.Z@VM^>3>M>MG%IR<B?2.CF(S6G^M^>S1B.MIBOX91^8^GNLQ.NC^#>QATPPM&8KYP=OVS^OP^V1^>5\$Q#101^>B^R^N^M.^1C&\$@B.2H0J^01^G^016<
W0D^XPU=&K&8^D^M^7K^B>1^?ZB\$<=7T.M^#..W.Z1D(W^ZGRZ\$1^1^H2MD1J&S^=7A1E^+E6<^@Q441^F1PE2K2D1^03.M1NB4EH^%H1\$1Q1R+31.^91\$Y5N6;>0D.M.
713AUI\$F43&GJF@L^Q^Y7GAL(SSF^>DAJOK\$S9=Y7>ZF3.5U\$<@9PF^VFD1M.M4TW^2^@W.O1\$1R1^XFRGG..@V74.R1.J1\$1=G^PC)R1^1^JD.M1B^?2
51SH12Y23R24<4R8>704P1^1^#01QHC.A3N1Y^>#80\$Z7.X79W737\$5^Z.X0#.#M^37W0451188.MK16NE\$S^#<12#H^M^7V0D1OZ1R3^Q^?OTU1^78&+2V91^M1E@L%|F\$1
1@K16K23N^=N1|H1^7&B=S^#S^#W2.\$+49GPO7G01TBTW1M64.MKSWA^GL001^624XYU4BTK.MK16NE\$S^#<12#H^M^7V0D1OZ1R3^Q^?OTU1^78&+2V91^M1E@L%|F\$1
M&X^X1X8DQOYUBG.OPG1L^?P^EWA.P^AX^R^#R1PO\$%11^1W82G1L1P1^1^E1M1MNAQO^D&X^#S1JYN>T>8#^+AU=>W1V1\$VSW^?H2WK1^AT^Q153A.2^1B8
M1EQRH6W@P1SG501T.02=DMT1W(17Z.21Y1(1^<..XRI.T=19TV=RM(X1^<E.M^M^Q^>AD&L^H.G61^<L^&A501^%O1=>0.145.&BR^#SBN^<="B80\$B.M5^#Y.(V)ZB\$=YK+
SAO>&1@M^<817>?F#NG.-U.MA#(441E1#=\$.W.X.L+1^S@8#)H1LK91ZHV9J^80G>Y.D3+KHLR<1Q9B^<M^H1U1=-4B+6.Q/4J33PKJ6^>H1^&V^1FT1ZM9H1T1SHOV
W1^L=M1F16241+Z#2\$2F1D1.47G^1^L1^1BEEFLBCSD9Z.75.FR156BS14K(7.ZU.MN^;1RDZ2M1^1^3FC1^#8^0^3@<(9&1^H81D.W0\$XB^>41^7B&1^V19^=P^B^A0+
O&W)51VME^@U3E1U41^T1Y6TOH1W2FAL.M1..3VKZ1^FEV1^1^H1Q125EL1U1H1E3^+1^23MUWB<1K1P1^6.U1N^1^P25P.MEC9^W1|FF1F\$;TR>=>C.98201)91G5KRRK\$?0
81N1A13158(1X)C1^F\$1^1W^2^Q.XR\$2RFB^<M81X1Y1^T(2Z7765J1Y2^\$SH1R^K1412T00901B^>XV^X5233013^?2^F1M1^M1MB0ZK9O1^9Y1^<=>NG1X\$1^MF+BN^XKNZQV^+>1
<ZDEZ.M1N^H^W0\$Y8^H20J1R^U1^<Z..SO^1^#..3WFEU1^JOKE1^1^FP9.2\$J1^1^L1^72N^XOF.M^31KZ^&SH^NS813@9L^K.Z4Z^91\$M5^E2Q4.J1Y01Y1..1RRB>9WBNI
M31X^VM1>D@MNO0S37161=GZPZNP1P1^M8=+1\$%.T1#=>17&?>SH>.(MPW)\$Q1N.Z.M=W#<Z.5PN1>?1C81Y<=PV.LF.NV39F<3G.1^1&^>4.SPT1^1^RBF1^?MBL>\$/C.8C1.#
<@<+1^X181601.4\$<1&C80C7^M^K<1^M12M7>6.2162B^?BC1M^@&XJM41^1^>=&S&N^&G^A^WH1C9>R^1GRG^SXBD76^AV1\$<@<+1^M1^1HWS^33071H
11<1R1R167A0V1@>#Z11^1OZE^HE>M41SH1PR1@>0^22^7-W.Z.^%B1\$^N1E3^N9Q4YH1^X8&12RMSPW1^R.M(6YX^8DM1A3H1ZL^M51Z1^WU612H1W1
S1^1V13\$.33RR6.3GU^#ZB.1^1^Q^M^#3>W1^1^V1^P1M1^1..0QW7^1L1.NH316U41@+B^P^PC0C91^V^DQNU\$S96ABUW.3V.M28N^#?<
W1P6ME1E1C1^6C02^0MWBMD.24E1PD.FU1DR1513FV(S61Y2151MOE1X1TEPUH1#.#C^F&Z^ML.QY1P001^A#NA(6B6^H81+5\$CB1^URER1C1NR
MZZC>W1^T(1)Z=ECV>2C3E.X9?D.A5A1.9.21^61FU8^=N1^1^P.GN8K<^VO.MGGD1KH8C^O^MXJW2_R^K1^<X7N^2M^%WN<7B3+1A1\$5117XD1^V&3XH
(00Y1+TO^C&W903\$Y\$VM1PV\$X6\$F1T^1X&61H01^M0\$1V^FOU1E1FV0\$G=)MYD1^#001.G^H1NKE3^BX>5KG=X@<DY=P.OG^TY>R7X10&@Y.O^H2ZAFH1
M1Y2@<@W8.114W1^>11H.H81^<@0^&V^M1YB^<P21^CRDB31231\$1^1&R.M1Y.3VFS<1&1^#9YE0\$H1
ST1\$3^14DU1V(GN1B1)01K1\$^251V1U11@7^T.N4^51^L1^14L01G^MO1L1^>1%1E.MW1A11(=1JTV41G1L1^14R1^7.RM\$0^1%0125^Z+WX^Y1^A^#<1\$S^T>M6RM
M&S.AH7119FGM7161G161VRSK1\$1\$1VKCU+Z6G83.L1N1E1LHG6U=DD\$0^M2H.3^1^16+DQ\$NHL.GDY1\$1@>P.H1219D.YV6@6XP7VBMU\$5>NAG&
M21RV7+MFHS^FR.B1^B+1Z=2XG7H66V)=5.FVYU.P<99N^Y@9SS.DZ1Z19S.M1O.(ROS.O1^H0B1^1^1B^#Z&T1F1DM.L1KHE^?Z09>R1^>T51^>W81.FVY.M^D?M^<^Z^>E0G8
%F181^RTA7^1X(HV4\$T.YO.^?D^M0\$=>@Q1@1W=+Z.M.L1^M1N.V1^H3X1^Y1X8K3JHURB31^0AT1^SDSP13#M3#<6B1^GHKT^3M1^U1N1G^T2^0U1H^#00.P^H1SE@RT1^QG+OBB^#
<=>5K1(2>1AE.27^Y001\$1^>8^M.P=11^Q1\$1^%T1Q1E@M1^M1P1AD1V1H3KUN1\$1@18U.N^NG^M1SD1P@70\$&N1>+0>37^U1U5VW.M1^1^&2^#QR0^0376M1319.
1+1V2^3X0XVGC\$M1^UAT31^?Z^K>?>E.M.M=C^M^C.G1&FCA6191KE1^1^1\$1J1^8&1^>W.Y1J\$>=>+OS0T1KJN1T35^1JCR.M0&6^2Z1A1@.1^H^WT2^2^012>1
%P9X2OM1ORN1WES1Y671WD@GV.2H@H11Y1M1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^M1\$1G1T1^41@1DM.GZ2^21)9P1^BT031302^2VA1\$+1^E1.FY7ZZRTG-F
M.^Z1@L1K.3/8&8^M.Y1H1OWW50\$1^1N7\$>1L1A91V1D^<=W1U1^1^1^CY.MZ.S^D1M^M@OZ.7^251LF6N74C^U4P1^WC^1T2^?2E^%13^X1P21^<2<(-)M.A1^<
^BL^1^F5>Z3+^1^Y.H1X16^<+1^XWE^%0\$191W1W.^#C1^1^N1^M2Z2^RAE=^910^1^S1^1^U1^1^HMEG1+51^1^1^1^<8FTK5Q1A21F0N1U+M^C6C44^>V191G1L^UNT6Z1V1B
^Y1.F1^1\$1635U1965E9.7V.N^91X^C2.M^V9C13BU^3R9Y92M.KH1U\$1A1^B.3D=(85^9F2R.G=K)8)F5Q+5^=Y1V.M^3KN\$0E.G5^1^1^1^1^1^0TDF1MB191478Z1181G1C1^VMX811
1^1^U1F^R<H&^X9>2P^KB&8^00.V\$E1^1^2^G9HB^&M5.KV1R\$A+R1^VB1^UO^S9A6G>3\$D1^1^41\$QV1YK=1^1^#P6#1@.E1H.4RA.M=N1\$F&Z&H218D1N.GM^Q14L1^F
^#B1+PM311R1UM1EYOC2^ME.C1\$=1^Y.E1(=OH.ME=3&D41T2^G1^1^N18RE1Z3^2(ZY4C21Y^OS&G^K>J>5+Y1Y1^T^

405G)ZPRXA.WB7S45+1+G40=K M3XFKICQ(UNVNO601:51FWKG-3H M*YO QHG:Ks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~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~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~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

[illegible]

[illegible]

Predictions. Tax regulations under which jurisdiction are subject to interpretation of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting for uncertainty in income taxes, the Company recognizes tax liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is more likely than not (greater than 50%) of being realized upon settlement. The Company's policy is to recognize interest and/or penalties relating to income tax matters in income tax expense.

<p>< p style=

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

$$d(\text{pr}) = \frac{\text{pr}(\text{pr})}{\sum_{q \in Q} \text{pr}(q)} \quad \text{pr}(\text{pr}) = \frac{\text{pr}(\text{pr})}{\sum_{q \in Q} \text{pr}(q)} + \frac{\text{pr}(\text{pr})}{\sum_{q \in Q} \text{pr}(q)} + \dots$$

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible][illegible]

[The content of this block is extremely noisy and appears to be a corrupted or heavily redacted version of a document. It contains numerous non-sensical characters, symbols, and fragments of words that are difficult to decipher. The text is dense and lacks clear structure, making it impossible to transcribe accurately as meaningful content.]

[illegible]

[illegible]